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Zusammenfassung 
Anorganisches Phosphat (inorganic phosphate, Pi) ist essentiel für viele 
metabolische Prozesse, der Pi Spiegel ist reguliert durch das Zusammenspiel von 
intestinaler Absorption und renaler Resorption. Mitglieder der Na+-abhängigen Pi-
Transporterfamilien SLC20 (PiT) und SLC34 (NaPi) sind verantwortlich für die 
apikale Aufnahme von Pi in Epithelzellen im Dünndarm und im proximalen Tubulus 
der Niere. 
NaPi-IIb (SLC34A2) ist verantwortlich für den Grossteil des aktiven Transportes im 
Darmepithel. In Mäusen ohne funktionellem NaPi-IIb (KO) ist die Aufnahme von Pi in 
Enterozyten stark vermindert, was jedoch nur zu moderat erhöhter Pi Ausscheidung 
im Stuhl führt, welche durch eine erhöhte renale Resorption kompensiert wird. 
Desweiteren führen Mutationen in NaPi-IIb beim Menschen zu pulmonaler alveolärer 
Mikrolithiasis. Es sind jedoch keine Beeinträchtigungen der Pi Homöostase bekannt. 
Dies weisst auf einen alternativen Mechanismus der intestinalen Pi Absorption hin, in 
welchem der parazelluläre Weg eine entscheidende Rolle einnehmen könnte. Unter 
normalen Ernährungsbedingungen scheint der Pi Gradient ausreichend zu sein um 
eine passive Absorption im Darm zu ermöglichen und NaPi-IIb KO Mäuse mit 
ausreichend Pi zu versorgen. NaPi-IIb ist ein Transporter mit hoher Pi-Affinität und ist 
stark reguliert durch den Pi Gehalt in der Nahrung. Deshalb könnte die Rolle von 
NaPi-IIb vorallem wichtig sein, sobald der Pi Anteil in der Nahrung limitiert ist. Das 
Ziel dieser Studie ist die Rolle von NaPi-IIb in der intestinalen Pi Absorption zu 
untersuchen. Dazu adaptierten wir KO Mäuse an eine Diät mit tiefem Pi Gehalt. Nach 
unserer Hypothese wäre unter solchen Bedingungen NaPi-IIb der dominante 
Transportmechanismus für Pi. Um weitere regulatorische Mechanismen zu 
untersuchen, welche das Fehlen von NaPi-IIb kompensieren, wurden KO und Wildtyp 
(WT) Mäuse an eine Diät mit hohem (HPD) oder tiefen (LPD) Pi-Gehalt adaptiert. 
Wie in WT Tieren führt die HPD auch bei KO Mäusen zu einer erhöhten Pi 
Ausscheidung in Kot und Urin, was darauf hindeutet, dass auch ohne transzellulären 
Transport eine erhöhte Aufnahme von Pi erfolgt. Jedoch war unter HPD 
Bedingungen bei KO Mäusen die fäkale Pi Ausscheidung höher und die Menge an Pi 
im Urin geringer als bei WT Tieren. Umgekehrt führte LPD in beiden Genotypen zu 
reduzierter Pi Ausscheidung in Kot und Urin, diese kompensatorischen Mechanismen 
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erlaubte es WT Mäusen die Pi Homöostase aufrecht zu erhalten. In KO Mäusen war 
die reduzierte renale Exkretion nicht ausreichend um die beeinträchtigte intestinale 
Absorption zu kompensieren. Dies führte zu einer transienten Erniedrigung der 
Plasma Pi Konzentration. Trotz dieser transienten Hypophosphatämie war die 
zirkulierende Konzentration von Vitamin D3, Parathormon (PTH) und  des Fibroblast 
Growth Factorsr 23 (FGF23) vergleichbar mit den Werten der WT Tiere. Jedoch 
erhöhte die LPD in KO Mäusen die renale Ausscheidung von Ca2+, 
Desoxypyridionlin, einem Marker für Osteoklastenaktivität im Knochen, und 
Kortikosteron im Urin und führte zu einer verringerten Knochendichte im Vergleich 
zum WT. Diese Beobachtungen deuten darauf hin, dass KO Mäuse beginnen 
Knochen zu resorbieren um die Konzentration von Pi im Blut aufrecht zu erhalten 
sobald der Pi Gehalt in der Nahrung knapp wird. 
In Experimenten in Ussing-Kammern wurde die parazelluläre Durchlässigkeit für Pi 
sowie Na+ und Cl- in intestinalen Zellkulturmodellen sowie Darmsegmenten von Maus 
und Ratte gemessen. Messungen der Diffusionspotentiale in Zellkultur zeigten, dass 
die Tight Junctions (TJ) durchlässig sind für Pi, wobei monovalentes Pi (H2PO4
-) die 
höhere Permeabilität aufwies als divalentes Pi (HPO4
2-). Dies konnte bestätigt 
werden in Messungen von verschiedenen Darmabschnitten von Ratte und Maus. 
Unsere ex vivo Experimente deuten darauf hin, dass alle Darmabschnitte vom 
Duodenum bis zum Kolon einen parazellulären Weg für Pi aufweisen. 
Intressanterweise war die Permeabilität der TJ für Na+, Cl- und Pi unverändert in 
NaPi-IIb KO Mäusen. 
Zusammengefasst implizieren unsere Beobachtungen, dass der parazelluläre Weg 
ausreicht unter normalen Bedingungen um KO Mäuse (und wahrscheinlich Patienten 
mit NaPi-IIb Mutationen) mit ausreichend Pi zu versorgen. Sobald jedoch der Pi 
Gehalt in der Nahrung limitiert ist, könnte der Pi Gradient nicht genügend sein, um 
die passive Absorption anzutreiben, und die Niere kann nicht mehr für die 
beeinträchtigte Pi Absorption im Darm aufkommen. Daraus erschliesst sich, das die 
Hauptrolle von NaPi-IIb im Darm darin besteht Pi aufzufangen, wenn der Organismus 
mit niedriger Verfügbarkeit von Pi zu kämpfen hat. Knochen dienen als endliche 
alternative Pi Quelle für den Organismus in der Abwesenheit von NaPi-IIb. 
Da Pi in vielen biochemischen Prozessen involviert ist, ist es nicht weiter erstaunlich, 
dass Änderungen im Pi Gehalt der Nahrung nicht nur Konsequenzen für die Pi 
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Homöostase hat, sondern weitreichende systemische Auswirkunen hat. Eine renale 
Trasnkriptomsanalyse von Mäusen adaptiert auf HPD und LPD zeigte, dass 
Slc16a14 (MCT14) stark heraufreguliert ist unter HPD Bedingungen. MCT14 ist ein 
nicht charakterisiertes Mitglied der Familie von Monokarboxylattransportern. Die 
Niere zeigt die höchste Expression von MCT14 mRNA in Mäusen. Ein Antikörper 
wurde entwickelt und dessen Spezifität bestätigt, um mRNA Änderungen auf 
Proteinebene zu untersuchen und MCT14 in der Niere zu lokalisieren. Mit Hilfe 
dieses Antikörpers wurde MCT14 in der luminalen Membrane des dicken 
aufsteigenden Schenkels der Henle'schen Schleife (TAL) der Niere lokalisiert. 
Desweiteren konnte bestätigt werden, dass auch die MCT14 Proteinmenge erhöht 
ist, wie auf mRNA Ebene bei erhöhter Pi Zufuhr über die Nahrung. Um 
Transportsubstrat(e) zu identifizieren wurde MCT14 in Oozyten von Xenopus laevis 
exprimiert, wo der Transporter nachweislich in die Membran integriert wurde. Es 
konnte jedoch kein Transport von Pi oder den klassischen Substraten der SLC16 
Familie gemessen werden. Zusammengefasst ist die Expression von MCT14 
reguliert über den Pi Gehalt der Nahrung und angereichert in der Niere, wo er 
spezifisch im TAL lokalisiert ist. 
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Summary 
Phosphate (Pi) is essential for many metabolic processes, and its levels are 
regulated by integrating intestinal absorption and renal reabsorption. Luminal uptake 
of Pi into epithelial cells of the small intestine and kidney proximal tubule is mediated 
by members of the Na+-dependent Pi transporter families SLC20 (PiT) and SLC34 
(NaPi). 
NaPi-IIb (SLC34A2) accounts for most of the active transport of Pi into intestinal 
epithelial cells. Ablation of NaPi-IIb in mice abolishes Pi uptake into enterocytes but 
leads to only a moderate increase in fecal excretion of Pi, which is compensated by 
higher renal reabsorption. Additionally, patients with mutations in NaPi-IIb develop 
pulmonary alveolar microlithiasis, but no alterations in Pi homeostasis have been 
reported. This suggests another way for Pi absorption, and the paracellular pathway 
might be a crucial mechanism. As long as the luminal Pi concentration is high enough 
to provide a diffusion gradient, intestinal passive absorption seems to be sufficient to 
provide NaPi-IIb deficient mice with Pi under normal dietary conditions. However 
since NaPi-IIb is a high affinity transporter and is regulated by dietary Pi, its role may 
become more important once dietary Pi availability is restricted. In this study we 
aimed to explore the role of NaPi-IIb in intestinal Pi absorption by challenging NaPi-
Iib deficient mice with a low Pi diet, as we hypothesized that under low Pi conditions 
NaPi-IIb would be the predominant transport pathway for Pi. Moreover, we explored 
the regulatory mechanisms that help to compensate for the loss of NaPi-Iib. To this 
end, wild type (WT) and NaPi-IIb deficient mice were challenged with high (HPD) or 
low (LPD) dietary Pi. 
As in WT animals, HPD lead to increased fecal and urinary excretion of Pi in NaPi-IIb 
deficient mice, indicating a high delivery of Pi from the intestinal lumen into the 
circulation even in the absence of transcellular transport. Moreover, fecal Pi was 
higher and urinary Pi lower in knockout than in wild type mice fed HPD, whereas 
hormonal levels and plasma Pi were similar in both genotypes. In contrast, LPD 
decreased fecal and urinary Pi excretion in both genotypes. These compensatory 
changes allowed WT mice to remain normophosphatemic. However, the reduction in 
renal excretion was not sufficient to compensate the impaired intestinal Pi absorption 
in NaPi-IIb depleted animals, and plasma Pi levels declined transiently in these mice. 
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Despite this transient hypophosphatemia, NaPi-IIb deficient mice fed low Pi still 
showed levels of vitamin D3, PTH and FGF23  that were comparable to the values of 
their WT littermates. Instead, upon feeding low Pi, NaPi-IIb deficient animals had 
higher urinary excretion of Ca2+, deoxypyridionline, a marker of osteoclast activity in 
bone, and chorticosterone, and lower bone mineral density than WT mice. These 
data suggests that NaPi-IIb deficient mice start to resorb bone, in order to maintain 
circulating levels of Pi upon dietary Pi restriction. 
We set up Ussing chamber experiments with rodent intestinal segments as well as 
with intestinal cell cultures lines to assess paracellular permeabilities for major cat- 
and anions including Pi. Dilution potential measurements in intestinal cell culture 
models indicated that the tight junction (TJ) is permeable to Pi, with monovalent Pi 
(H2PO4
-) having a higher permeability than divalent Pi (HPO4
2-). These findings could 
be confirmed in measurements in various intestinal segments from rat and mouse. 
Moreover, our ex vivo experiments indicated that all intestinal segments from 
duodenum to colon may have a paracellular pathway for Pi.  Of interest, no 
differences in the permeabilities for Na+, Cl- and Pi of intestinal TJs was observed 
between WT and NaPi-IIb deficient mice.  
Together, our observations suggests that the paracellular pathway is sufficient to 
provide NaPi-IIb deficient animals (and potentially also to patients with mutations in 
NaPi-IIb) with enough Pi as long as dietary Pi is not limited. However, as soon as 
dietary Pi is restricted, the gradient across the intestinal epithelia might not be 
enough to support this function, and the kidney cannot compensate for the impaired 
intestinal absorption in NaPi-IIb depleted mice. Thus, the main role of NaPi-IIb in 
intestine is to scavenge Pi from diet when the organism is challenged with low Pi 
availability. Under conditions, when NaPi-IIb is absent, bone may provide an 
alternative but finite source of Pi for the organism. 
Since Pi is involved in many biochemical processes, it is not surprising that the 
dietary content of Pi does not only alter Pi homeostasis, but has broader systemic 
impact. A renal transcriptome analysis on mice adapted to high or low dietary Pi was 
performed to identify renal and intestinal transcripts regulated by changes in dietary 
Pi intake. Transcriptome analysis revealed that Slc16a14 (MCT14) is strongly 
upregulated upon HPD. MCT14 is an orphan member of the monocarboxylate 
transporter family. In mouse, MCT14 mRNA abundance is highest in kidney. To 
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analyze its tissue distribution and regulation on protein level an antibody was 
developed and validated. Using this antibody, MCT14 was localized to the luminal 
membrane of the thick ascending limb of the loop of Henle (TAL). Further, the 
increased mRNA abundance induced by HPD could be confirmed on protein level. In 
order to identify the transport substrate(s), we expressed MCT14 in Xenopus laevis 
oocytes where MCT14 was integrated into the plasma membrane. However, no 
transport was detected for the classical substrates of the SLC16 family or for Pi. In 
summary, MCT14 is an orphan transporter regulated by phosphate and highly 
enriched in kidney localizing to the luminal membrane of the TAL. 
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Chapter 1 
1. Introduction  
1.1 Inorganic phosphate 
Inorganic Phosphate (Pi) is among the most abundant intracellular anion and 
essential for many biochemical processes. Due to its nature as a titratable acid, it 
acts as a buffer in plasma and urine, where it is present in its monovalent (H2PO4
-) 
and divalent (HPO4
2-) forms under physiological conditions. But beyond buffering Pi 
serves in energy storage and transfer when bound and released from ATP, it builds 
part of the backbone of DNA and RNA, and defines the polarity of phospholipids of 
the cell membrane. Intracellular signaling often involves phosphorylation and 
dephosphorylation of target proteins by kinases and phosphatases, respectively. 
Moreover, in higher organisms Pi is part of the skeleton in form of hydroxyapatite for 
physical support of structure. Hence Pi has a variety of important functions in life and 
its homeostasis is of vital importance, mainly maintained by the coordinated interplay 
of intestinal absorption and renal reabsorption. We ingest between 700 and 1200 mg 
of Pi per day; urinary and fecal excretion reflect ingested and absorbed Pi under 
normal conditions. Pi can be stored in bones complexed with calcium and released 
upon Pi depletion; under normal condition bone resorption and bone formation are in 
balance, with a daily exchange of around 300 mg of Pi. Around 700 g of Pi or 85% of 
total body Pi is stored in bones and teeth, 14% resides intracellularly in soft tissue 
and only 1% of total Pi content is found in the extracellular fluid, of which 15% is 
bound to protein. Serum Pi concentration is maintained between 0.8 to 1.45 mM 
under normal conditions. Since a vast majority of Pi in the body is present as 
hydroxyapatite, it is no surprise that many factors impacting Pi homeostasis 
ultimately alter also calcium balance. 
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The interaction of organs involved in Pi homeostais is coordinated by a complex 
hormonal network and dysregulation of Pi homeostasis has severe adverse effects, 
as hypophosphatemia can lead to skeletal malformation and muscle weakness and 
an excess of Pi is associated with an increased cardiovascular mortality. 
Hyperphosphatemia occurring in patients with chronic kidney disease leads to 
vascular calcification and secondary hyperparathyroidism. 
  
Figure 1: Quantitative Pi balance. The intestine and the kidney are the main organs to (re) absorb and 
maintain Pi balance. Bones serve as an exchangeable pool of Pi. Taken from Hruska et al. (2008) [1]. 
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1.2 Phosphate transport 
1.2.1 Sodium dependent phosphate transporters 
Transepithelial Pi transport is an important component to maintain Pi homeostasis, 
since the small intestine absorbs Pi from the diet and the kidney reabsorbs Pi from 
the glomerular filtrate. Pi transport across the membrane of epithelial cells occurs in a 
secondary active fashion, as Pi has to be imported into cells against its concentration 
gradient. The energy is provided by the Na+ concentration gradient generated by the 
Na+/K+-ATPase located at the basolateral site of epithelial cells [2].The SLC34 family 
of Na+ dependent Pi transporters plays a major role in intestinal uptake and renal 
reabsorption. The family consists of three members NaPi-IIa (SLC34A1), NaPi-IIb 
(SLC34A2) and NaPi-IIc (SLC34A3). Members of the SLC34 family favor transport of 
divalent Pi [3,4]. NaPi-IIa and NaPi-IIb transport three Na+ along with one Pi, which 
leads to a net import of a positive charge, thus their transport is electrogenic [3]. In 
contrast NaPi-IIc translocates only two Na+ with Pi resulting in electroneutral 
transport [5]. Tough only two Na+ are translocated, NaPi-IIc requires the interaction of 
three Na+ to initiate the transport cycle [6]. Pi transport of SLC34 isoforms shows a 
pH dependency, which is not solely explained by the titration of divalent Pi, since 
protons might also compete with Na+ for binding [7]. NaPi-IIa and NaPi-IIc are 
localized to the brush border membrane (BBM) of proximal tubular cells in the kidney, 
where they reabsorb Pi [8,9]. Of interest, in mice NaPi-IIa seems to account for the 
majority of phosphate transport, since ablation of NaPi-IIa leads to severe Pi wasting 
in urine and decreased Pi uptake [10]. Inducible deletion of NaPi-IIc in kidney has no 
impact on urinary Pi excretion in mice [11], whereas in humans genetics 
demonstrated that the contribution of NaPi-IIa and NaPi-IIc appears to be more 
similar [12]. NaPi-IIa and NaPi-IIc are mainly expressed in kidney whereas NaPi-IIb is 
localized to the luminal membrane in the small intestine [13,14] and is also expressed 
in testis, lungs and lactating mammary glands [13]. NaPi-IIa and NaPi-IIc show a 
similar affinity for Pi with an apparent Km <100 µM and around 40 mM for Na
+ at pH 
7.4 [15,16], which is below the range of concentration typically found in the renal 
proximal tubule; therefore they probably transport Pi close to their maximal capacity. 
NaPi-IIb displays a lower affinity for Pi of about 10 µM, which might be due to the 
more acidic environment of the small intestine and the consequently lower availability 
of divalent Pi [16]. The primary structure of the SLC34 transporters ranges from 599 
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to about 689 amino acids, with sequence differences mainly in the C- and N-termini 
[2]. All members are predicted to have twelve transmembrane domains, C- and N-
terminus intracellular and a big extracellular loop between the fourth and fifth 
transmembrane domain [17]. SLC34 members harbor a PDZ binding domain in their 
C-terminus, which is of importance for apical expression and regulatory mechanisms 
[18,19]. The 3D structure for SLC34 members is unknown, but a computational 
approach using the structure of VcINDY (bacterial Na+ dependent dicarboxylate 
transporter) as a template predicted a structure of NaPi-IIa revealing important 
residues for substrate binding, which were experimentally confirmed in Xenopus 
laevis oocytes heterologously expressing the corresponding NaPi-IIa mutants [20,21]. 
The other known Pi transporters, Pit-1 and Pit-2, belong to the SLC20 family. In 
contrast to the SLC34 family they favor monovalent Pi and transport Pi together with 
Na+ in a 1:2 ratio, hence they are electrogenic [22,23]. Up to date they have been 
granted little contribution in transpepithelial Pi transport. They have a much wider 
tissue distribution than the SLC34 isoforms. Pit-1 might play a role in bone Pi 
handling, parathyroid function, as well as in vascular calcification observed in 
hyperphosphatemic conditions. Pit-2 mutations have been identified in patients 
suffering from basal ganglia calcification [24], and knock-out mice show increased Pi 
levels in the cerebral spinal fluid, decreased body length and bone mineral density 
[25]. These observations might suggest an important role of SLC20 isoforms apart 
from intestinal and renal Pi re-/absorption; even though Pit-2 expression was shown 
in the BBM of renal proximal tubules, its exact role in Pi homeostasis needs further 
investigation.  
 
Table 1: Na
+
-dependent Pi transporters of the SLC34 and SLC20 families 
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Apical entry of Pi into epithelial cells of kidney and intestine has been studied 
extensively, but only little is known about the basolateral efflux mechanism in those 
cells. It has been reported that xenotropic and polytropic virus receptor XPR1 can 
mediate the efflux of Pi in cultured cells [26]. Transport studies in Xenopus laevis 
oocytes failed to proof Pi efflux activity mediated by XPR1, including our own 
unpublished observation. Nevertheless, XPR1 seems to be one of the few proteins in 
mammals that contains the SPX domain, which is a domain shared by many proteins 
involved in plant and fungal Pi sensing and transport. XPR1 shares sequence 
homologies with the plant phosphate PHO1 and the yeast SYG1. Both proteins seem 
to be involved in phosphate transport or sensing. Recently, it was reported that the 
SPX domain might offer a binding site for inositol poly phosphate [27], the 
concentration of which change upon Pi availability. The authors suggest that this 
inositol poly phosphate concentration might be part of the Pi sensing mechanism, to 
trigger response to Pi starvation [27]. Indeed a protein named Pi uptake stimulator 
(PiUS) identified in uptake experiments performed in Xenopus laevis oocytes turned 
out to be a hexakisphosphate kinase [28], able to convert inositol-6-phosphate into 
inositol-7-phosphate. This might suggest that XPR1 has a role in Pi sensing, and that 
the observed mediation of Pi efflux in cell culture could be through regulatory or 
accessory action of XPR1. Inducible renal specific ablation of Xpr1 in mice leads to 
hypophosphatemia accompanied hyperphosphaturia and impaired bone 
mineralization [29]. Pi efflux in isolated proximal tubular cells is impaired upon Xpr1 
deletion. Despite this Pi related effects, those mice excrete massive amounts of 
glucose, amino acids and albumin [29] indicating severe renal damage. This severe 
phenotype might suggest that Xpr1 might be involved in more than just the 
suggested Pi efflux. 
1.2.2 Intestinal Pi absorption 
Dietary Pi is mainly absorbed in the small intestine with a possible contribution of the 
colon. Though experiments using radiolabeled Pi [30] or enemas with very high Pi 
concentrations [31] highlight that the colon has the ability to absorb Pi, the 
physiological relevance of this transport remains elusive, since many studies point 
out the higher absorptive capacity for Pi in the small intestine. Additionally, solidity of 
colon content might make Pi less available for absorption in the large intestine. 
Several studies propose two different mechanisms by which Pi is absorbed in the 
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intestine: passive diffusion along the paracellular route and secondary active 
transport across the apical membrane of intestinal cells. Early reports indicated that 
an intragastric bolus of Pi in rats increased plasma Pi levels linearly with increasing 
Pi concentration of the bolus [32], indicating a passive diffusion mechanism since no 
saturation was observed. However everted gut sac experiments showed Na+ 
dependency of Pi transport in rachitic chick ileum [33]. Further experiments in Ussing 
chambers, using rat jejunum, suggested a two component transport, with a linear 
relationship of transport at luminal Pi concentrations above 1 mM, whereas below 1 
mM Pi transport appeared more complex and an active transport system seemed 
more likely, since a passive system alone would cause a Pi flux from blood to the 
intestinal lumen following the chemical gradient [34]. These observations were 
confirmed in intestinal transport studies in humans [35,36], confirming the existence 
of both transport mechanisms for Pi in the gastrointestinal tract. Since then the active 
transcellular transport was extensively studied and cloning of NaPi-IIb [13] revealed 
at least a part of the molecular mechanism behind. 
Transcellular Pi transport in mice occurs mostly in ileum. In contrast rats show higher 
transport in duodenum and jejunum, which seems also to be the case for humans 
[14,37]. This difference in Pi transport between rats and mice is also reflected in the 
expression pattern of NaPi-IIb, since NaPi-IIb is expressed in enterocytes of the 
corresponding segments (Figure 2) [14]. The transporter is expressed along the 
whole intestinal villi, whereas no expression is observed in crypt cells [38]. NaPi-IIb 
appears to be the major transporter for Pi in the small intestine with possible (but 
untested) contribution of Pit-1 and Pit-2 [39]. Though both Pit-transporters have been 
detected in BBM preparations of small intestine [37,40], their subcellular distribution 
has not been fully characterized by immunohistochemistry; Pit-1 mRNA has been 
localized throughout the whole epithelum including crypts in intestine [41]. The 
relative contribution of Pit-1 and Pit-2 in intestinal Pi transport remains elusive, but 
knock out animal models suggest a dominant role of NaPi-IIb in intestinal Na+/Pi 
cotransport [42,43]. Constitutive deletion of NaPi-IIb has proven to be embryonically 
lethal, likely due to impaired Pi absorption from the maternal circulation [42]. In 
humans mutations in NaPi-IIb manifest with pulmonary and testicular microlithiasis, 
deposits of Pi and calcium in lungs, but no changes in serum Pi levels are observed 
[44]. No information about any possible compensatory mechanism or hormonal 
changes in these patients is available. These data indicate that there is another 
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transport mechanism, most likely passive diffusion across the paracellular route, 
which provides patients and NaPi-IIb deficient mice sufficiently with Pi. The 
abundance of NaPi-IIb in intestine is regulated by several factors like glucocorticoids 
[45] and estrogen, but the two major stimulators are vitamin D3 and low dietary Pi 
content [46]. Animals fed a low Pi diet show increased uptake of Pi into intestinal 
BBMV and NaPi-IIb protein abundance compared to animals fed high Pi diet [38]. 
Similar effects were observed in animals injected with vitamin D3 [47]. Co-
immunoprecipitation and Förster resonance energy transfer (FRET) experiments 
show a physical interaction between NaPi-IIb and NHERF1, likely through the PDZ 
domain in the C-terminal tail of NaPi-IIb [48]. Adaptation of NaPi-IIb to dietary Pi was 
impaired in NHERF1 deficient mice [48], suggesting an important role of NHERF1 in 
the regulation of NaPi-IIb in a similar fashion to NaPi-IIa in kidney (see 1.2.3) [49]. Up 
to date no other major Pi transporter in the intestine is known, though there are 
reports for a pH dependent mechanism in goat duodenum, where NaPi-IIb is absent 
[50], and in the intestinal Caco2BBE cell line [51], but the molecular mechanism 
behind remains elusive. 
 
Figure 2: a) Representation of intestinal Pi transport mechanisms mediated by NaPi-IIb which is 
driven by the basolateral Na
+
/K
+
-ATPase. Mechanisms for Pi export or paracellular diffusion remain to 
be identified. The subcellular localization of Pit-1/2 has not been determined. Adapted from Forster Ian 
unpublished. b) NaPi-IIb expression in enterocytes in WT and NaPi-IIb deficient mice. Adapted from 
Sabbagh et al. (2009) [52] 
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Compared to transcellular transport of Pi, only little is known about paracellular Pi 
fluxes across the intestinal epithelium. Passive diffusion through the tight junctions 
requires a chemical gradient for Pi from the lumen of the intestine to the blood. It has 
been reported that under normal dietary conditions luminal Pi concentrations exceed 
the levels in serum [53] consistent with our own observation, providing a gradient for 
passive absorption of Pi across the intestinal epithelium. Epithelia form physical and 
chemical barriers between two body cavities and tight junctions seal the space 
between adjacent cells, by interaction of junctional proteins from each neighboring 
cell, preventing free passage of ions, other molecules, and cells [54]. Thus passive 
diffusion along the paracellular pathway requires the presence of pore forming 
complexes in the tight junction, which are rather substrate specific and help to 
maintain barrier function of the epithelium. The claudins are a family of tight junction 
proteins, which form strands along the tight junction that interact with the strands of 
claudins of adjacent cells and contribute to transepithelial resistance [55-57]. Freeze 
fracture images indicated that increasing the number of tight junction strands 
correlates with increasing transepithelial resistance and paracellular transport [54,58]. 
Diffusion potential measurements and flux studies suggested that the conductance of 
tight junctions is charge and size selective [59,60]. Claudin-2 was then the first 
claudin to be identified as a paracellular cation channel (Figure 3) [61]. Nowadays, 
there are 27 claudin genes, though not all of them are expressed in every species, 
where some have barrier and some conductive properties [54]. Several of them have 
been characterized as anion or cation selective, but up to date there has been no 
association of a particular claudin with Pi permeability across epithelia; furthermore 
whether claudins participate in Pi uptake in the intestine is still to be determined. 
However, the linear correlation between Pi fluxes and luminal Pi concentrations at 
high luminal Pi [32,35], strongly indicates a paracellular contribution. Additionally the 
relatively mild phenotype in mice with deletion of NaPi-IIb, despite the absence of 
transport of Pi into ileal BBMV [43] supports this hypothesis. One might also consider 
the reduction of NaPi-IIb expression and the lower uptakes observed in animals fed a 
high Pi diet [47]. Moreover, one may take also into account that NaPi-IIb might be 
already saturated at normal dietary conditions with the given luminal Pi concentration 
[53]. Still there is a higher delivery of Pi from the intestine, despite lower NaPi-IIb, 
possibly driven by the higher chemical gradient provided by the diet, since those mice 
excrete much higher levels of Pi in urine. In the study presented here, we attempt to 
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get a better understanding of overall mechanisms of intestinal Pi absorption with the 
possible contribution of the paracellular pathway. 
 
Figure 3: a) Schematic representation of tight junction strands connecting two adjacent cells and a 
corresponding freeze fracture electron microscopy picture of microvilli and the tight junction strands 
beneath. b) Intracellular space between two adjacent cells. In each membrane are shown two claudins 
interacting in trans, and the cis interaction between claudins of neighboring cells, which are thought to 
represent the strands observed in the freeze fracture image. The interacting claudins form a selective 
pore for the paracellular pathway, in which selectivity depends on the expressed claudin. Modified 
from Zihni et al. (2016) [62]. 
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1.2.3 Renal phosphate reabsorption 
The glomerulus in the kidney freely filters Pi, and consecutive nephron segments 
reabsorb Pi form the primary filtrate to prevent its loss. Approximately 90% of the 
filtered Pi is reabsorbed [63]. The proximal tubule is the main segment involved in 
renal Pi reabsorption, and the contribution of later segments to overall Pi 
reabsorption is not entirely clear [64,65]. Under normal conditions the initial proximal 
tubule (S1) is the segment contributing the most to Pi reabsorption, reflecting the 
expression of NaPi-IIa, NaPi-IIc and Pit-2 (Figure 4) [9,66,67]. The amount of Pi 
excreted in the urine is proportional to the amount of Na+/Pi cotransporters expressed 
in the BBM of the proximal tubule [63]. Under dietary Pi restriction the abundance of 
NaPi-IIa, NaPi-IIc and Pit-2 is enhanced and expression of NaPi-IIa extends to S2 
and S3 segments of the proximal tubule [68], resulting in reduced Pi excretion in 
urine. Different time courses in adaptation to low dietary Pi for the three transporters 
are observed, where NaPi-IIa regulation appears to be the fastest [69]. There are 
several factors involved in modulating Pi excretion, the most prominent phosphaturic 
hormones are parathyroid hormone (PTH) [70] and fibroblast growth factor 23 
(FGF23) [71], that act by decreasing the amount of Na+/Pi cotransporters expressed 
in the kidney. As already discussed, NaPi-IIa has a major role in renal Pi handling, 
and its expression and hormonal regulation seems to depend on the interaction with 
NHERF1 (NHE3 regulatory factor 1) through its C-terminal PDZ-binding domain 
[72,73]. Physical interaction between the two proteins is important for stable retention 
of NaPi-IIa in the BBM [74]. NHERF1 indirectly associates with actin [75], and 
thereby anchors NaPi-IIa in the membrane. Phosphaturic factors as PTH [76,77] and 
FGF23 [71,78] lead to a phosphorylation at the interaction domain of NHERF1 and 
hence reduce binding to NaPi-IIa, further leading to the retraction of NaPi-IIa from the 
membrane and targeting to lysosomes for degradation [79]. Additionally, deletion of 
Nherf1 in mice results in lower NaPi-IIa abundance and hyperphoshaturia [49]. 
Mutations of NHERF1 in humans have been reported to cause hypophosphatemia 
supporting the findings in mice [80]. Similarly, the ablation of Nherf3 (Pdzk1) in mice 
impairs the regulation of NaPi-IIc, though a direct physical interaction has not been 
demonstrated. Nherf3 ablation has no effect on NaPi-IIa or renal Pi excretion [81]. 
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Figure 4: a) Renal distribution of Na
+
-dependent Pi transporters. b) Representation of Na
+
-dependent 
Pi transport across a proximal tubular cell. NaPi-IIa and NaPI-IIc are expressed apically and favor 
transport of divalent Pi, whereas Pit-2, also expressed in the apical membrane, prefers monovalent Pi. 
Transport is energized by the basolateral Na
+
/K
+
-ATPase. Basolateral efflux mechanism remains to be 
identified. c) Immunofluorescence staining of NaPi-IIa, NaPi-IIc and Pit-2 in the apical membrane of a 
cell in S1 of proximal tubules, where transporters are shown in green, red represents β-actin 
(phalloidin) and blue represents nuclear (DAPI) staining. Adapted from Biber et al. (2013) [2]. 
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1.3 Hormonal Regulation 
The total amount of Pi transporters in BBM of intestine and kidney are tightly 
regulated by a hormonal network including PTH, FGF23, and vitamin D3. Vitamin D3 
increases Pi absorption in the gut, whereas PTH and FGF23 both act as 
phosphaturic factors to decrease plasma levels of Pi (Figure 5). Furthermore, vitamin 
D3 and PTH are major regulators of Ca
2+ homeostasis, where both hormones 
promote an increase in circulating Ca2+. These hormones do not only exert effects on 
Pi and Ca2+ transport but also regulate each other in a cross talk between organs. 
 
Figure 5: Pi homeostasis is maintained by intestinal absorption, renal reabsorption and bone 
formation/reabsorption. Vitamin D3 stimulates intestinal absorption and the expression of FGF23, 
whereas PTH synthesis is inhibited. PTH inhibits renal reabsorption and promotes vitamin D3 and 
FGF23 production. FGF23 suppresses renal reabsorption as well as PTH and vitamin D3 synthesis. 
Modified from Bergwitz et al. (2010) [82]. 
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1.3.1 Vitamin D3 
The production and activation of vitamin D3 involves several organs starting in the 
skin, where 7-dehydrocholesterol and ergosterol are converted into cholecalciferol 
due to the exposure to ultraviolet light. Cholecalciferol is then hydroxylated by 
CYP2R1 in liver to 25-hydroxycholecalciferol [83,84], which upon another 
hydroxylation in the renal proximal tubule by the 1α-hydroxylase (CYP27B1) is turned 
into the active form 1,25-dihydroxycholecalciferol [85]. Another enzyme in the 
proximal tubule CYP24A1 is responsible for the inactivation of vitamin D3 through 24-
hydroxylation [86,87]. The 1α-hydroxylase is induced by hypophosphatemia, 
hypocalcemia and PTH [82], hence these conditions enhance vitamin D3 production. 
FGF23 and vitamin D3 itself increase the expression of renal CYP24A1 to inactivate 
vitamin D3 [88]. 
Vitamin D3 acts on target organs by binding the vitamin D receptor (VDR). VDR is a 
cytosolic protein and acts as a nuclear receptor. Upon binding its ligand, VDR 
dimerizes with retinoid-X-receptor [89,90], translocates to the nucleus and modulates 
expression of genes with a VDR responsive element [91], though there have been 
also non-transcriptional effects reported [92]. VDR deficient mice show low levels of 
serum Pi and FGF23, impaired bone formation, and have a shorter life span [93].  
In the intestine vitamin D3 induces the expression of the TRPV6 (transient receptor 
potential cation channel subfamily V member 6) Ca2+ channel and the plasma 
membrane Ca2+-ATPase leading to increased Ca2+ absorption [94]. In addition, the 
renal expression of TRPV5 and calbindin-D28K is enhanced and thereby renal Ca
2+ 
reabsorption also increases [95]. In enterocytes vitamin D3 also enhances the RNA 
and protein expression of NaPi-IIb [38] and Pit-2 [96]. Consistently, VDR knock out 
mice show a decreased amount of NaPi-IIb mRNA and develop hypophosphatemia 
and hypocalcemia [97] similar to the phenotype of Cyp27b1 knock out mice [98]. In 
contrast animals injected with vitamin D3 had no increase in NaPi-IIb mRNA but 
protein abundance of the cotransporter was upregulated [38], indicating that there 
are also transcription independent effects. In addition to vitamin D3, a major 
stimulator of intestinal Pi transport is dietary Pi depletion that was initially assumed to 
act through vitamin D3 to enhance transcription of NaPi-IIb. However when VDR 
knock out animals were challenged with a low Pi diet, intestinal abundance of NaPi-
IIb was increased as in the wild type animals, suggesting that dietary restriction can 
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induce NaPi-IIb independently of vitamin D3 [47]. In bone, vitamin D3 stimulates 
osteoclasts [99], in order to increase bone resorption and hence promotes the 
release of Pi and Ca2+. In osteoblasts and osteocytes vitamin D3 enhances the 
production and release of FGF23. The promotor region of FGF23 harbors a vitamin 
D3 responsive element [100], and as indicated above VDR deficient mice have 
hypophosphatemia, hyperparathyroidism, and low levels of plasma FGF23. A high Pi 
and Ca2+ diet corrects these alterations, suggesting that Pi can regulate FGF23 in a 
vitamin D3 independent manner. Activation of VDR in the parathyroid gland 
suppresses the transcription of PTH-gene harboring an VDR-responsive element 
[101]. 
1.3.2 Parathyroid hormone 
PTH is synthesized as a prepro-peptide consisting of a 25-amino acid signal 
sequence, a 6-amino acid prosequence and a 84-amino acid sequence exerting the 
hormonal activity. The signal- and prosequence are cleaved in the endoplasmic 
reticulum and Golgi, and the active (1-84) PTH is stored in secretory vesicles [82]. 
The release of PTH is stimulated by low serum Ca2+ and high Pi. Plasma levels of 
Ca2+ are sensed by the parathyroid glands through the calcium sensing receptor 
(CaSR). The CaSR is G-protein coupled receptor; upon binding of Ca2+ to the 
receptor, Gq associated phospholipase C catalyzes the hydrolysis of PIP2 into IP3 and 
diacylglycerol (DAG) [102]. IP3 leads to a release of Ca
2+ from the endoplasmic 
reticulum to activate Ca2+-sensitive proteases to cleave PTH in secretory vesicles 
and inactivate it [82]. High intracellular Ca2+ as well as DAG-activated PKC also 
inhibits PTH expression and release. On the contrary, inactivation of the CaSR in 
situations of low plasma Ca2+ stimulates the synthesis and release of PTH [103]. 
Hyperphosphatemia is also a strong stimulator for PTH synthesis and secretion; 
though the mechanism by which Pi levels are sensed by the parathyroid gland are 
not known, high Pi leads to increased PTH mRNA stability, through protein binding at 
the 3’-UTR [104]. Hyperphosphatemia induces PTH independent of Ca2+, since cell 
culture experiments showed and increased secretion of PTH despite high levels of 
Ca2+ [105]. Oral application of Pi in humans leads to an increase of circulating PTH 
after 45 minutes [106], similarly rats show an increase in PTH after intravenous and 
intragastric Pi administration [107]. Intravenous administration led to a massive 
phosphaturia and a drop in serum Ca2+ within 10 minutes, whereas intragastric Pi 
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application caused a delayed phosphaturia without altering Ca2+. Phosphaturia was 
blunted in parathyroidectomized rats, which show a higher creatinine clearance 
without alteration of renal Pi transporter expression. 
PTH exerts its effect on target cells through the PTH-receptor (PTHR1). PTHR1 is a 
G-protein coupled receptor that activates PKC signaling by coupling to Gq and PKA 
signaling by coupling to Gs and therefore cAMP production by adenylyl cyclases; both 
pathways were shown to activate MAPK signaling. In renal proximal tubules PTH 
reduces the membrane abundance of NaPi-IIa, NaPi-IIc and Pit-2 and thereby 
promotes phosphaturia [9,108]. PTHR1 is expressed on apical and basolateral sites 
of these cells, where apical binding of PTH is associated with Gq-signaling and 
basolateral with Gs and consequently PKA signaling [109].  
Inhibition of either PKA or PKC dependent action suggests both to be involved in the 
regulation of renal Pi transport [109]. PKA phosphorylates NHERF1 in the PDZ 
domain that interacts with the PDZ-binding domain of NaPi-IIa, lowering the 
interaction affinity. As already indicated (1.2.3) the reduced binding to NHERF1 
allows NaPi-IIa to be retrieved from the membrane and consecutively to be routed for  
lysosomal degradation [76,77]. Mice expressing a PTHR1 deficient in Gq-dependent 
activation of PKC do not develop hypophosphatemia when hyperparathyroidism is 
induced by Ca2+ free diet [110]. This suggests that PTH induced phosphaturia is at 
least partially dependent on Gq and PKC signaling. The mechanism behind PTH 
induced downregulation of NaPi-IIc and Pit-2 remains elusive, but NaPi-IIc seems to 
undergo degradation in a different compartment than NaPi-IIa (i.e. lysosomes) upon 
PTH signaling. 
PTH also enhances Ca2+ reabsorption in the distal convoluted tubule in the kidney, 
by stimulating the transport activity of TRPV5 as well as the expression of calbindin 
D28K and the Na
+/Ca2+-exchanger NCX [111]. Additionally it increases expression of 
CYP27B1, resulting in an increased production of active vitamin D3 [112], in order to 
stimulate intestinal absorption of Ca2+. 
In bone, PTH induces resorption mediated by osteoclasts. This activation is indirect, 
since osteoclasts do not express PTHR1. Continuous administration of PTH results in 
reduced expression of osteoprotegrin a member of the TNF-receptor family and 
increased abundance of RANKL (itself a TNF ligand). These changes trigger 
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osteoclast precursors to mature and resorb bone [113]. Additionally PTH increases 
the expression of FGF23 in osteoblasts and osteocytes. The increased expression of 
FGF23 seems to be dependent on PKA activity upon PTHR1 activation, which 
promotes FGF23 mRNA synthesis possibly through the transcription factor Nurr1 
[114]. Consequently FGF23 concentration is reduced after parathyroidectomy [115]. 
PTH ablation in mice leads to a renal loss of Ca2+, high Pi levels due to Pi retention, 
decreased circulating vitamin D3 and FGF23 concentrations and abnormal bone 
formation [82,116,117]. 
1.3.3 FGF23 
The fibroblast growth factors are a family of 22 peptides involved among other 
processes in organogenesis, development, and wound healing. Most FGFs have a 
heparin binding domain with high affinity for heparan sulfates, which is critical for their 
receptor binding and signaling function [118]. The binding to heparan sulfate in the 
extracellular matrix restricts FGF action locally, thus most of them act in a paracrine 
and autocrine fashion [119]. However the FGF19 subfamily lacks the domain for 
heparan sulfate binding, facilitating their release and enables them to act as 
endocrine factors [120]. FGFs act through FGF receptors (FGFR1-4), which consist 
of three extracellular immunoglobulin like domains, a transmembrane domain and an 
intracellular tyrosine kinase [118,120]. Heparan sulfate is essential for formation of 
the FGF-FGFR complex [119]; the lack of the heparin binding domain in endocrine 
FGFs is compensated by Klotho as a cofactor to bind the receptor [121]. The Klotho 
family of single transmembrane domain proteins consists of three members α, β and 
γKlotho. FGFRs dimerize upon binding of FGFs, followed by an autophosphorylation. 
FGF23 belongs to the endocrine FGFs, it binds to FGFR1, 3 and 4 in complex with 
αKlotho [122]. Though recently it has been shown that FGF23 can induce cardiac 
hypertrophy through FGFR4 in absence of αKlotho [123]. FGF23 is a 251 amino acid 
glycoprotein [124] and is mainly expressed in osteoblasts [125] and osteocytes [126] 
in bone, tough expression in other tissues like heart, parathyroid gland, small 
intestine, thymus and brain [118,127]. FGF23 expression has also been detected in 
renal cysts in a mouse model for polycystic kidney disease (PKD1) [128], and 
elevated FGF23 levels is a common feature in patients suffering from CKD. The 
protein consists of an N-terminal hydrophobic signaling sequence, an N-terminal 
FGF-like domain and a C-terminal sequence containing binding sites for the FGFR 
26 
 
(Figure 6) [118]. The N- and C-terminal domains are separated by a proteolytic 
cleavage site (RXXR) [129]. Proteolytic cleavage leads to inactivation of FGF23 
[130], and the C-terminal fragment probably competes for binding to the receptor with 
the intact FGF23, potentially further decreasing the action of FGF23 [131]. There are 
four O-glycosylation sites around the RXXR site [118,127], and glycosylation through 
the N-acetylgalactos aminyltransferase 3 (GALNT3) prevents cleavage at the RXXR 
site [132]. Consequently Galnt3 deficient mice have lower levels of circulating 
FGF23, even though FGF23 gene expression is dramatically increased. The 
production of FGF23 is stimulated by high serum levels of Pi, vitamin D3 and PTH 
[133,134]. There is also evidence that Ca2+ might reduce FGF23 levels [135]. 
Additionally in vitro experiments using HEK293 cells showed an increased 
expression when stimulated with high concentrations of Pi [136]. The increase in 
GALNT3 might just match increased expression of FGF23 or further stabilize 
circulating FGF23 levels. 
 
Figure 6: Structure of the full length intact fibroblast growth factor 23 (framed in red) after removal of 
the N-terminal signal peptide. The RXXR motive between position 
176
R and 
179
R is the site for 
proteolytic cleavage and inactivation of FGF23. 
178
T represents one of the glycosylation sites, which 
prevent FGF23 from being cleaved upon glycosylation. Modified from Razzaque et al. (2007) [137]. 
 
In kidney FGF23 inhibits Pi reabsorption as well as vitamin D3 synthesis. The effect 
on renal Pi transport is likely to be mediated by FGFR1, since administration of 
FGF23 to FGFR3 and FGFR4 ablated mice leads to a reduction of serum Pi levels, 
whereas in FGFR1 deficient mice the FGF23-dependent serum Pi decline is absent 
[138]. Receptor binding increases extracellular signaling regulated kinase (ERK1/2) 
phosphorylation, which phosphorylates the SGK1 [71]. SGK1 acts on the same 
phosphorylation site in the PDZ domain of NHERF1 which is targeted by PTH 
signaling (see 1.3.2) [71,76,78]. Consequently, NaPi-IIa is internalized and targeted 
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for lysosomal degradation. This effect is absent in Klotho deficient mice and similarly 
in mice with FGF23 ablation [71] these mice have hyperphosphatemia, high levels of 
vitamin D3 and suffer from tissue calcification, highlighting the importance of Klotho in 
FGF23 function. Furthermore, FGF23 reduces plasma vitamin D3 levels, since it 
decreases the expression of CYP27B1 and upregulates mRNA and protein 
abundance of CYP24A1 in a MAPK dependent fashion [139,140]. Inhibition of the 
MAPK pathway blunts this effect [141]. It was also reported that FGF23 leads to a 
downregulation of intestinal NaPi-IIb [142], but this might be a secondary effect due 
to decreased plasma vitamin D3 levels. There is also evidence that FGF23 stimulates 
Ca2+ reabsorption in the kidney through activation of TRPV5 in the distal convoluted 
tubule [143]. 
Parathyroid glands are equipped with FGFR1 and 3 as well as with Klotho [144]; 
administration of FGF23 was shown to downregulate PTH mRNA levels in 
parathyroid glands and decreases serum PTH [144]. The effect of FGF23 is ERK1/2 
dependent, since its inhibition prevents the effect of FGF23 on PTH [144].  
Furthermore FGF23 increases expression of CaSR and VDR, sensitizing the 
parathyroid gland for PTH repressive signals [145]. 
1.3.4 Glucocorticoids 
Glucocorticoids (GCs) are steroid hormones synthetized by the cortex of the adrenal 
gland from cholesterol. Their effects are mediated by a cytoplasmic receptor, which 
once it is bound to its ligand translocates to the nucleus and regulates the expression 
of target genes containing GC-response elements. While cortisol is the main GC in 
humans, corticosterone (17-deoxycortisol) is the main counterpart in several other 
species including rodents. 
Although their role is not entirely clear, there is evidence that GCs alter Pi 
homeostasis. GCs administration to several experimental animals models lowered 
serum levels of Pi and induced phosphaturia [146-149]. The site of action was 
assumed to be in the renal proximal tubule, where GC receptors are expressed. 
Indeed the GC dexamethasone decreased Na+-dependent uptake of Pi into renal 
BBMV in rats [150] and reduced NaPi-IIa mRNA and protein abundance [151]. 
Further it has been demonstrated that GC administration also results in a 
downregulation of intestinal NaPi-IIb mRNA and protein [152]. However, the 
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molecular mechanisms by which GC modulate Na+-dependent Pi cotransporters has 
not been resolved yet. 
GCs also alter bone remodeling through an increase in bone resorption and 
decreased bone formation [153,154]. Long term treatment with GCs has been shown 
to decrease bone mineral density and induces osteoporosis [155,156]. Osteoblast 
specific ablation of the GC receptor in mice prevents these effects [157], indicating 
that GCs directly act on osteoblasts to inhibit bone formation. Additionally, GCs inhibit 
differentiation and induce apoptosis of osteoblasts and osteocytes [158,159], further 
decreasing bone formation rate. GCs also increase osteoclast number through 
RANKL-RANK and osteoprotegrin dependent differentiation (see 1.3.2), resulting in 
an increase in bone resorption [160,161]. Ca2+ absorption is also decreased by GCs  
whereas renal excretion is increased [162], indirectly modulating other factor acting 
on Ca2+ homeostasis and thereby bone resorption/formation. Possible bone mediated 
effects on Pi homeostasis through GCs still need to be determined. 
 
Table 2: Hormonal effect on Pi and Ca
2+
 homeostasis and regulatory feedback 
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1.4 Hereditary phosphate disorders 
As indicated above, Pi homeostasis is maintained through a complex system of 
hormones that coordinate the expression of renal and intestinal Na+/Pi-transporters. 
A defect in any of the mediators of Pi balance can have large systemic effects. There 
are several pathological states, where patients suffer from hyperphosphaturia often 
accompanied by impaired skeletal integrity and hereditary hypophosphatemic rickets 
[163]. Pi depletion is not always reflected in plasma Pi concentrations, since only a 
minority of total body Pi is present in extracellular fluid [164]. Major causes of renal Pi 
wasting are mutations impairing Pi transporters or their regulators. Several mutations 
have been identified within the SLC34A1 (NaPi-IIa) gene that result in different 
clinical outcomes. The first report identified heterozygous mutations in 
hypophosphatemic patients suffering from nephrolithiasis and osteoporosis [165]. 
Although co-injection of Xenopus laevis oocytes with wild type and mutant NaPi-IIa 
cRNA indicated altered function of the mutant [165], these findings could not be 
confirmed independently [166]. A homozygous in-frame duplication of 21 base pairs 
was later identified in two siblings, suffering from Fanconi syndrome [167]. Fanconi 
syndrome is characterized by renal wasting of metabolites including severe 
hyperphosphaturia. Renal Pi wasting resulted in hypophosphatemic rickets and 
stunted growth. The siblings had elevated levels of vitamin D3 [168], normal PTH and 
hypercalciuria. High vitamin D3 might be the cause of hypercalciuria, by increasing 
intestinal Ca2+ absorption. Since the siblings also suffered from hypophosphatemic 
rickets, decreased bone formation might increase the hypercalciuria. In vitro studies 
confirmed the dysfunction of mutated NaPi-IIa. Several additional studies reported 
homozygous mutations of NaPi-IIa in infants with idiopathic hypercalcemia and 
nephrocalcinosis [169,170]. In these patients, high vitamin D3 levels triggered by 
hypophosphatemia are suspected to lead to kidney stones. In most cases, the 
mutation impairs the trafficking and/or stability of the transporter in the apical 
membrane.  Interestingly hereditary hypophosphatemic rickets with hypercalciuria 
(HHRH) is caused by several mutations in the SLC34A3 (NaPi-IIc) gene [171,172], 
which was rather surprising since animal models suggested a minimal role of NaPi-IIc 
in renal reabsorption [10,11]. HHRH is characterized by reduced renal Pi absorption, 
hence hypophosphatemia, elevated vitamin D3, causing a suppression of PTH, 
leading to increased Ca2+ absorption and renal excretion [163]. Patients suffer from 
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rickets, short growth, bone pain and muscle weakness.  Commonly patients also 
develop tubular calcification due to high urinary excretion of Pi and Ca2+. Mutations in 
SLC34A2 (NaPi-IIb) are considered as the main cause of pulmonary alveolar 
microlithiasis (PAM) and probably also of testicular microlithiasis [44]. In the lung, 
NaPi-IIb is expressed in the apical membrane of type II alveolar cells [173]; these are 
the cells responsible for the production of surfactant, which is rich in phospholipids 
particularly dipalmitoylphosphatidylcholine.  In contrast to other epithelia, alveolar 
NaPi-IIb has been proposed to mediate the extrusion of intracellular Pi produced by 
the metabolism of phospholipids. Therefore, its absence it expected to result in 
intracellular accumulation of Pi, that would favor the formation of mineral deposits (Pi 
complex with Ca2+) in the airways. However, in the few cases for which data is 
available, mutations in NaPi-IIb do not alter the plasma levels of Pi. This is in 
agreement with data obtained with NaPi-IIb deficient mice, in which the lack of the 
transporter in the intestine is compensated by the kidney. 
Autosomal dominant hypophosphatemic rickets is a disorder caused by a mutation 
affecting one of the arginine residues in the RXXR motive in FGF23 [174], resulting in 
a cleavage resistant hormone. Degradation-resistant FGF23 decreases renal Pi 
absorption and vitamin D3 synthesis. Thus patients develop hypophosphatemia along 
with rickets. X-linked dominant hypophophatemic rickets and autosomal recessive 
hypophosphatemic rickets are also due to inappropriately high levels of FGF23, 
caused by mutations in either the PHEX [175] or DMP-1 genes, respectively [176]. In 
vitro studies suggest that both genes are involved in the regulation of FGF23 in bone, 
but the exact mechanism behind is not fully resolved. Mouse models deficient for 
Phex [177,178] and Dmp-1 [176] replicate the phenotype associated with increased 
FGF23 expression, and show increased renal Pi excretion and impaired bone 
mineralization. Double ablation of Dmp-1 and Phex has no additive effect and the 
common phenotype of both models suggests that FGF23 regulation by both proteins 
involves the same pathway [179], whereas the function of Dmp-1 appears Phex 
dependent [180]. 
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1.5 Monocarboxylate transporters 
1.5.1 The monocarboxylate transporter family 
The SLC16 gene family of solute carriers consists of 14 members (see Figure 7). The 
first four members (MCT1-4) were characterized as transporters for 
mononcarboxylates such as lactate, pyruvate, and ketone bodies in a H+-dependent 
manner, leading to name the family as MCTs (monocarboxylate transporter) [181]. 
MCT7 is the only other member to be associated with transport of monocarboxylates 
in a H+-dependent manner [182]. Characterization of other members of the MCT 
family revealed that the substrate spectrum exceeds monocarboxylates, thus, the 
name might be misleading. MCT8 was characterized as a transporter for the thyroid 
hormones triiodothyronine and tetraiodothyronine [183,184]. MCT10 was identified as 
a transporter for aromatic amino acids and is also known as TAT1 (T-type amino acid 
transporter 1) [185]. It shares the highest sequence homology with MCT8 and it also 
has the capacity to transport thyroid hormones. MCT12 is associated with juvenile 
cataract and has recently been identified as creatine transporter [186]. MCT9 is 
associated with elevated carnitine levels and subsequent transport studies confirmed 
transport [187]. The other members of the family remain orphans. Tough they do not 
share substrates, all MCTs are predicted to contain twelve transmembrane domains 
with intracellular N- and C-termini as well as a big intracellular loop between 
transmembrane domain six and seven [181]. Proteolytic cleavage experiments of 
MCT1 in red blood cells confirmed the predicted topology, since the intracellular N- 
and C-termini as well as the intracellular loop were not accessible for proteolytic 
cleavage in intact blood cells but in leaky ghosts [188].  
1.5.2 Classical monocarboxylate transporters 
MCT1 is expressed in tissues relying on oxidative phosphorylation like heart, 
providing those cells with lactate as respiratory fuel [181,189]. In liver it provides 
lactate to perform gluconeogenesis or lipogenesis [190]. In contrast MCT4 is 
expressed in glycolytic tissues to export the lactate produced during glycolysis [191].  
MCT1, 3 and 4 interact with CD147 (basignin), an immunoglobulin-like protein that 
acts as an accessory protein to increase MCT abundance in the membrane 
[192,193]. It has been shown that the sorting of MCT1 to the right pole of an epithelial 
cell relies on CD147 [192]. Tissue specific expression of different isoforms reflects 
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the activity of the tissue: MCT4 is expressed in white muscle fibers to export lactate 
produced during glycolysis, MCT1 on the other hand is expressed in the red muscle 
fibers to fuel β-oxidation [194]. The low affinity of MCT4 for lactate restricts glycolysis 
in white muscle fibers due to raising levels of lactate in the cell, causing muscle 
fatigue, MCT1 with a higher affinity imports lactate then into red muscle fibers [194]. 
This mechanism might prevent an excess of lactate and thus acidic load released to 
the system. A similar mechanism is present in the nervous system, where astrocytes 
express MCT4 and MCT2 is localized in the postsynaptic density in neurons 
[195,196], containing a lot of mitochondria reflecting the oxidative capacity. 
 
Figure 7: Phylogenetic tree of the MCT/SLC16 family. Both SLC and MCT numbers are given since 
MCT numbering was done based on the order of characterization, whereas SLC16 numbers were 
introduced once cDNA sequences were available. Only MCT1-4 are confirmed monocarboxylate 
transporters, with MCT7 been the only other member likely to transport monocarboxylates in H
+
-
dependent manner. Adapted from Halestrap (2013) [190]. 
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1.5.3 Monocarboxylate transporters in the kidney 
A renal transcriptome analysis on murine kidneys detected mRNA of several classical 
and orphan MCTs, including MCT1, MCT2, MCT5, MCT6, MCT7, MCT8, MCT9, 
MCT10 (TAT1), MCT13 and MCT14 [197]. Luminal uptake of monocarboxylates from 
urine is mediated by two members of the SLC5 family, namely SMCT1 (SLC5A8) and 
SMCT2 (SLC5A12), both localized in the proximal tubule [198,199]. MCT1 resides in 
the basolateral membrane of those tubules [200] facilitating the efflux of reabsorbed 
monocarboxylates. MCT2 is localized to the basolateral side of cells of the thick 
ascending limb of the loop of Henle and the distal convoluted tubule [200]. Both 
transporters can mediate import and efflux lactate depending on the cellular 
environment. The renal proximal tubule is involved in gluconeogenesis and uses β-
oxidation for energy metabolism [201]; MCT1 might also provide tubules with lactate 
from blood as a substrate for those processes.  
MCT8 [200], MCT10 [185] and MCT12 [202] (though no mRNA was detected by the 
transcriptomic screen) are all expressed at the basolateral membrane of proximal 
tubules. Consistently with the expression of MCT8, those cells express the type I 
iodotyronine 5’-deiodinase, which converts tetraiodothyronine to triiodothyronine 
[203]. Thyroid hormones regulate the function and maturation of proximal tubules; 
however, the possible role of MCT8 in this process remains to be determined. 
MCT10 exports aromatic amino acids that were reabsorbed from the glomerular 
filtrate [185]. Mutations of MCT12 are associated with increased amounts of 
guanidinoacetate in urine [202]. However, functional studies showed that MCT12 
transports creatine but not its precursor guanidinoacetate [186,202].  
1.5.4 MCT14 
Only little is known about MCT14. First reports indicated that this orphan transporter 
is expressed at mRNA level in the mammary gland of lactating cows and along the 
whole bovine intestinal tract [204,205]. Recently, its expression was also 
characterized in the central nervous system of mouse, where it is located in 
excitatory and inhibitory neurons as well as epithelial cells in the brain [206]. This 
study also provided the analysis of the relative expression of MCT14 in several 
tissues; MCT14 was highly expressed in the kidney, but also  in testis, uterus and 
liver [206]. MCT14 was detected in a renal transcriptome analysis of mice adapted to 
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high Pi or low Pi diet respectively (unpublished data). The function of this protein and 
its contribution in the adaptation to dietary Pi content is still unknown. Phylogenetic 
analysis indicates that MCT14 is closer related the MCT8, 9 and 10 than to the 
classical members of the family [206], which might suggest that its role involves 
transport of other solutes than monocarboxylates. 
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Chapter 2 
2. Aims 
The general aim of this study was to explore the mechanisms underlying intestinal Pi 
absorption. Active transcellular transport mediated by the Na+-dependent Pi 
transporter NaPi-IIb is well characterized, but little is known about the rleative 
importance of this transport pathway and a possible passive absorption of Pi along 
the paracellular pathway. Current pharmacological approaches to treat 
hyperphosphatemia in CKD patients involve the use of Pi binders and the 
development of NaPi-IIb inhibitors is considered as a potential alternative or 
complementary method. Thus, it is important to understand the nature of different 
pathways for intestinal Pi absorption and their relative contribution. NaPi-IIb is a high 
affinity transporter strongly upregulated upon dietary Pi restriction. Furthermore 
patients with mutations in NaPi-IIb suffer from pulmonary alveolar microlithiasis, but 
no adverse effect on Pi homeostasis is reported. Therefore we postulate that Pi is 
mainly absorbed passively through the paracellular pathway as long as dietary Pi 
supply is sufficient to drive passive diffusion, whereas once dietary Pi is restricted the 
presence of NaPi-IIb may be crucial. 
Based on the considerations above, the aims of this study were: 
1. To examine the role of NaPi-IIb in intestinal absorption of Pi under normal Pi 
dietary conditions (generation of a NaPi-IIb deficient  mouse model) 
2. To investigate the role of NaPi-IIb under high and low dietary Pi conditions 
(using the NaPi-IIb deficient model) 
3. To test the permeability of intestinal tight junctions to Pi (in Ussing chamber 
experiments) 
Furthermore we aimed to characterize the orphan Slc16a14/ MCT14 transporter, 
whose transcript was found to be highly regulated by dietary Pi in the kidneys of 
mice. For that, we investigated: 
1. Its pattern of expression along the  renal tubule 
2. Its substrate specificity (transport experiments in Xenopus laevis oocytes 
heterologously expressing MCT14) 
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Intestinal Depletion of NaPi-IIb/Slc34a2 in Mice:
Renal and Hormonal Adaptation
Nati Hernando, Komuraiah Myakala, Fabia Simona, Thomas Kn€opfel, Linto Thomas, Heini Murer,
Carsten A Wagner, and J€urg Biber
Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP). University of Zurich, Zurich, Switzerland
ABSTRACT
The Naþ-dependent phosphate-cotransporter NaPi-IIb (SLC34A2) is widely expressed, with intestine, lung, and testis among
the organs with highest levels of mRNA abundance. In mice, the intestinal expression of NaPi-IIb is restricted to the ileum, where the
cotransporter localizes speciﬁcally at the brush border membrane (BBM) and mediates the active transport of inorganic phosphate
(Pi). Constitutive full ablation of NaPi-IIb is embryonically lethal whereas the global but inducible removal of the transporter in young
mice leads to intestinal loss of Pi and lung calciﬁcations. Here we report the generation of a constitutive but intestinal-speciﬁc NaPi-
IIb/Slc34a2–deﬁcient mouse model. Constitutive intestinal ablation of NaPi-IIb results in viable pups with normal growth.
Homozygous mice are characterized by fecal wasting of Pi and complete absence of Na/Pi cotransport activity in BBM vesicles
(BBMVs) isolated from ileum. In contrast, the urinary excretion of Pi is reduced in these animals. The plasma levels of Pi are similar in
wild-type and NaPi-IIb–deﬁcientmice. In females, the reduced phosphaturia associates with higher expression of NaPi-IIa and higher
Na/Pi cotransport activity in renal BBMVs, as well as with reduced plasma levels of intact FGF-23. A similar trend is found in males.
Thus, NaPi-IIb is the only luminal Naþ-dependent Pi transporter in themurine ileum and its absence is fully compensated for in adult
females by a mechanism involving the bone-kidney axis. The contribution of this mechanism to the adaptive response is less
apparent in adult males. © 2015 American Society for Bone and Mineral Research.
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Introduction
Homeostasis of inorganic phosphate (Pi) is a multiorganprocess that ensures relatively constant levels of Pi in
plasma (for review see Bergwitz and J€uppner(1) and Hu and
colleagues(2)). The improper control of plasma Pi concentration
results in a wide range of pathological states, with hypophos-
phatemia resulting in abnormal skeletal growth and rickets,
whereas hyperphosphatemia is currently considered as a major
risk factor for vascular calciﬁcation and mortality (for review see
Alizadeh Naderi and Reilly(3) and Paloian and Giachelli(4)). The
concentration of Pi in plasma is controlled by the coordinated
action of intestine, kidneys, and bones (for review see Bergwitz
and J€uppner(1) and Hu and colleagues(2)). The epithelial cells of
intestine and kidney are equipped with apically located
Na/Pi-cotransporters belonging to the SLC34 and SLC20
families. The intestine expresses NaPi-IIb/SLC34A2 and PiT2/
SLC20A2 whereas the renal proximal tubule expresses NaPi-IIa/
SLC34A1, NaPi-IIc/SLC34A3, and PiT2/SLC20A2 (for review see
Biber and colleagues,(5) Forster and colleagues,(6) and Wagner
and colleagues(7)).
The pattern of expression of NaPi-IIb along the intestinal tract
is species-dependent. Thus, the cotransporter is expressed in the
duodenum and jejunum of rats, whereas it is not detectable in
the ileum.(8) Higher expression of the cotransporter mRNA in the
duodenum than the ileum has also been reported in human
mRNA samples.(9) Instead, the ileum is the only intestinal
segment expressing signiﬁcant levels of NaPi-IIb in mice.(10) In
the intestinal epithelia, the cotransporter is speciﬁcally located
at the brush border membrane (BBM) of enterocytes, along the
entire axis of the villi.(8,11) In addition to intestine, NaPi-IIb is
expressed in other organs, including lung and testis. Genetic
studies have shown a clear association of mutations in the
transporter with pulmonary alveolar microlithiasis (PAM) and
probably with testicular microlithiasis.(12) There are also some
indications for overexpression of NaPi-IIb in breast and epithelial
ovarian cancers.(13,14)
Absorption of dietary Pi occurs through a combination of
passive and active transport processes across the intestinal
epithelia(15) (for review see Lee and Marks(16) and Marks and
colleagues(17)). The intrinsic properties of NaPi-IIb parallel the
kinetic and regulatory features of the active component: its
expression is regulated by the dietary content of Pi as well as by
the circulating levels of the steroid hormone 1,25-dihydrox-
yvitamin D3 (1,25(OH)2D3), whereas its activity is reduced by
high luminal pH.(11,18) In mice, the intestinal abundance of NaPi-
IIb adapts to changes in dietary Pi, increasing in response to
diets with low content of Pi and decreasing upon high dietary Pi.
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Although chronic changes in Pi intake regulate the levels of 1,25
(OH)2D3, the dietary adaptation of the cotransporter seems to be
independent from the vitamin D3 levels, because it is preserved
in animal models in which either the signaling or the expression
of 1,25(OH)2D3 is abolished.
(19,20) Still, 1,25(OH)2D3 is per se a
main regulator of Pi homeostasis by promoting the expression
of NaPi-IIb in the intestinal microvilli.(18,21) It remains unclear
whether the effect of 1,25(OH)2D3 on NaPi-IIb abundance is
dependent or independent from changes in gene expression.
Thus, mice injected with cholecalciferol have higher levels of
NaPi-IIb protein in the absence of changes in mRNA expres-
sion(18) and the levels of the transcript are normal in vitamin D
receptor (VDR) knockouts,(20) whereas injection of 1,25(OH)2D3
in young rats results in upregulation of the cotransporter at the
mRNA and protein level and the activity of the human promoter
increases after 1,25(OH)2D3 treatment.
(21) Under steady-state
conditions, the intestinal absorption of Pi in healthy adults is
matched by an equivalent urinary excretion. In mice, renal
reabsorption of Pi is mediated to a major extent by NaPi-IIa, with
some minor contribution of NaPi-IIc and PiT2.(22–24) The
expression of these cotransporters in the BBM of proximal
tubules is under tight hormonal control, with parathyroid
hormone (PTH) and ﬁbroblast grown factor 23 (FGF-23) playing a
major role (for review see Biber and colleagues(5) and Wagner
and colleagues(7)).
Full ablation of NaPi-IIb is embryonically lethal,(25) whereas
the global but inducible removal of the transporter leads to
increased fecal excretion of Pi and reduced phosphaturia.(15) In
order to decipher the speciﬁc contribution of intestinal NaPi-IIb
to Pi homeostasis, we created a constitutive but intestinal-
speciﬁc NaPi-IIb knockout mouse model and characterized its
phenotype in terms of intestinal, renal, and hormonal adapta-
tion, in both females and males.
Materials and Methods
Generation of intestinal-specific NaPi-IIb/Slc34a2
knockout mice
The features of the targeting vector engineered to generate
ﬂoxed transgenic mice is shown in Fig. 1A. This vector consisted
of a 2.5-kb fragment of the Slc34a2 gene that encodes the last
350 amino acids of the transporter, ﬂanked by loxP sites. The 50
Fig. 1. Generation of intestinal-speciﬁc NaPi-IIb/Slc34a2 knockout mice. (A) Schematic representation of the Slc34a2 gene (top), targeting vector
(middle), and ﬂoxed allele (bottom). The gene consists of 13 exons (E), with the starting codon in E2 and the stop codon in E13 (both indicated by
asterisks). The targeting vector contains 50 and 30 homology arms of 2.9 and 1.7 kb, respectively, 2 LoxP sites (shaded triangles) ﬂanking a 2.5 kb genomic
fragment, a neo cassette (PGK-neo) ﬂanked by FRT sites (black ellipses), and the herpes simplex virus thymidine kinase (HSV-TK). (B) Southern blot of
genomic DNA isolated from untransfected ES cells and from three selected clones. DNA samples were digested with the restriction enzymes whose sites
are indicated above the ﬂoxed allele (Bs¼ BsrGI, Bg¼ BglII, S¼ SpeI) and incubated with the 32P-labelled probes whose location is shown below the
ﬂoxed allele. (C) Structure of the conditional allele upon removal of the neo cassette by cross-breedingwith 64FlpeB6mice. Genotypingwas done by PCR
on genomic DNA, using the a1 and a2 primers. An example of the genotyping is shown below. (D) Structure of the allele upon Cre-mediated removal of
the ﬂoxed-sequence (top). Topology of NaPi-IIb (bottom): recombination results in a truncated cotransporter.
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and 30 homologous arms consisted of genomic fragments of
2.9 kb and 1.7 kb, respectively. The neomycin resistance gene
driven by the phosphoglycerate kinase (PGK) promoter was
ﬂanked by Flp recombinase target (frt) sites and inserted
between the 2.5-kb ﬂoxed fragment and the 30 loxP site. The
thymidine kinase from the herpes simplex virus (HSV-TK) was
cloned downstream of the 30 homologous arm. Upon electro-
poration of the vector into 129SV embryonic stem (ES) cells, the
PGK-neo and HSV-TK elements were used for positive and
negative selection of clones, respectively. Selected clones were
tested for homologous recombination by Southern blot using
two different probes (Fig. 1A, B). For that, genomic DNA isolated
from three selected clones as well as from untransfected ES cells
was digested with either BsrGI or BglII/SpeI and hybridized with
the 32P-labeled probe according to standard procedures.
Hybridization of the probe “a” to DNA digested with BsrGI
should label a single fragment of 6.3 kb corresponding to the
wild-type allele in untransfected cells; an additional 8.8-kb
fragment representing the ﬂoxed allele is expected in electro-
porated cells upon homologous recombination of the targeting
vector. Hybridization of the probe “b” to DNA digested with
BglII and SpeI should label fragments of 5.7 kb and 2.3 kb
corresponding to the wild-type and recombined allele, respec-
tively. One recombinant clone was used to produce ﬂoxed-
Slc34a2 mice. Electroporation of ES cell as well as generation of
ﬂoxed animals was done in collaboration with Dr. E Hummler
from the Transgenic Animal Facility of the University of
Lausanne (TAF UNIL) as described.(26) The neo-cassette was
removed from the transgene by crossing heterozygous ﬂoxed-
Slc34a2 pups with 64FlpeB6 mice purchased from The Jackson
Laboratory (Bar Harbor, MN, USA) (Fig. 1C). Ablation of Slc34a2 in
intestinal cells was then achieved by breeding ﬂoxed-Slc34a2,
devoid of neo, with villin-Cre mice (a kind gift from Dr. Gerhard
Rogler, Department of Gastroenterology and Hepatology,
University of Zurich, Zurich, Switzerland). A PCR genotyping
protocol was set up to identify wild-type (Slc34a2þ/þ),
conditional heterozygous (Slc34a2f/þ), and homozygous
(Slc34a2f/f) pups positive for Cre. Genotyping was done with a
pair of forward (CCTTCTCCGCGTCTAAGG) and reverse
(GCCTTGACACACTGTTG) primers ﬂanking the 50 loxP site, using
genomic DNA isolated from ear punches as a template. The
size of the generated amplicons is 550 bp for the wild-
type allele and 600 bp for the ﬂoxed allele (Fig. 1C). The
sequence of the primers used to detect the presence of
Cre-recombinase was TCGCTGCATTACCGGTCGATGC and CCAT-
GAGTGAACGAACCTGGTCG for the forward and reverse oligo-
nucleotides, respectively, with an amplicon size of about 400 bp.
Animal handling and collection of samples
Experiments were performed with 3-month-old males and
females. Animals were fed with standard diet (KLIBA, SA)
containing 0.8% Pi, 1% Caþþ, and 800 u/kg vitamin D3. Three
days prior to collection of biological samples, mice were placed
individually in metabolic cages (Tecniplast). Stool and urine
(under mineral oil) were collected during the last 24 hours. On
the last day,micewere anaesthetizedwith ketamine/xylazine i.p.
prior to the collection of blood and organs. Heparinized blood
was immediately centrifuged and plasma was aliquotted into
several tubes, whereas dissected ileum was rinsed with cold PBS
and inverted prior to collection of the mucosa by scraping.
Plasma and organs were immediately frozen in liquid nitrogen
until further use. Animal experiments were approved by the
local veterinary authority (Kantonales Veterin€aramt Z€urich) and
animal handling complied with the Swiss Animal Welfare laws.
Quantification of mRNA expression by real-time PCR
Total RNA was extracted from ileum mucosa, lung, testis, and
femurs (upon removal of bone marrow) and reverse-transcribed
to cDNA by standard methods (RNAeasy Minikit from Qiagen;
Hombrechtikon, Switzerland; TaqMan Reverse Transcription Kit
from Applied Biosystems; Zug, Switzerland). The cDNA was
ampliﬁed by PCR with the TaqMan Universal PCR Master Mix in
the presence of speciﬁc pairs of forward (Fw) and reverse (Rv)
primers and FAM/TAMRA-labeled probes (Pb). To quantify the
expression of NaPi-IIb/Slc34a2 mRNA, we designed a set of
primers and labeled-probe annealing within the sequence
contained between both loxP sites (Fig. 1A): the forward and
reverse primers anneal to exons 10 and 12, respectively, whereas
the probe anneals to exon 11. The sequences of the primers and
probes are shown in Table 1. The expressions of the genes of
interest were normalized to the expression of either hypoxan-
thine phosphoribosyltransferase (HPRT) or 18S according to the
formula R¼ 2[Ct(control)–Ct(test gene)], where R is the relative ratio
and Ct indicates the cycle number at a given threshold.
Uptakes of 32P and 3H-D-glucose into intestinal and renal
BBM vesicles
Frozen ileum mucosa as well as frozen decapsulated kidneys
were homogenized with a buffer containing 300 mM mannitol,
5 mM EGTA, and 12 mM Tris-HCl, pH 7.1, supplemented with
protease and phosphatase inhibitors. BBM vesicles (BBMVs)
were then isolated by the Mgþþ-precipitation technique as
reported,(27) and ﬁnally resuspended in a buffer containing
300 mM mannitol and 20 mM HEPES-Tris, pH 7.4. Uptakes were
performed according to the ﬁltration technique as described,(28)
by incubating BBMVs in three different solutions: 0 mM Naþ,
Table 1. Sequences of the Forward and Reverse Primers as Well
as the Probes Used for Quantiﬁcation of mRNA Expressions
Gene Primer
Fw NaPi-IIb 50-GAAGACCCTGAATACTGATTTCC-30
Rv NaPi-IIb 50-GATATGCCCTCTCAATGCTG-30
Pb NaPi-IIb 50-AGGCATGACCTTCATCGTGCAAAGC-30
Fw FGF-23 50-GTATGGATCTCCACGGCAAC-30
Rv FGF-23 50-AGTGATGCTTCTGCGACAAGT-30
Pb FGF-23 50-TTTTTGGATCGCTTCACTTCAGCCC-30
Fw GALNT3 50-GAGAAAGAGCGAGGGGAAAC-30
Rv GALNT3 50-GTGGACCATGCTTCATTGTG-30
Pb GALNT3 50-ACACCCGACCACCTGAATGTATTGAAC-30
Fw VDR 50-AGGCCCACACTCAGCTTCT-30
Rv VDR 50-ACAGGTCCAGGGTCACAGAG-30
Pb VDR 50-TACACCCCCTCACTGGACATGATGG-30
Fw PHEX 50-GCTGCCAGAGAACAAGTGC-30
Rv PHEX 50-TCCTCAGCTATGCCAGGAAG-30
Pb PHEX 50-CAGTCCTCCACAATTTAGGGTCAATGGTG-30
Fw BMP1 50-ACAGCAAACAGCCCGAAG-30
Rv BMP1 50-TCCAATCACAAACGGGATG-30
Pb BMP1 50-CCATCCATCAAAGCTGCAGGAAACTC-30
Fw DMP1 50-TCTCCCAGTTGCCAGATACC-30
Rv DMP1 50-TCTCCAGATTCACTGCTGTCC-30
Pb DMP1 50-CTCTGAAGAGAGGACGGGTGATTTGG-30
Fw¼ forward; Rv¼ reverse; Pb¼probe.
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100 mM Naþ, and 100 mM Naþ plus 6 mM phosphonoformic
acid (PFA). All reactions were done in the presence of 0.1 mM
KH2PO4 and 0.1 mM D-glucose, together with
32P and 3H-D-
glucose as tracer. Uptakes into intestinal BBMVs were done in a
single set of experiments,whereas uptakes into renal BBMVswere
done independently in three sets ofmice, each containing at least
7 animals per gender and genotype. Because there is a certain
degree of interexperiment variability (see Results), values within
each of the three sets of experiments have been normalized as
percentage of the uptakes in the presence of Naþ (total uptakes)
in the corresponding wild-types (Slc34a2þ/þ). Similar normaliza-
tion was done for the intestinal uptakes. The protein concentra-
tion of the BBMVs and homogenates was quantiﬁed with a
protein determination kit (Bio-Rad, Cressier, Switzerland).
Western blots
Samples of BBMorhomogenates containing 20or 40mgof proteins
were electrophoresed in 9% SDS-PAGE gels and transferred to
polyvinylideneﬂuoride (PVDF)membranes (Millipore, Schaffhausen,
Switzerland). Upon blocking with 5% milk powder in Tris-buffered
saline (TBS), membranes were incubated overnight with primary
antibodies against NaPi-IIa,(29) NaPi-IIb,(11) NaPi-IIc,(30) klotho
(TransGenic Inc, Kobe, Japan), and b-actin (Sigma-Aldrich, Buchs,
Switzerland), followed by 2 hours of incubation with the
corresponding secondary antibody (GE Healthcare, Glattbrugg,
Switzerland).Afteradditionof theappropriatedsubstrate (Millipore),
chemiluminescence signals were detected with the LAS-4000
luminescent image analyzer (Fujiﬁlm) and further quantiﬁed
(ImageJ). Quantiﬁcations are shown as ratios to actin.
Immunofluorescence
Animals were perfused with 3% paraformaldehyde in 0.1 M
sodium-cacodylate and tissues were then ﬁxed as reported.(31)
Ileum cryosections were processed for antigen retrieval with
1% SDS in PBS at room temperature for 5 min. Upon overnight
incubation with the NaPi-IIb antibody, samples were exposed
for 1 hour to the Alexa-594 secondary antibody (Invitrogen,
Dietikon, Switzerland) together with Alexa 488-coupled
phalloidin (Invitrogen) and 4,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich). Immunoﬂuorescence signalswere detectedwith
an epiﬂuorescence microscope (Leica).
Quantification of Pi and Caþþ in stool, urine, and plasma
Stool was processed as reported(15) by reconstituting dried stool
pellets during 3 days in 0.6 M HCl, followed by a short
centrifugation to remove undissolved material. The content of
Pi in stool, urine, and plasma was determined according to the
Fiske Subarow method (Sigma-Aldrich) and the concentration of
Caþþ was assessed with the QuantiChrom Calcium assay kit
(BioAssay Systems, Hayward, CA, USA). Pi determinationwas done
in several rounds of quantiﬁcation, each containing a mixture of
genders and genotypes, whereas the concentration of Caþþ was
quantiﬁed simultaneously in all groups. Urinary excretions were
normalized to the concentration of creatinine that was quantiﬁed
according to the Jaffemethod (WakoChemicals, Neuss, Germany).
Quantification of PTH, FGF-23, and 1,25(OH)2D3 in
plasma
The concentrations of intact PTH and FGF-23 (intact and C-
terminal fragments) were quantiﬁed by ELISA (Immunotopics
International, San Clemente, CA, USA and KAINOS, Sissach,
Switzerland), whereas the levels of 1,25(OH)2D3 were determined
by radioimmunoassay (Immunodiagnostic System, Frankfurt am
Main, Germany). We strictly followed the manufacturers’ proto-
cols. PTH, intact FGF-23, and 1,25(OH)2D3 were measured
independently in two sets of experiments. The ﬁrst set consisted
of animals of both genders and three genotypes, whereas only
wild-type and homozygous males and females were analyzed in
the second set of experiments. TheC-terminal fragment of FGF-23
was measured only in samples from the ﬁrst batch of animals.
Within each experiment, samples from all mice were quantiﬁed
simultaneously. Hormonal measurements in each of the two
batches of animals resulted in very different mean values (see
Results), thus preventing the pooling of raw date. Therefore, all
values were normalized as a percentage of the concentration in
the corresponding wild-type (Slc34a2þ/þ) females.
Statistical analysis
Differences between groups were analyzed by t test or ANOVA/
Bonferroni test, as indicated. Values of p< 0.05 were considered
signiﬁcant. All data are shown as mean SE.
Results
Generation and validation of an intestinal-specific
NaPi-IIb/Slc34a2 knockout mice
The ﬁrst step to generate intestinal-speciﬁc NaPi-IIb/Slc34a2
knockouts was to produce ﬂoxed-Slc34a2 transgenic mice by
homologous recombination between the genomic DNA of
129SV-ES cells and the targeting vector show in Fig. 1A.
Homologous recombination was conﬁrmed by Southern blot
using two different probes (Fig. 1A, B). Hybridization of both
probes to genomic DNA isolated from three selected ES cell
clones labeled DNA fragments of the expected size (Fig. 1B). A
single clone was microinjected into blastocysts derived from
C57BL/6 mice that were then implanted into NMRI pseudopreg-
nant females. The neo-cassette was removed from the ﬂoxed
offspring by breeding themwith 64FlpeB6mice in which the Flp
recombinase is under control of the human beta-actin promoter.
Upon excision of the neo-cassette, ﬂoxed animals were mated
with villin-Cre mice in which the expression of Cre recombinase
is driven by the villin promoter. Further crossbreeding produced
wild-type (Slc34a2þ/þ), conditional heterozygous (Slc34a2f/þ),
and homozygous mice (Slc34a2f/f) positive for Cre recombinase
(Fig. 1C). Removal of the loxP-ﬂanked sequence by Cre
recombinase should result in a truncated transcript lacking
the last 350 codons (Fig. 1D).
The abundance of Slc34a2 mRNA was measured by real-time
PCR using primers and probe annealing within the ﬂoxed
fragment. This analysis indicated a reduced mRNA expression
in the ileum of Slc34a2f/þ mice compared with Slc34a2þ/þ
littermates, whereas the transcript was hardly detected in
Slc34a2f/f animals (Fig. 2A). The mRNA expression of the
cotransporter in lung (Fig. 2B) and testis (Fig. 2C) was similar
in Slc34a2þ/þ and Slc34a2f/f mice.
Western blot analysis using a NaPi-IIb antibody(11) indicated
that the abundance of the cotransporter is reduced in BBM
isolated from ileum of Slc34a2f/þ mice as compared with
Slc34a2þ/þ littermates, whereas the cotransporter is undetect-
able in samples from Slc34a2f/f animals. Similar effects were
detected in females (Fig. 2D) and males (Fig. 2E). As reported
recently for Slc34a3 knockout mice,(23) there is high heteroge-
neity in the abundance of NaPi-IIb within the wild-type and
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Fig. 2. Expressionof Slc34a2mRNAandprotein. ThemRNAexpressionwasquantiﬁedby real timePCR in total RNAsamples extracted from(A) ileum, (B) lungs, and (C)
testis of Slc34a2þ/þ (þ/þ), Slc34a2f/þ (f/þ), and/or Slc34a2f/f (f/f) males. The expression of the cotransporter was normalized to the one of HPRT. Data are given as
mean SE. Thenumberofmicepergroup is indicated inparentheses. ***p 0.001versuswild-type,ANOVAtest.NaPi-IIbproteinabundancewasanalyzedbyWestern
blot (D, E) and immunoﬂuorescence (F).WesternblotswereperformedwithBBM isolated from ileumof (D) female and (E)malemice. Actinwasusedas loadingcontrol.
Data are given as mean SE and statistical signiﬁcances were calculated with ANOVA test. **p 0.01 and ***p 0.001, versus wild-types. Immunoﬂuorescence was
performed on ileum samples from males. The cotransporter signal is shown in green, the actin staining in red, and the nuclear ﬂuorescence in blue.
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heterozygous groups, which may be due to different feeding
behaviors of individual animals. Immunostaining of ileum
samples with the same NaPi-IIb antibody revealed an apical
signal in tissue collected from Slc34a2þ/þ but not from Slc34a2f/f
mice, conﬁrming the absence of NaPi-IIb in ileum of homozy-
gous animals (Fig. 2F).
Effect of NaPi-IIb/Slc34a2 knockdown on the uptake of
Pi into ileal BBMVs
Uptakes of 32P into BBMVs isolated from ileum were carried out
in the presence/absence of Naþ (to determine the total uptake
as well as the Naþ-dependent and independent components),
with or without PFA in the Naþmedia (to discriminate between
Slc34-dependent and independent mechanisms of the Naþ-
dependent component). (32) Absolute values for the total
uptakes (column a) in wild-type animals (Slc34a2þ/þ) were (in
pmol 32P/mg protein/min) 0.32 0.03 for females and
0.41 0.06 for males. As shown in Fig. 3A and B, in both
genders the Naþ-dependent uptake (columns labeled “c”)
represented around 95% of the total uptake of Pi (columns
labeled “a”), with a very small contribution of Naþ-independent
processes (columns labeled “b”). With the exception of this Naþ-
independent component that remained unaffected, uptakes of
32P into ileal BBMVs were reduced by around 40% in Slc34a2f/þ
animals and were almost fully abolished in Slc34a2f/f mice. The
reduction in the PFA-insensitive uptake detected in Slc34a2f/f
females (columns labeled “d”) probably reﬂects the inability of
PFA, at the used concentration, to fully inhibit the Slc34-
dependent component (columns labeled “e”). For every given
genotype, the incorporation of 32Pi was comparable in BBMVs
from females and males. The uptake of 3H-D-glucose was similar
in Slc34a2þ/þ, Slc34a2f/þ, and Slc34a2f/f mice and was insensitive
to PFA (Fig. 3C, D).
Effect of NaPi-IIb/Slc34a2 knockdown on fecal, urinary,
and plasma concentrations of Pi and Caþþ
The absence of NaPi-IIb from the BBM of ileum resulted in a
higher fecal excretion of Pi in Slc34a2f/f mice as compared with
their corresponding Slc34a2þ/þ littermates (Fig. 4A). The
excretion in Slc34a2f/þ mice was unaffected (Fig. 4A), despite
the clear reduction in NaPi-IIb protein abundance and in the ileal
uptake of Pi. The urinary excretion of Pi was reduced in Slc34a2f/f
Fig. 3. Effect of Slc34a2 knockdown on the uptake of Pi into intestinal BBMVs. Uptakes were performed with BBMVs isolated from ileum of (A, C) female
and (B, D) male Slc34a2þ/þ (þ/þ, white columns), Slc34a2f/þ (f/þ, gray columns), and Slc34a2f/f (f/f, black columns). For each experimental group, the
components of the uptakes are indicated as follows: (a) total uptake, corresponding to the uptakemeasured in the presence of Naþ; (b) Naþ-independent
uptake, the incorporation obtained in the absence of Naþ; (c) Naþ-dependent uptake, calculated by subtracting the value obtained in the absence of Naþ
from that in the presence of Naþ; (d) PFA-insensitive uptake: calculated by subtracting the Naþ-independent uptake from that measured in the presence
of Naþ plus PFA; (e) PFA-sensitive uptake: calculated by subtracting the PFA-insensitive component from the Naþ-dependent uptake. Data are presented
as mean SE. The number of females per group was 9 Slc34a2þ/þ, 7 Slc34a2f/þ, and 7 Slc34a2f/f, whereas the size of the male groups was 8 Slc34a2þ/þ,
7 Slc34a2f/þ, and 8 Slc34a2f/f. Statistical signiﬁcances between groups were calculated with ANOVA/Bonferroni test: **p 0.01; ***p 0.001.
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mice, whereas no changes were detected in Slc34a2f/þ
littermates (Fig. 4B). The concentration of Pi in plasma was
similar in all groups regardless of the presence or absence of the
cotransporter (Fig. 4C). For all genotypes, the concentration of Pi
in stool, urine, and plasma was similar in females and males. The
fecal excretion (Fig. 4D) and the plasma levels of Caþþ (Fig. 4F)
were not affected by the absence of intestinal NaPi-IIb. However,
the urinary excretion of Caþþ was reduced Slc34a2f/f compared
with their corresponding Slc34a2þ/þ littermates (Fig. 4E). The
urinary concentrations of Naþ and Kþ were similar in all
genotypes (data not shown).
Effect of NaPi-IIb/Slc34a2 knockdown on the uptake of Pi
into renal BBMVs and on the expression of renal Pi
transporters
Uptake of 32P into renal BBMVs isolated from Slc34a2þ/þ
and Slc34a2f/f animals were performed in the same conditions
as reported for the intestinal experiments. Absolute values
for the total uptake (Fig. 5A, B, column “a”) in wild-type
mice (Slc34a2þ/þ) ranged between 1 and 5 pmol 32P/mg
protein/min in three independent experiments. When
measured in parallel, similar total uptake was detected in
wild-type females and males (3.46 0.41 versus 4.97 0.71
and 1.25 0.18 versus 1.00 0.10, in two independent
experiments). As shown in Fig. 5A, the total uptake (column
“a”) and the Naþ-dependent component (column “c”)
were signiﬁcantly upregulated in BBMVs from females
Slc34a2f/f as compared with Slc34a2þ/þ littermates. Similar
tendency for higher uptake values was also detected in male
Slc34a2f/f, though it did not reach statistical signiﬁcance
(Fig. 5B).
The expression of NaPi-IIa was increased in renal BBM from
female Slc34a2f/f compared with their Slc34a2þ/þ littermates
(Fig. 5C). A similar trend was observed in males, though it
did not reach statistical signiﬁcance (Fig. 5D). In males and
females, the abundance of NaPi-IIc was similar in both
genotypes (Fig. 5C, D).
Effect of NaPi-IIb/Slc34a2 knockdown on Pi-regulating
factors
The plasma concentrations of 1,25(OH)2D3, intact PTH, and
intact FGF-23 were measured in two independent sets of
experiments, whereas the levels of the C-terminal fragment of
FGF-23 were quantiﬁed only in the ﬁrst set of experiments. In
all cases, concentrations were normalized to the levels in the
corresponding Slc34a2þ/þ females. The absolute hormonal
values in Slc34a2þ/þ females in two experiments were (in pg/
mL): 119 8.0 and 58 9.1 for 1,25(OH)2D3, 165 44 and
90 32 for PTH, and 76 8.8 and 201 10.9 for the intact FGF-
23. The concentration of the C-terminal FGF-23 fragment in
Slc34a2þ/þ females was 307 20 pg/mL. The plasma levels of
1,25(OH)2D3 were similar in Slc34a2
f/f and Slc34a2þ/þ litter-
mates, both in females and in males (Fig. 6A). The concen-
trations of PTH (Fig. 6B) as well as of the C-terminal FGF-23
fragment (Fig. 6C) were comparable in Slc34a2f/f, Slc34a2f/þ,
and Slc34a2þ/þ mice, in both females and males. In contrast,
the levels of intact FGF-23 were signiﬁcantly lower in
homozygous females compared with their wild-type litter-
mates (Fig. 6D). A similar trend for reduced intact FGF-23 in
Slc34a2f/f was observed in males, but it did not reach statistical
signiﬁcance (Fig. 6D).
The abundance of klotho in renal homogenates was
comparable in Slc34a2f/f and Slc34a2þ/þ mice, both in females
(Fig. 6E, left panel) and in males (Fig. 6E, right panel).
Effect of NaPi-IIb/Slc34a2 knockdown on FGF-23
regulators
The impact of NaPi-IIb depletion on the mRNA expression of
several bone factors proposed to regulate FGF-23 (Fig. 7A) was
analyzed. Although the expression of N-acetylgalactosaminyl-
transferase (GALNT3; Fig. 7B) as well as FGF-23 (Fig. 7C) and VDR
transcripts (Fig. 7D) tended to be reduced in bones from
Slc34a2f/f females compared with the corresponding Slc34a2þ/þ
littermates, only the changes on VDR were statistically
signiﬁcant. The expressions of the phosphate-regulating gene
with homology to endopeptidases on the X-chromosome
(PHEX; Fig. 7E), bone morphogenetic protein 1 (BMP1; Fig. 7F),
and dentin matrix protein-1 (DMP1; Fig. 7G) were similar in all
groups of animals.
Fig. 4. Effect of Slc34a2 knockdown on Pi and Caþþ levels. The
concentrations of (A–C) Pi and (D–F) Caþþ were measured in (A, D) stool,
(B, E) urine, and (C, F) plasma. Samples were collected from Slc34a2þ/þ
(þ/þ, white columns), Slc34a2f/þ (f/þ, gray columns), and/or Slc34a2f/f (f/f,
black columns), both females (F) and males (M). Data are given as
mean SE. Thenumberofmiceanalyzedpergroup is indicatedwithin the
bars. Statistical signiﬁcances between groups were calculated with
ANOVA/Bonferroni test: *p 0.05; ***p 0.001; (a) *p 0.05 between
genders.
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Discussion
To study the speciﬁc contribution of intestinal NaPi-IIb/Slc34a2
to Pi homeostasis, we generated a constitutive but tissue-
speciﬁc knockout mouse model in which ablation of the
cotransporter is achieved by villin-driven Cre recombinase.
Constitutive depletion of intestinal Slc34a2 results in viable and
fertile pups. Adult homozygous mice show fecal wasting of
Pi that correlates with almost complete absence of Na/Pi
cotransport activity in ileal BBMVs. The urinary excretion of Pi
is reduced in homozygous animals whereas the plasma levels of
Pi are similar in wild-type and knockout animals. In females, the
reduced phosphaturia associates with increased Na/Pi cotrans-
port activity in renal BBMVs, increased expression of NaPi-IIa,
and reduced circulating levels of intact FGF-23.
As indicated, the expression of the Cre recombinase was
driven by the promoter of villin, a Caþþ-regulated actin-binding
protein detected in several epithelia.(33) Slc34a2 mRNA is widely
expressed and, in addition to intestine, two of the tissues with
higher mRNA levels are the lungs and testis.(34) In humans,
mutations of SLC34A2 associate with PAM, an autosomal-
recessive disease characterized by intra-alveolar accumulation
of Pi-containing microliths.(12) This PAM phenotype was repro-
duced in mice with global and inducible depletion of the
cotransporter.(15) There are also some indications suggesting a
correlation between mutations of SLC34A2 and testicular micro-
lithiasis.(12) The expression of the cotransporter mRNA remains
unchanged in lungs and testis of Slc34a2f/f mice (Fig. 2B, C),
suggesting that the villin-driven Cre system efﬁciently ablates the
Slc34a2 gene in ileum, without affecting its expression in other
organs in which the cotransporter is known to play a critical role.
Shibasaki and colleagues(25) reported that the constitutive and
global knockout of Slc34a2 results in intrauterine death of
homozygous pups, probably due to impaired absorption of Pi
from the maternal circulation. This is consistent with the high
expression of the cotransporter mRNA detected in placenta.(35)
Fig. 5. Effect of Slc34a2 knockdown on the uptake of Pi into renal BBMVs and on the expression of renal cotransporters. The incorporation of 32P in renal
BBMVs was measured in three independent sets of experiments in samples from (A) female and (B) male Slc34a2þ/þ (þ/þ, white columns) and Slc34a2f/f
(f/f, black columns). The components of the uptakes are indicated as follows: (a) total uptake, (b) Naþ-independent uptake, (c) Naþ-dependent uptake,
(d) PFA-insensitive uptake, and (e) PFA-sensitive uptake. Data are presented as mean SE. The number of females per group was 24 Slc34a2þ/þ and
24 Slc34a2f/f; the size of the male groups was 23 Slc34a2þ/þ and 25 Slc34a2f/f. Statistical signiﬁcances versus the corresponding wild-type values were
calculated with ANOVA/Bonferroni test: **p 0.01. Western blots with NaPi-IIa and NaPi-IIc antibodies in renal BBM from (C) female and (D) male
Slc34a2þ/þ (þ/þ) and Slc34a2f/f (f/f). Actin was used as loading control. Statistical signiﬁcances were calculated with t test: *p 0.05.
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Unlike the global model, breeding of intestinal-speciﬁc heterozy-
gous produced the expected Mendelian ratio of wild-type/
heterozygous/homozygous pups (data not shown). Therefore,
the constitutive intestinal depletion of the cotransporter does not
seem to have any deleterious effects and produces viable pups.
Our data demonstrates that NaPi-IIb is responsible for up to
95% of the Naþ-dependent uptake of Pi in the ileum and that its
absence results in fecal wasting of Pi, in both males and females
(Figs. 3 and 4). In both genders, the intestinal loss is at least
partially compensated by reduced urinary output, allowing
Slc34a2f/f mice to remain normophosphatemic (Fig. 4). These
ﬁndings are in agreement with a previous report from Sabbagh
and colleagues(15) showing that the Naþ-dependent incorpo-
ration of 32P into everted sacs is hardly detectable in the ileum of
mice with global and inducible removal of the transporter.
Normophosphatemia, increased fecal output, and reduced
phosphaturia were also reported in this inducible model.
Alterations in the urinary excretion of Pi usually reﬂect
changes in the capacity of the renal proximal tubule to reabsorb
Pi from the primary urine. Our transport studies in renal
BBM indicate that the reduced phosphaturia exhibited
by homozygous females correlates with increased total and
Naþ-dependent uptake of Pi (Fig. 5A). The expression of the
Naþ/Pi cotransporters NaPi-IIa/Slc34a1 and NaPi-IIc/Slc34a3 in
the BBM of renal proximal tubules is regulated by many of the
factors that control the renal reabsorption of Pi. In mice, NaPi-IIa
plays a major quantitative role because its absence results in
massively reduced renal uptake of Pi, hyperphosphaturia, and
hypophosphatemia,(22) whereas depletion of NaPi-IIc has no
effect on Pi homeostasis.(23,24) Consistent with the renal uptake
data, we found that the expression of NaPi-IIa is upregulated in
female Slc34a2f/f mice (Fig. 5).
The expression of NaPi-IIb is under the control of 1,25(OH)2D3,
which via posttranscriptional and perhaps also transcriptional
mechanisms increases the abundance of the cotransporter,
thereby enhancing the absorption of dietary Pi. The plasma levels
of 1,25(OH)2D3 depend on the intrarenal activation of 25(OH)D3
by the Cyp27b1/1a-hydroxylase as well as on its catabolism
by the Cyp24a1/24a-hydroxylase.(36) The concentration of
1,25(OH)2D3 increases upon dietary restriction of Pi, due to
higher synthesis and reduced catabolism.(36) However, in adult
mice the intestinal loss of Pi caused by the absence of NaPi-IIb
does not trigger a similar upregulation of 1,25(OH)2D3 (Fig. 6A).
This ﬁnding is compatible with the report from Sabbagh and
Fig. 6. Effect of Slc34a2 knockdown on regulators of Pi homeostasis. Plasma concentrations of (A) 1,25(OH)2D3, (B) PTH, (C) C-terminal fragment of FGF-
23, and (D) intact FGF-23 weremeasured either in two or one independent sets of experiments (seeMaterials andMethods). Measurements were done in
samples from Slc34a2þ/þ (þ/þ, white columns), Slc34a2f/þ (f/þ, gray columns), and/or Slc34a2f/f (f/f, black columns), both females (F) and males (M).
Within each experiment, samples from all groups ofmicewere processed simultaneously. Data are given asmean SE. The number ofmice analyzed per
group is indicated within the bars. Statistical signiﬁcances were calculated with ANOVA/Bonferroni test: **p 0.01 versus the corresponding wild-type;
(a) p 0.05 between genders. (E) Western blot with a klotho antibody of renal homogenates from Slc34a2þ/þ (þ/þ) and Slc34a2f/f (f/f) females (left panel)
and males (right panel).
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Fig. 7. Effect of Slc34a2 knockdown on regulators of FGF-23. (A) Proposed working model showing some of the factors involved in transcriptional and
posttranscriptional regulation of FGF-23 (adapted from Feng and colleagues(49)). The expression of (B) GALNT3, (C) FGF-23, (D) VDR, (E) PHEX, (F) BMP1,
and (G) DMP1 mRNAs in bones was analyzed by real-time PCR in samples from Slc34a2þ/þ (þ/þ,white columns) and Slc34a2f/f (f/f, black columns) mice,
bothmale (M) and female (F). The expression of the genes was normalized to the expression of 18S. Each gene was simultaneously analyzed in all groups
of mice. Data are given as mean SE. The number of mice analyzed per group is indicated within the bars. Statistical signiﬁcances were calculated using
ANOVA/Bonferroni test: *p 0.05.
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colleagues(15) showing that the plasma concentration of 1,25
(OH)2D3 was increased 4 weeks after deletion of the cotrans-
porter, but normalized thereafter. Regarding the renal expression
of both hydroxylases, the mRNA abundance of Cyp27b1
was similar in Slc34a2f/f and Slc34a2þ/þ littermates of both
genders, whereas the expression of Cyp24a1 was reduced in
male Slc34a2f/f as compared with Slc34a2þ/þ mice (data not
shown).
As indicated, the reduced phosphaturia caused by depletion of
Slc34a2correlates in femaleswith increaseduptakeof Pi into renal
BBMand increasedexpressionofNaPi-IIa. The urinary excretion of
Pi as well as the abundance of NaPi-IIa in the proximal BBM are
regulated by several hormones, with PTH and FGF-23 playing a
major role (for review see Bergwitz and J€uppner(1)). Both
hormones are involved in feedback loops with each other as
well as with 1,25(OH)2D3 and they both reduce the expression of
NaPi-IIa in the proximal tubule triggering a phosphaturic
response.(31,37–40) Therefore, their levels may decrease when Pi
reabsorption is stimulated. However, our data suggests that the
reduced phosphaturia observed in Slc34a2f/f mice cannot be
explained on the basis of lower PTH levels (Fig. 6B).
FGF-23 is a 251–amino acid peptide hormonemostly produced
by osteocytes. The active form secreted into the circulation
consists of amino acids 25 to 251 and acts on its target tissue by
simultaneously binding to FGF receptors and klotho (for review
see Hu and colleagues(2)). Active FGF-23 is proteolytically
processed at a subtilisin-like site, resulting in inactive N-terminal
and C-terminal fragments.(41) Similar to PTH, FGF-23 induces a
phosphaturic effect by promoting the endocytosis of NaPi-IIa and
NaPi-IIc from the proximal BBM.(39,42) Furthermore, both hor-
mones have been proposed to share similar mechanisms to
induce the retrieval of NaPi-IIa from the apical microvilli.(40) We
measured the concentration of FGF-23 using two different ELISA
kits: one kit detects the C-terminal fragment and therefore can
measure, in principle, both the non-cleaved (active) and cleaved
(inactive) forms, whereas the second kit detects only the non-
cleaved peptide. The reduction in intact FGF-23 observed in of
Slc34a2f/f females (Fig. 6D) supports the observations of increased
NaPi-IIa abundance and higher Pi uptake in renal BBM of the
female homozygous. The reduction in intact FGF-23 without
signiﬁcant changes in 1,25(OH)2D3 is interesting, considering the
key role of 1,25(OH)2D3 inmaintaining Pi homeostasis and FGF-23
expression, and the fact that its levels are increased in mice with
constitutive ablation of either NaPi-IIa(22) or NaPi-IIc.(24) However,
and as indicated above, only a transient increase of 1,25(OH)2D3
has been reported inNaPi-IIb–inducible knockouts.(15) In addition
to the role as co-receptor, klotho has also been shown to control
themembrane expressionofNaPi-IIa independently of FGF-23, by
amechanism that involves its glucuronidase activity. Thus, in vivo
administration of klotho leads to hypophosphatemia, hyper-
phosphaturia, and reduced expression of NaPi-IIa both in wild-
type and FGF23-deﬁcient mice.(43) Moreover, klotho inhibits the
transport of Pi in renal proximal cells prior to any measurable
reduction in the abundance of NaPi-IIa. The abundance of klotho
was not inﬂuenced by the absence of intestinal NaPi-IIb (Fig. 6E).
The hormonal data reported here are in agreement with the
data from Sabbagh and colleagues,(15) describing only a
transient upregulation of 1,25(OH)2D3, lack of changes of PTH,
and persistent downregulation of intact FGF-23 upon inducible
and global removal of Slc34a2.
FGF-23 is O-glycosylated at a threonine residue that overlaps
with the subtilisin-like cleavage site. Glycosylation is mediated
by GALNT3, and protects the modiﬁed peptide from proteolytic
cleavage and inactivation(44) (Fig. 7A). Consequently, mutations
of FGF-23 that prevent its cleavage result in higher levels of
intact FGF-23, causing autosomal dominant hypophosphatemic
rickets,(45,46) whereas mutations in GALNT3 result in low
concentrations of intact FGF-23 and hyperphosphatemic familial
tumoral calcinosis (for review see Bergwitz and J€uppner(1) and
Strom and J€uppner(46)). The lack of changes in the levels of the
FGF-23 C-terminal fragment together with the reduction in the
intact form (Fig. 6C, D) may suggest that Slc34a2f/f females adapt
to the absence of NaPi-IIb by increasing the proteolytic
processing of FGF-23. Although the expression of GALNT3
mRNA tended to be reduced in bones from female Slc34a2f/f
(Fig. 7B), the change did not reach statistical signiﬁcance. The
transcription of the FGF-23 gene is activated by 1,25(OH)2D3 in a
VDR-dependent manner and administration of 1,25(OH)2D3
results in a dose-dependent increase of FGF-23 in wild-type
mice; instead, VDR-deﬁcient mice have low basal levels of FGF-
23 and do not respond to 1,25(OH)2D3.
(47,48) Although the
plasma levels of 1,25(OH)2D3 remained unchanged in Slc34a2-
depleted animals (Fig. 6A), the expression of the VDR was
reduced in bones from Slc34a2f/f females (Fig. 7D). The lower
levels of VDR in homozygous females could potentially blunt the
transcriptional effect of 1,25(OH)2D3 in FGF-23 expression.
However, the reduction in the mRNA expression of FGF-23 was
below statistical signiﬁcance.
In addition to GALNT3 and 1,25(OH)2D3, the expression and
stability of FGF-23 is regulated, among other factors, by a
cascade of proteins that includes PHEX, the proprotein
convertase 2/7B2 complex (7B2.PC2), BMP1, and DMP1
(Fig. 7A). (49) PHEX is a Zn-metalloprotease recently shown to
promote the expression of 7B2, a cofactor required for activation
of the subtilisin-like proprotein convertase PC2.(50) The 7B2.PC2
complex seems to directly induce the proteolytic inactivation of
FGF-23 and indirectly inhibit FGF-23 mRNA transcription.(50) The
effect on transcription involves proteolytic activation of BMP1,
itself a Zn-metalloprotease that in turn targets DMP1. The C-
terminal fragment of DMP1 inhibits the transcription of FGF-
23.(51) In consequence, activation of this protein cascade reduces
the active FGF-23 by promoting its proteolytic processing while
preventing its transcription. Consistently, mutations in PHEX(52)
and DMP1(53) result in higher FGF-23 levels and hypophospha-
temia (for review see Bergwitz and J€uppner(1) and Strom and
J€uppner(46)). With the exception of the 7B2.PC2 complex, the
expression of the other components of this pathway was
detected inmRNA from bone. However, themRNA expression of
PHEX, BMP1, and DMP1 were not modiﬁed in Slc34a2-depleted
mice.
In homozygous males, the compensatory changes on Pi renal
transport, NaPi-IIa abundance, and FGF-23 plasma concentra-
tion were less evident than in females. Further studies should
address whether the reduction in the urinary output of Pi in
males correlates with changes in other renal parameters such as
glomerular ﬁltration rate or the distal tubular handling of Pi.
The possibility that females and males have different thresholds
for triggering compensatory changes, and therefore that the
adaptive response could be similar in younger (or older) mice
of both genders, cannot be ruled out. For some parameters,
the normalization of results from two independent sets of mice
may have contributed to mask real differences in the pooled
results.
In summary, we have shown that speciﬁc removal of the Naþ/
Pi cotransporter NaPi-IIb/Slc34a2 from the intestinal epithelia
results in almost complete loss of active transport of Pi in ileal
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BBMVs, leading to increased fecal excretion and a compensatory
reduction of the renal output of Pi. All these changes are
comparable in females and males. In females, the adaptation to
the absence of the intestinal cotransporter seems to involve the
bone-kidney axis, with lower levels of FGF-23. Lower FGF-23 in
turn allows stimulation of renal Pi reabsorption due to higher
expression of NaPi-IIa and therefore increased uptake of Pi into
renal BBM. These changes are less apparent in males. The cause
for the gender differences remain to be elucidated.
Disclosures
The authors state that they have no conﬂicts of interest
Acknowledgments
This study was supported by a grant from the Swiss National
Science Foundation (31003A-127288 to JB and NH). We
gratefully acknowledge Nicole Kampik for helping with the
tissue ﬁxation, as well as the technical support of Udo
Schnitzbauer, Nicole Gehring, and Eva Maria Pastor-Arroyo.
The use of the ZIRP Core Facility for Rodent Phenotyping is also
acknowledged.
Authors’ roles: Study design: NH, HM, CAW, and JB. Study
conduct: NH, KM, FS, TK, and LT. Data collection: NH, KM, FS, TK,
and LT. Data analysis: NH, KM, FS, TK, LT, HM, CAW, and JB. Data
interpretation: NH, KM, FS, TK, LT, HM, CAW, and JB. Drafting
manuscript: NH. Revisingmanuscript content: NH, KM, FS, TK, LT,
HM, CAW, and JB. Approving ﬁnal version manuscript: NH, KM,
FS, TK, LT, HM, CAW, and JB. NH, KM, FS, TK, LT, HM, CAW, and JB
take responsibility for the integrity of the data analysis.
References
1. Bergwitz C, J€uppner H. Regulation of phosphate homeostasis by
PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.
2. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23
and Klotho: physiology and pathophysiology of an endocrine
network of mineral metabolism. Annu Rev Physiol. 2013;75:
503–33.
3. Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal
phosphate wasting. Nat Rev Nephrol. 2010 Nov;6(11):657–65.
4. Paloian NJ, Giachelli CM. A current understanding of vascular
calciﬁcation in CKD. Am J Physiol Renal Physiol. 2014 Oct 15;307(8):
F891–900.
5. Biber J, Hernando N, Forster I. Phosphate transporters and their
function. Annu Rev Physiol. 2013;75:535–50.
6. Forster IC, Hernando N, Biber J, Murer H. Phosphate transporters
of the SLC20 and SLC34 families. Mol Aspects Med. 2013;34(2-3):
386–95.
7. Wagner CA, Hernando N, Forster IC, Biber J. The SLC34 family of
sodium-dependent phosphate transporters. Pﬂugers Archiv.
2014;466(1):139–53.
8. Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Na-
dependent phosphate transporters by dietary phosphate. Am J
Physiol Renal Physiol. 2009;297(5):F1466–75.
9. Xu H, Bai L, Collins JF, Ghishan FK. Molecular cloning, functional
characterization, tissue distribution, and chromosomal localization
of a human, small intestinal sodium-phosphate (Naþ-Pi) transporter
(SLC34A2). Genomics. 1999;62(2):281–4.
10. Radanovic T, Wagner CA, Murer H, Biber J. Regulation of intestinal
phosphate transport. I. Segmental expression and adaptation to
low-P(i) diet of the type IIb Na(þ)-P(i) cotransporter in mouse small
intestine. Am J Physiol Gastrointest Liver Physiol. 2005;288(3):
G496–500.
11. Hilﬁker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J.
Characterization of a murine type II sodium-phosphate cotrans-
porter expressed in mammalian small intestine. Proc Natl Acad Sci U
S A. 1998;95(24):14564–9.
12. Corut A, Senyigit A, Ugur SA, et al. Mutations in SLC34A2 cause
pulmonary alveolar microlithiasis and are possibly associated with
testicular microlithiasis. Am J Hum Genet. 2006;79(4):650–6.
13. Chen DR, Chien SY, Kuo SJ, et al. SLC34A2 as a novel marker for
diagnosis and targeted therapy of breast cancer. Anticancer Res.
2010;30(10):4135–40.
14. Shyian M, Gryshkova V, Kostianets O, et al. Quantitative analysis of
SLC34A2 expression in different types of ovarian tumors. Exp Oncol.
2011;33(2):94–8.
15. Sabbagh Y, O’Brien SP, Song W, et al. Intestinal npt2b plays a major
role in phosphate absorption and homeostasis. J Am Soc Nephrol.
2009;20(11):2348–58.
16. Lee GJ, Marks J. Intestinal phosphate transport: a therapeutic target
in chronic kidney disease and beyond? Pediatr Nephrol. 2015
Mar;30(3):363–71.
17. Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the
renal-gastrointestinal axis. Am J Physiol Renal Physiol. 2010;299(2):
F285–296.
18. Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small
intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake.
Am J Physiol. 1999;277(4 Pt 1):G756–762.
19. Capuano P, Radanovic T, Wagner CA, et al. Intestinal and renal
adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D
receptor- and 1alphaOHase-deﬁcientmice. Am J Physiol Cell Physiol.
2005;288(2):C429–434.
20. Segawa H, Kaneko I, Yamanaka S, et al. Intestinal Na-P(i)
cotransporter adaptation to dietary P(i) content in vitamin D
receptor null mice. Am J Physiol Renal Physiol. 2004;287(1):F39–47.
21. Xu H, Bai L, Collins JF, Ghishan FK. Age-dependent regulation of rat
intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2)
vitamin D(3). Am J Physiol Cell Physiol. 2002;282(3):C487–93.
22. Beck L, et al. Targeted inactivation of Npt2 in mice leads to severe
renal phosphate wasting, hypercalciuria, and skeletal abnormalities.
Proc Natl Acad Sci U S.A. 1998;95(9):5372–7.
23. Myakala K, Motta S, Murer H, et al. Renal-speciﬁc and inducible
depletion of NaPi-IIc/Slc34a3, the cotransporter mutated in HHRH,
does not affect phosphate or calcium homeostasis in mice. Am J
Physiol Renal Physiol. 2014 Apr 15;306(8):F833–43.
24. Segawa H, Onitsuka A, Kuwahata M, et al. Type IIc sodium-
dependent phosphate transporter regulates calcium metabolism. J
Am Soc Nephrol. 2009;20(1):104–13.
25. Shibasaki Y, Etoh N, Hayasaka M, et al. Targeted deletion of the
tybe IIb Na(þ)-dependent Pi-co-transporter, NaPi-IIb, results in early
embryonic lethality. Biochem Biophys Res Commun. 2009;381-
(4):482–6.
26. Porret A, Merillat AM, Guichard S, Beermann F, Hummler E. Tissue-
speciﬁc transgenic and knockout mice. Methods Mol Biol.
2006;337:185–205.
27. Biber J, Stieger B, Stange G, Murer H. Isolation of renal proximal
tubular brush-border membranes. Nat Protoc. 2007;2(6):1356–9.
28. Stoll R, Kinne R, Murer H. Effect of dietary phosphate intake on
phosphate transport by isolated rat renal brush-border vesicles.
Biochem J. 1979;180(3):465–70.
29. Custer M, Lotscher M, Biber J, Murer H, Kaissling B. Expression of Na-
P(i) cotransport in rat kidney: localization by RT-PCR and
immunohistochemistry. Am J Physiol. 1994;266(5 Pt 2):F767–74.
30. Nowik M, Picard N, Stange G, et al. Renal phosphaturia during
metabolic acidosis revisited: molecular mechanisms for decreased
renal phosphate reabsorption. Pﬂugers Arch. 2008;457(2):
539–49.
31. Lotscher M, Kaissling B, Biber J, Murer H, Kempson SA, Levi M.
Regulation of rat renal Na/Pi-cotransporter by parathyroid hormone:
immunohistochemistry. Kidney Int. 1996;49(4):1010–11.
32. Villa-Bellosta R, Sorribas V. Role of rat sodium/phosphate cotrans-
porters in the cell membrane transport of arsenate. Toxicol Appl
Pharmacol. 2008;232(1):125–34.
1936 HERNANDO ET AL. Journal of Bone and Mineral Research
33. Khurana S, George SP. Regulation of cell structure and function by
actin-binding proteins: villin’s perspective. FEBS Lett. 2008;582(14):
2128–39.
34. Nishimura M, Naito S. Tissue-speciﬁc mRNA expression proﬁles of
human solute carrier transporter superfamilies. Drug Metab
Pharmacokinet. 2008;23(1):22–44.
35. Ma Y, Samaraweera M, Cooke-Hubley S, et al. Neither absence nor
excess of FGF23 disturbs murine fetal-placental phosphorus
homeostasis or prenatal skeletal development and mineralization.
Endocrinology. 2014;155(5):1596–605.
36. Perwad F, Portale AA. Vitamin D metabolism in the kidney:
regulation by phosphorus and ﬁbroblast growth factor 23. Mol
Cell Endocrinol. 2011;347(1-2):17–24.
37. Deliot N, Hernando N, Horst-Liu Z, et al. Parathyroid hormone
treatment induces dissociation of type IIa Naþ-P(i) cotransporter-
Naþ/Hþ exchanger regulatory factor-1 complexes. Am J Physiol Cell
Physiol. 2005;289(1):C159–67.
38. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-
2a and NaPi-2c expression and induces hypophosphatemia in vivo
predominantly via FGF receptor 1. Am J Physiol Renal Physiol.
2009;297(2):F282–91.
39. Segawa H, Kawakami E, Kaneko I, et al. Effect of hydrolysis-resistant
FGF23-R179Q on dietary phosphate regulation of the renal type-II
Na/Pi transporter. Pﬂugers Archiv. 2003;446(5):585–92.
40. Weinman EJ, Steplock D, Shenolikar S, Biswas R. Fibroblast growth
factor-23-mediated inhibition of renal phosphate transport in mice
requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1)
and synergizes with parathyroid hormone. J Biol Chem. 2011;286(43):
37216–21.
41. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for
autosomal dominant hypophosphatemic, rickets is resistant to
proteolytic cleavage and causes hypophosphatemia in vivo.
Endocrinology. 2002;143(8):3179–82.
42. Saito H, Kusano K, Kinosaki M, et al. Human ﬁbroblast growth factor-
23 mutants suppress Naþ-dependent phosphate co-transport
activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol
Chem. 2003;278(4):2206–11.
43. Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance
acting as an autocrine enzyme in the renal proximal tubule. FASEB J.
2010;24(9):3438–50.
44. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase
T3 and familial tumoral calcinosis. Secretion of ﬁbroblast growth
factor 23 requires O-glycosylation. J Biol Chem. 2006;281(27):
18370–7.
45. White KE, Evans WE, O’Riordan JLH, et al. ADHR Consortium.
Autosomal dominant hypophosphataemic rickets is associated with
mutations in FGF23. Nat Genet. 2000;26(3):345–8.
46. Strom TM, J€uppner H. PHEX, FGF23, DMP1 and beyond. Curr Opin
Nephrol Hypertens. 2008;17(4):357–62.
47. Kolek OI, Hines ER, Jones MD, et al. 1 alpha, 25-Dihydroxyvitamin D3
upregulates FGF23 gene expression in bone: the ﬁnal link in a renal-
gastrointestinal-skeletal axis that controls phosphate transport.
Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1036–42.
48. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by
1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol
Chem. 2005;280(4):2543–9.
49. Feng JQ, Clinkenbeard EL, Yuan B, White KE, Drezner MK. Osteocyte
regulation of phosphate homeostasis and bone mineralization
underlies the pathophysiology of the heritable disorders of rickets
and osteomalacia. Bone. 2013;54(2):213–21.
50. Yuan B, Feng JQ, Bowman S, et al. Hexa-D-arginine treatment
increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues
the HYP phenotype. J Bone Miner Res. 2013;28(1):56–72.
51. Martin A, David V, Li H, Dai B, Feng JQ, Quarles LD. Overexpression of
the DMP1 C-terminal fragment stimulates FGF23 and exacerbates
the hypophosphatemic rickets phenotype in Hyp mice. Mol
Endocrinol. 2012;26(11):1883–95.
52. Holm IA, Huang X, Kunkel LM. Mutational analysis of the PEX gene in
patients with X-linked hypophosphatemic rickets. Am J Hum Genet.
1997;60(4):790–7.
53. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1
mutations in autosomal recessive hypophosphatemia implicate a
bone matrix protein in the regulation of phosphate homeostasis.
Nat Genet. 2006;38(11):1248–50.
Journal of Bone and Mineral Research INTESTINAL DEPLETION OF NAPI-IIB/SLC34A2 IN MICE 1937
50 
 
3.2 The intestinal phosphate transporter NaPi-IIb 
(Slc34a2) is required to protect bone during 
dietary phosphate restriction 
 
Thomas Knöpfel1, Eva M. Pastor1, Udo Schnitzbauer1, Denise Kratschmar2,  
Alex Odermatt2, Nati Hernando1*, Carsten A. Wagner1* 
 
1Institute of Physiology, University of Zurich, Switzerland, 2Division of Molecular and 
Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel 
*N. Hernando and C.A. Wagner contributed equally and share last authorship 
 
 
Own contribution:  
Thomas Knöpfel (TK) contributed to the experimental design of the study and the 
animal experiments. TK performed western blots, quantitative real time PCR, urine 
analysis and microcomputer tomography of bones. The manuscript including figures 
was drafted by TK. 
  
51 
 
Abstract 
NaPi-IIb (Slc34a1) is a Na+-dependent phosphate (Pi) transporter that accounts for 
the majority of the active transport of phosphate into epithelial cells of the small 
intestine. Its abundance in the intestinal brush border membrane is regulated by 
dietary phosphate, being high during dietary Pi restriction. Intestinal ablation of NaPi-
IIb in mice leads to increased fecal excretion of phosphate, which is compensated by 
enhanced renal Pi reabsorption to maintain phosphate homeostasis. Here we report 
the response of NaPi-IIb deficient mice to alterations in dietary phosphate content. As 
in wild type animals, high phosphate load increases fecal and urinary excretion of 
phosphate in NaPi-IIb deficient mice, whereas phosphate restriction decreases 
intestinal and urinary phosphate excretion. However under dietary phosphate 
restriction, plasma phosphate levels decline more rapidly in NaPi-IIb deficient mice. 
Despite hypophosphatemia, NaPi-IIb deficient mice fed low phosphate show 
comparable levels of vitamin D3, parathyroid hormone and fibroblast growth factor 23 
to wild type littermates. Furthermore, the expression of renal cotransporters is also 
similar in both groups of mice. Instead, upon feeding low phosphate, NaPi-IIb 
deficient animals show a more pronounced increase in urinary excretion of calcium, 
cortiscosterone and the bone resorption marker deoxypyridionline, as well as lower 
bone mineral density than wild type mice. These data suggests that NaPi-IIb 
mediated phosphate absorption during dietary phosphate restriction prevents 
excessive demineralization of bone as an alternative source of phosphate.   
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Introduction 
Phosphate (Pi) is a vital compound for many biological functions including energy 
metabolism, intracellular signaling, structural composition of cellular membranes, and 
bone mineralization. Hence Pi homeostasis is regulated by the coordinated interplay 
of different organs and endocrine networks. The intestine absorbs Pi from the diet 
and kidneys reabsorb Pi from the primary filtrate. Additionally, the bones serve as a 
reservoir for Pi, where it can be deposited as hydroxyapatite or released, in case Pi 
supply gets low (1, 2). Under normal conditions bone formation through osteoblasts is 
in balance with bone resorption mediated by osteoclasts. Several hormones such as 
parathyroid hormone (PTH) or glucocorticoids can stimulate osteoclast activity and 
thereby increase bone mineral release and promote demineralization (3, 4). 
The Slc34 family of Na+-dependent Pi transporters plays an essential role in Pi 
homeostasis. In the intestine of mice, transcellular transport of Pi occurs mainly in the 
ileum, where NaPi-IIb (Slc34a2) is localized (5, 6). Indeed, NaPi-IIb appears to be the 
major murine intestinal Pi transporter, as its depletion results in abrogation of Na+-
dependent transport of Pi and fecal loss of Pi (7, 8). Although mutations in NaPi-IIb 
have been described as a main cause of pulmonary alveolar microlithiasis in humans 
(9), Pi metabolism of these patients has not been investigated. NaPi-IIa (Slc34a1) 
and NaPi-IIc (Slc34a3) are responsible for the renal reabsorption of Pi. Both 
transporters are localized in the brush border membrane (BBM) of the renal proximal 
tubular cells (10, 11). NaPi-IIa accounts for the majority of Pi reabsorption, since its 
ablation in mice leads to severe renal Pi wasting and hypophosphatemia, resulting in 
underdeveloped bone trabeculae, impaired bone formation and nephrocalcinosis (12, 
13). Hypophosphatemia and nephrocalcinosis have been also reported in patients 
with mutations in NaPi-IIa (14, 15), and gene wide association studies indicate a 
strong correlation between NaPi-IIa and plasma levels of Pi (16). In contrast, deletion 
of NaPi-IIc does not impair Pi homeostasis in mice (17, 18); however, many studies 
have reported mutations in NaPi-IIc in patients with hereditary hypophosphatemic 
rickets with hypercalciuria (for review see (19, 20)). The Slc20 family of Na+- 
dependent Pi transporters consists of Pit1 and Pit2, both showing broad tissue 
distribution including the epithelia of intestine and the renal proximal tubule (21). 
Their contribution to intestinal and renal transport of Pi remains to be tested, though 
the renal expression of Pit2 is regulated by factors controlling Pi homeostasis (22). 
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The abundance of Slc34 transporters is regulated by a hormonal network consisting 
of PTH, fibroblast growth factor 23 (FGF23) and vitamin D3 (for review see (23, 24)). 
PTH and FGF23 target the kidney to promote phosphaturia by removing NaPi-IIa and 
NaPi-IIc from the BBM of proximal cells (for review see (25)), whereas vitamin D3 
acts on the intestine to stimulate absorption of Pi by increasing the expression of 
NaPi-IIb (26). In addition, each of these hormones controls the levels of the other two 
(for review see (23, 24)). Defects in any of these hormonal regulators of Pi 
homeostasis have a large impact on mineral homeostasis. 
Dietary Pi content influences the levels of Pi-regulating hormones and Pi-
transporters. Thus, low dietary Pi as well as hypophosphatemia increase the 
abundance of NaPi-IIa, NaPi-IIc and NaPi-IIb (22, 27-30) and thereby promote 
intestinal absorption and renal reabsorption. These changes are at least in part 
secondary to higher circulating levels of vitamin D3 and reduced concentrations of 
FGF23 and PTH (28). However, studies in VDR KO mice indicate that stimulation of 
NaPi-IIb also occurs in a vitamin D3 independent fashion (29, 30). The reduced levels 
of FGF23 and PTH triggered by hypophosphatemia remove the suppression of renal 
NaPi-IIa and NaPi-IIc and thereby enhance renal Pi reabsorption. In contrast, high 
levels of dietary Pi as well as hyperphosphatemia  stimulate PTH and FGF23 and 
reduce vitamin D3 (28, 31, 32). In addition to its phosphaturic effect, high FGF23 also 
reduces the production of vitamin D3 and increases its degradation (33), blunting the 
stimulatory effect on intestinal Pi absorption. Besides their effects on Pi handling, 
vitamin D3 and PTH also control the levels of plasma Ca
2+ by stimulating the 
expression of intestinal (TPRV6, calbindin D9K and Ca
2+-ATPase) and renal (TRPV5, 
calbindin D28K and NCX1) proteins involved in epithelial Ca
2+ transport (for review see 
(34, 35)) as well as by stimulation of osteoclasts and thereby bone resorption (36).  
As discussed above, intestinal ablation of NaPi-IIb in mice abolishes Na+-dependent 
Pi uptake into intestinal BBM (7, 8). However, under standard dietary condition these 
mice only show slightly increased fecal Pi losses, which is compensated by reduced 
urinary excretion, thus preserving normophosphatemia. Since the expression of 
NaPi-IIb is upregulated by low dietary Pi (37), the role of NaPi-IIb may become more 
important once dietary Pi is restricted. In this study we compare the effect of the 
dietary Pi content particularly Pi-restriction, in wild type and intestinal-specific NaPi-
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IIb deficient mice and show that under these conditions, NaPi-IIb deficient mice 
demineralize bone which may help to prevent more severe hypophosphatemia. 
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Methods 
Animal handling 
Experiments were performed in two month old floxed-Slc34a2 male mice expressing 
villin-driven Cre recombinase (NaPi-IIbf/f) (8) and their wild type litter mates (WT, 
NaPi-IIb-/-). Mice were initially fed normal diets (0.8 % Pi, 1 % calcium) while housed 
in metabolic cages (Tecniplast, Buguggiate, Italy) to collect basal urinary (under 
mineral oil) and stool samples. Then, they were randomized in three groups: two of 
them received either a low (LPD; 0.1 % Pi, 1 % calcium) or high (HPD; 1.2 % Pi, 1 % 
calcium) Pi diet (Kliba Promivi AG, Switzerland) for 3 days, whereas the third group 
was fed the low Pi diet for 14 days. During the whole procedure mice were fed ad 
libitum with free access to water. Three days before harvesting samples, animals 
were placed in metabolic cages to collect urine and stool samples. Mice were then 
anesthetized using ketamine and xylazine. Upon opening the abdominal cavity, blood 
was collected from the vena cava and centrifuged at 4°C in heparinized tubes for 7 
minutes at 7000 rpm; plasma was aliquoted and immediately frozen in liquid nitrogen. 
Organs were harvested and frozen in liquid nitrogen. Plasma, organs and scrapings 
from mucosa of ileum were stored at -80°C for further analysis. Urine was centrifuged 
at 10000 rpm for 10 minutes and stored at -20°C. Experiments were approved by the 
local veterinary authority (Veterinäramt Zürich) and performed according to Swiss 
Animal Welfare laws. 
Plasma, urine and stool parameters 
The levels of Pi in stool, urine and plasma were colorimetrically determined according 
to the Fiske Subbarow method (38). For determination of fecal Pi content, dried stool 
samples were first dissolved in 0.6 M HCl for three days, homogenized and 
centrifuged as reported (7). The Jaffe method was used to measure urinary 
creatinine (39). Urinary calcium, sodium, potassium, magnesium and chloride as well 
as plasma calcium and creatinine were measured on a UniCel DxC 800 Synchron 
Clinical System (Beckman Coulter), a service provided by the Zürich Integrative 
Rodent Physiology (ZIRP) facility.  
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FGF23, PTH, vitamin D and DPD measurement 
FGF23 (intact) and PTH (intact) levels in plasma were analyzed by ELISA 
(Immunotopics International, San Clemente, CA, USA). For plasma 1,25 (OH)2- 
Vitamin D3 measurements, a radioimmunoassay kit (Immunodiagnostic System, 
Frankfurt am Main, Germany) was used. Urinary deoxypyridionline (DPD) was 
assessed with an enzymatic immunoassay kit (MicroVue DPD EIA, Quidel 
Corporation, Athens, USA). All assays were performed according to the 
manufacturers’ protocol. 
Renal brush border membrane vesicle and homogenate preparation 
Brush border membrane vesicles (BBMV) were prepared from frozen kidneys as 
described before (40). A polytron (PT 10-35, Kinematica GmbH, Lucerne) was used 
to homogenize kidneys in a buffer containing 300 mM mannitol, 5 mM EGTA, 12 mM 
Tris-HCl (pH 7.1) and complete mini protease inhibitor cocktail (Roche, Switzerland). 
A small aliquot of the homogenate was frozen and stored at -80°C for western blot 
analysis. Upon addition of MgCl2 (12 mM final concentration), the remaining 
homogenate was kept on ice for 15 minutes followed by centrifugation at 4500 rpm 
for 15 minutes at 4°C. The resulting supernatant was further centrifuged at 17500 
rpm for 30 minutes at 4°C to collect BBMV. The pellet, containing BBMV was 
resuspended in a buffer composed of 300 mM mannitol and 20 mM HEPES-Tris (pH 
7.4).  
Uptake of 32P-phosphate, 3H-D-glucose and 14C-isoleucine into renal BBMV 
Uptakes were done according to the reported filtration technique (41). Freshly 
prepared BBMV were incubated in solutions containing either 100 mM NaCl or 100 
mM KCl, both solutions supplemented with 0.1 mM Pi and 32P labelled tracer.  3H-D-
glucose and 14C-leucine uptakes were measured following the same protocol using 
solutions containing 0.1 mM D-glucose and 0.1 mM isoleucine together with the 
indicated radiolabeled tracers. Uptakes were left to proceed for either 30 seconds 
(3H-Glucose and 14C-leucine) or 1 minute (32P). The incorporation of traces into the 
BBMV was measured with a β-counter (Packard BioScience). Remaining BBMVs 
were snap-frozen and stored at -80°C for western blot analysis. 
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Total membrane fractions from ileum 
Scrapings from mucosa of ileum were homogenized in a buffer containing 200 mM 
mannitol, 80 mM HEPES, 41 mM KOH, and protease inhibitors, with pH adjusted to 
7.5. Homogenization was performed with MagNa Lyser Green Beads (Roche), in a 
Precellys 24 Homogenizer. Upon centrifugation at 800 rpm for 20 minutes at 4°C, 
supernatants were further centrifuged at 41’000 rpm for 30 minutes at 4°C, and 
pellets containing total membrane proteins were resuspendend in the same buffer 
used for homogenization. 
 
Western blot  
A Bio Rad DC protein assay kit (BioRad, Cressier, Switzerland) was used to measure 
the protein concentration of renal homogenates and BBMV as well as of total 
membrane fractions from ileum. Then, 20 µg of proteins were mixed with Laemmli 
sample buffer (0.38 M Tris base, 8% SDS, 4 mM EDTA, 40% (v/v) glycerol, pH 
adjusted to 6.8 with HCl, and 40 mg/10 ml of bromphenol blue) and loaded on 9% or 
12% acrylamide SDS-PAGE. A standard tank system (Mini Trans-Blot, Bio-Rad) was 
used to transfer proteins from gels onto polyvinylidene difluoride (PVDF) membranes 
(Immobilon-P, Millipore, Schaffhausen, Switzerland). Tris buffered saline (TBS) 
containing 5% fat free powder milk was used to block membranes for 30 minutes at 
room temperature. Then, PVDF membranes were incubated overnight at 4°C with 
primary antibodies against NaPi-IIa (10), NaPi-IIb (ref), NaPi-IIc (42), TRPV5 (43), 
CaSR (Thermofisher Scientific), Calbindin D28k (SWANT, Marly, Switzerland), 
Cyp24a1 (Protein Tech, Manchester, United Kingdom), and β-actin (Sigma-Aldrich, 
Buchs, Switzerland). Upon three consecutive washing steps with TBS, membranes 
were again blocked and incubated for 2 hours at room temperature with the 
appropriate (anti- mouse or-rabbit) secondary antibody linked to horse radish 
peroxidase (HRP) (Promega AG, Dübendorf, Switzerland). After three washes with 
TBS, membranes were exposed to HRP substrate (Western Chemiluminescence 
HRP Substrate, Millipore, Schaffhausen, Switzerland) for 5 minutes. 
Chemiluminiscence was detected with a LAS-4000 camera system (Fujifilm). 
Densitometric analysis was performed using ImagJ and normalized to β-actin. 
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Semi-quantitative real time RT-PCR 
Half a kidney was homogenized in RLT buffer supplemented with β-mercaptoethanol. 
RNA from homogenates was isolated using the Qiagen RNeasy Mini kit (Qiagen, 
Hombrechtikon, Switzerland) following the protocol provided by the supplier. TaqMan 
Reverse Transcription Kit (Applied Biosystems, Zug, Switzerland) was then used for 
reverse transcription of the isolated RNA according to the manufacturers’ protocol. 
To quantify relative gene expression, specific sets of primers and FAM/TAMRA-
labelled probes for Cyp27b1 (Mm01165918_g1,) and Slc34a2 (Microsynth, 
Switzerland) were used, and their abundance was normalized to the expression of 
hypoxanthine-guanine phosphoribosyltransferase (HPRT, Microsynth, Switzerland). 
KAPA PROBE FAST qPCR Kit Master Mix (KAPA BIOSYSTEMS, Boston USA) 
containing primers (5 µM) and probe (25 µM) was used to amplify cDNA in a 7500 
Fast Real Time PCR System (Applied Biosystems, Zug, Switzerland).  The cycle 
number at a given threshold (Ct) was measured and gene expression relative to the 
expression of HPRT was calculated according to the formula R=2^(CtHPRT-Ctgene of 
interest). 
Micro Computer Tomography 
Freshly isolated femurs were scanned in a Quantum GX microCT Imaging System 
(PerkinElmer) provided by the ZIRP facility. Distal epiphysis and subsequent 
diaphysis was imaged for 3 minutes using a 5 mm field of view at a tube current of 
100 µA and 90 kV tube voltage. Analyze 12.0 program (AnalyzeDirect, Inc., Overland 
Park, USA) was used to asses bone mineral density (BMD) and bone volume data. 
Bones were analyzed from the end of the patellar surface of the distal epiphysis and 
100 sections into the diaphysis were averaged. Grey scales of the scans were 
translated into BMD using a calibration curve obtained by scans of a 1200 mg/cm3 
hydroxy apatite phantom (Micro-CT HA Phantom, QRM GmbH, Moehrendorf, 
Germany). 
Glucocorticoids 
Urinary glucocorticoids (corticosterone, 11-dehydrocorticosterone and 5 alpha-
Dihydrocorticosterone was measured by ultra-pressure liquid chromatography-
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tandem mass spectrometry (UPLC-MS/MS) by our collaborators in Basel (Alex 
Odermatt and Denise Kratschmar). 
 
Statistical Analysis 
Unpaired students t-test or ANOVA with Bonferroni correction for multiple 
comparisons were used to analyze comparisons. P-values > 0.05 were considered 
as significant. Data is presented as Mean + SEM. 
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Results 
Intestinal ablation of NaPi-IIb and Pi deprivation causes transient 
hypophosphatemia and stimulates urinary calcium excretion 
Wild type mice and mice lacking intestinal NaPi-IIb expression were analyzed in 
metabolic cages under standard conditions as well as after 3 days HPD or LPD and 
14 days LPD (Figure 1A and Table 1). For both genotypes, the fecal excretion of Pi 
reflected the dietary Pi content: it was higher in animals fed high Pi and progressively 
lower in those fed low Pi as compared with mice kept on normal chow. Under all 
dietary conditions, there was a tendency for increased fecal Pi excretion in KO 
compared with WT mice, which was only significant during HPD conditions when 
absolute values were compared. However, the relative differences in fecal Pi 
excretion between both genotypes increased with decreasing levels of Pi in the diet: 
NaPi-IIb KO showed around 18% higher excretion than WT mice when fed normal or 
high Pi diets whereas the increase was 44% and 55% in the groups fed low Pi for 3 
and 14 days, respectively (supplementary Figure 1).  
Urinary Pi was quantified for the same dietary conditions. In both genotypes, the 
urinary content of Pi adapted to the dietary Pi content, being higher in mice fed HPD 
diet and progressively lower in the groups fed LPD as compared with mice receiving 
standard food (Figure 1B and Table 1). NaPi-IIb KO animals excreted significantly 
less Pi in urine than the WT littermates after 3 days of LPD adaptation, whereas no 
differences between genotypes were observed under 3 days of HPD or after 14 days 
of LPD.  
Plasma levels of Pi were measured during dietary adaptations (Figure 1C and Table 
1).  The different dietary conditions did not result in significant changes in plasma Pi 
values neither in WT nor in NaPi-IIb deficient mice. However, due to a transient trend 
for hypophosphatemia in NaPi-IIb KO fed LPD, plasma Pi was lower in mutant mice 
than in WT upon 3 days LPD. No differences between both genotypes were detected 
in the other dietary conditions.  
Urinary Ca2+ excretion was analyzed under normal dietary conditions as well as after 
3 days HPD or LPD and 14 days LPD (Figure 1D and Table 1). In both genotypes 
excretion was comparable in mice fed a normal diet or HPD for 3 days, whereas a 
drastic increase was observed in animals fed a LPD for either 3 or 14 days. This 
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increase was even stronger (more than 70%) in NaPi-IIb KO animals compared to 
WT mice.  
Additionally a higher volume of urine was excreted in NaPi-IIb KO mice after long 
term dietary Pi restriction (Table 1), but the creatinine clearance as an indicator for 
glomerular filtration rate (GFR) was not significantly altered and excretion of other 
measured ions was comparable to WT animals (Table 2). 
Plasma levels of Ca2+ progressively increased in the groups fed LPD compared with 
HPD (Figure 1D and Table 1). However, there were no differences between WT and 
NaPi-IIb KO animals under any dietary condition. 
 
Hormonal adaptation is similar in both genotypes 
WT and NaPi-IIb KO animals fed a LPD showed a transient increase in the levels of 
plasma 1,25-(OH)2 vitamin D3 compared to animals fed a HPD (Figure 2A). 1,25-
(OH)2 vitamin D3 levels were comparable in WT and NaPi-IIb KO mice under all 
conditions. Renal expression of Cyp27b1 mRNA and Cyp24a1 protein was analyzed 
in animals fed LPD for 14 days. There was no difference between WT and NaPi-IIb 
KO mice neither on the mRNA levels of the vitamin D3 activating enzyme Cyp27b1 
(Figure 2B), nor on the protein expression of the vitamin D3 catabolizing enzyme 
Cyp24a1 (Figure 2C). 
The concentration of plasma PTH was significantly lower in animals fed a LPD for 3 
days than in animals adapted to HPD (Figure 2D). Long term dietary Pi restriction led 
to an even further decrease in plasma PTH. However, both WT and NaPi-IIb KO 
animals showed similar PTH levels after adapting to the different dietary conditions. 
For intact FGF23 levels, a similar pattern to PTH was observed (Figure 2E), i.e. LPD 
resulted in a progressive reduction of plasma FGF23. No differences between 
genotypes were observed under the same conditions.  
Phosphate transport into renal BBMVs and expression of NaPi-IIa and NaPi-IIc 
is not altered 
Transport studies were performed in renal BBMVs from mice fed LPD diet for 14 
days. Uptakes were done in presence and absence of sodium, to determine sodium 
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dependent and independent components of Pi, leucine and glucose transport. Both 
WT and NaPi-IIb KO animals showed at least a 97% decrease of Pi uptake into renal 
BBMVs in the absence of sodium, but the sodium dependent and independent 
transport rates were similar in both genotypes (Figure 3A). Transport rates of leucine 
(Figure 3B) and glucose (Figure 3C) also showed a strong dependency on sodium 
(more than 80%), but intestinal ablation of NaPi-IIb did not affect uptakes.  
The protein abundance of NaPi-IIa and NaPi-IIc was assessed in the same BBMV 
preparations that were used for the uptake experiments (long term dietary Pi 
restriction). The expression of NaPi-IIa (Figure 3D) and NaPi-IIc (Figure 3E), was not 
affected by intestinal NaPi-IIb deficiency.  
NaPi-IIb protein abundance in ileum was increased after 3 and 14 days of LPD 
compared to HPD, whereas the cotransporter was not detected in NaPi-IIb deficient 
animals (Figure 3F) 
Pi restriction does not affect expression of proteins involved in renal calcium 
handling between genotypes 
The abundance of proteins involved in renal Ca2+ handling was assessed in apical 
membrane preparations and total kidney homogenates from WT and NaPi-IIb KO 
animals after 14 days dietary Pi restriction. The expression of the Ca2+ channel 
TRPV5 was analyzed in apical membranes (Figure 4A), whereas the abundance of 
the Ca2+ sensing receptor (CaSR, Figure 4B) and calbindin-D28k (Figure 4C) was 
quantified in renal homogenates. Similar levels of all three proteins were observed in 
WT and NaPi-IIb KO animals. 
Urinary excretion of deoxypyridionline and corticosterone, as well as bone 
mineral density are altered in Pi-restricted NaPi-IIb KO mice   
Urinary excretion of deoxypyridionline (DPD) was quantified as a marker for bone 
resorption (Figure 5A). The dietary content of Pi did not influence the urinary 
concentration of DPD in WT animals; however, LPD triggered a progressive increase 
in the amount of DPD excreted into urine by intestinal NaPi-IIb KO mice. No 
difference was observed between WT and NaPi-IIb KO fed a HPD or LPD for three 
days, whereas  after long term Pi restriction the levels of DPD in the urine of NaPi-IIb 
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KO animals were significantly higher (about 85%) than in the corresponding WT 
animals.  
Urinary corticosterone levels were higher in NaPi-IIb deficient animals than in WT 
litter mates after 14 days of dietary Pi restriction (Figure 5B). The corticosterone 
metabolites 11-dehydrocorticosterone and 5-alpha-dihydrocorticosterone were also 
increased in NaPi-IIb deficient animals (113.2±19.9 and 176.2±14.8, respectively) 
compared to WT (52.0±10.4 and 109.0±15.5, respectively). 
Bone mineral density (BMD) was measured in the femurs of WT and NaPi-II KO mice 
fed 14 days LPD. BMD significantly decreased in NaPi-IIb KO animals when 
challenged with a long term dietary Pi restriction, compared with the WT littermates 
(Figure 5B). The difference was detected both in cortical and trabecular bone tissue 
of femurs, though the changes were higher in trabecular bone. 
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Discussion 
NaPi-IIb has been considered to be the major apical phosphate transporter in the 
small intestine since its intestinal ablation in mice abolishes Na+-dependent uptake of 
Pi into intestinal sacks and BBMV from ileum (7, 8), indicating the loss of active 
transcellular transport of Pi in the small intestine. However, under standard feeding 
conditions the absence of NaPi-IIb only leads to a moderate fecal wasting of Pi, 
which is compensated by increased renal reabsorption, thus resulting in normal 
plasma Pi. This mild phenotype suggests an alternative transport pathway across the 
intestinal epithelium able to supply enough Pi, at least under normal dietary Pi. 
Passive absorption through the paracellular pathway may contribute to this process 
when a sufficient gradient of Pi is stablished across the epithelium. However, in 
response to low dietary Pi the expression of NaPi-IIb increases (27, 28), indicating 
that the active component may be required to adapt to a reduced oral supply of Pi. 
Therefore, we investigated whether the contribution of NaPi-IIb becomes higher once 
dietary Pi is limited.  
As observed in WT animals, the fecal excretion of Pi in NaPi-IIb KO also increased 
with HPD and decreased under LPD. However, under all dietary conditions, the fecal 
Pi output was higher in NaPi-IIa KO than WT, though the difference between 
genotypes was significant only in HPD when ANOVA was applied to the absolute 
values. The large differences in the fecal Pi content between the HPD and LPD 
groups probably masked the relatively smaller differences between genotypes in the 
normal and LPD; indeed, significant differences were observed in all feeding 
protocols when the NaPi-IIb KO values were normalized to the excretion of the 
dietary-matched WT. Moreover, normalization also indicated that the absence of 
NaPi-IIb had a larger impact in the Pi-restricted groups than in animals fed high Pi. 
This may indicate that the contribution of the active transport component (mediated 
mostly by NaPi-IIb) becomes bigger when dietary Pi is low: dietary restriction could 
theoretically result in lower Pi levels in the intestinal lumen, thus providing a lower 
gradient for passive transport of Pi across the epithelium. As expected, vitamin D3, a 
major stimulus for intestinal Pi absorption (26), was increased in animals fed the LPD 
compared to HPD. However, no differences were detected between KO and WT 
mice. This observation was further supported by the finding that the expression of 
Cyp27b1 and Cyp24a1 (mRNA and protein respectively) was similar in both groups 
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of mice. These renal enzymes are crucial in controlling the systemic levels of vitamin 
D3, since Cyp27b1 converts 25(OH)D3 into the active 1,25(OH)2D3, whereas 
Cyp24a1 catabolizes vitamin D3 (44). The higher NaPi-IIb abundance triggered by 
low dietary Pi/high vitamin D3 might further increase the relative difference in Pi 
transport between WT and NaPi-IIb KO animals, which is in agreement with the 
observed trend of bigger relative differences in Pi excretion as dietary Pi is restricted. 
Dietary loading with Pi triggers a phosphaturic response whereas urinary Pi is low 
upon dietary Pi restriction. These changes inversely correlate with the abundance of 
the renal transporters NaPi-IIa and NaPi-IIc, which in turn are controlled by the 
plasma levels of PTH, FGF23, and 1,25(OH)2D3. Thus, dietary supply of Pi increases 
the abundance of both hormones whereas Pi deficiency reduces their levels (28, 32). 
As for the fecal output, also the urinary excretion of Pi adapted in a similar fashion in 
NaPi-IIb KO and WT mice, increasing in response to HDP and decreasing upon 
dietary Pi restriction. Although the increase in renal Pi excretion triggered by the HPD 
was lower in NaPi-IIb KO compared to the WT mice, the massive phosphaturia also 
observed in NaPi-IIb depleted mice indicates that the component responsible for the 
passive intestinal transport of Pi is able to absorb a considerable amount of Pi which 
must be later excreted by the kidney. Instead, both genotypes excreted similar low 
amounts of Pi after adaptation to LPD. Since WT animals fed low Pi already 
increased renal Pi reabsorption to a point where almost no Pi is excreted with urine 
(especially after 14 days LPD), it is not surprising that the kidneys of KO mice cannot 
further compensate for the impaired intestinal absorption.  In agreement with urinary 
Pi excretion, the adaptation of PTH and FGF23 to changes in dietary Pi was also 
comparable in WT and NaPi-IIb deficient mice, as the levels of both hormones were 
strongly and similarly reduced in mice fed LPD. Consistently, transport of Pi into renal 
BBMV and protein expression of NaPi-IIa and NaPi-IIc was similar in WT and NaPi-
IIb deficient mice fed LPD during 14 days. The combination of increased fecal loss 
but similar urinary excretion of Pi detected in NaPi-IIb KO on LPD likely caused the 
more pronounced reduction in the plasma Pi levels in NaPi-IIb KO animals after 3 
days of LPD. In contrast, WT mice were able to maintain normal Pi values though a 
tendency for reduced plasma Pi was detected after 14 days of LPD. The pronounced 
and earlier fall in plasma Pi may indicate that NaPi-IIb KO animals need an extra-
renal compensatory mechanism when facing longer Pi restriction. 
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Chronic hypophosphatemia may lead to osteomalacia and hypophosphatemic rickets 
(45), due to the mobilization of Pi from bone and/or decreased mineralization of 
newly formed bone. The stronger increase in urinary Ca2+ excretion in the NaPi-IIb 
KO mice during LPD suggested bones as source for Pi: although a drastic increase 
of urinary Ca2+ was observed in both genotypes when fed a LPD (both 3 and 14 
days), urinary Ca2+ levels were more than 70% higher in NaPi-IIb KO mice than in 
their WT littermates. Since vitamin D3 stimulates not only Pi but also Ca
2+ absorption 
in the intestine (46), high vitamin D3 may contribute to the increase in plasma and 
urinary Ca2+ observed in both animal groups with prolonged Pi deprivation. Moreover, 
intestinal Ca2+ absorption may be enhanced by the absence of Pi reacting with free 
Ca2+ in the intestinal lumen. In addition, low PTH may lead to urinary wasting of Ca2+, 
as a main function of this hormone is to promote Ca2+ reabsorption in the kidney (47, 
48). However, none of these factors can explain the difference in urinary Ca2+ 
between WT and NaPi-IIb KO mice, since they were equally affected in both 
genotypes. Also, the renal expression of several proteins involved in Ca2+ transport, 
including TRPV5, calbindin-28K and the CaSR, was similar in WT and NaPi-IIb KO. 
Thus, in response to hypophosphatemia, bone resorption may be enhanced in NaPi-
IIb deficient mice releasing Pi, together with Ca2+, at the cost of bone mass loss. In 
turn, renal excretion of Ca2+ will be higher to remove excessive Ca2+. This 
interpretation is further supported by the changes in urinary excretion of DPD, a 
marker for bone resorption (49). DPD excretion was massively elevated in NaPi-IIb 
KO upon prolonged Pi restriction, whereas no indication for enhanced bone 
resorption was detected in dietary-matched WT. in agreement with the DPD data, the 
BMD was decreased in Pi-restricted NaPi-IIb deficient mice.  
NaPi-IIb deficient mice fed low Pi also showed higher urinary corticosterone, which is 
accepted to reflect its circulating levels. Glucocorticoids reduce bone formation rates 
(50) and increase osteoclast number, promoting bone resorption (51). The observed 
increase in excreted glucocorticoids might partially explain the reduced bone 
mineralization observed in NaPi-IIb deficient animals. Together, these observations 
strongly suggest that the compensation for the loss of active intestinal absorption of 
Pi requires the mobilization of Pi from bones when the dietary supply is low.  
In summary, we found that in response to dietary Pi restriction, renal compensation is 
not sufficient to maintain plasma Pi levels in mice lacking intestinal NaPi-IIb. Instead, 
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and unlike to WT mice, NaPi-IIb KO develop a transient hypophosphatemia followed 
by a compensatory mechanism that involves release of Pi from bone. Thus, active 
intestinal Pi absorption mediated by NaPi-IIb is critical to protect bone during periods 
of low dietary Pi availability. 
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Figure legends 
Figure 1:  Intestinal ablation of NaPi-IIb and Pi deprivation causes transient 
hypophosphatemia and stimulates urinary calcium excretion. Fecal (A), urinary (B) 
and plasma (C) concentrations of Pi as well as urinary (D) and plasma (E) levels of 
Ca2+ were measured in samples collected from wild type (WT) and NaPi-IIb deficient 
mice (KO). Mice were fed diets containing normal (N) and/or high (H) or low (L) 
amounts of Pi. The high Pi diet was provided for 3 days (3d) whereas the low Pi diet 
was provided for 3 (3d) and 14 days (14d).  Data is presented as mean + SEM 
(n=10) and was analyzed by ANOVA-Bonferroni. Significant differences are indicated 
as: a/* p<0.05, b/** p<0.01 and c/***p<0.001, where letters indicate significant changes 
versus normal diets (or versus the high Pi diet, if normal diet is not available), and 
asterisks mark differences between genotypes under the same dietary condition. 
Figure 2: Hormonal adaptation is similar in both genotypes. Circulating levels of 
1,25-(OH)2 vitamin D3 (A), PTH (D) and FGF23 (E) were measured in plasma 
collected from wild type (WT) and NaPi-IIb deficient mice (KO) fed diets containing 
high (H) or low (L) amounts of Pi. The high Pi diet was provided for 3 days (3d) 
whereas the low Pi diet was provided for 3 (3d) and 14 days (14d). Renal mRNA 
levels of Cyp27b1 (B) and renal protein abundance of Cyp24a1 (C) were measured 
after 14 days of Pi restriction. Data is presented as mean + SEM (n=10), and was 
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analyzed by ANOVA-Bonferroni. Significant differences are indicated as: a p<0.05, b 
p<0.01 and c p<0.001, were significances refer to high dietary Pi groups (no 
differences between genotypes were observed). 
Figure 3: Phosphate transport into renal BBMVs and expression of NaPi-IIa and 
NaPi-IIc is not altered. Uptakes of Pi (A), leucine (B) and glucose (C) were performed 
with renal BBMVs isolated from wild type (WT) and NaPi-IIb deficient mice (KO) after 
14 days of dietary Pi restriction. Experiments were carried out in the presence (Na) 
and absence (K) of Na+. The renal expression of NaPi-IIa (D) and NaPi-IIc (E) was 
quantified by Western blot of the same BBMV used for the uptake experiments; the 
bar graphs show the corresponding densitometric analysis normalized for the 
expression of β-actin. Differences between genotypes were analyzed by unpaired t-
test. The abundance of NaPi-IIb in ileum (F) was analyzed by Western blot in 
samples from wild type mice fed 3 days high or low Pi diets as well as 14 days low Pi; 
one sample of the corresponding dietary-matched NaPi-IIb deficient mice (KO) was 
also included. Densitometric analysis normalized for the expression of β-actin is 
shown as mean + SEM. Statistical differences versus the high dietary group were 
analyze by ANOVA-Bonferroni with * p<0.05 and ** p<0.01. 
Figure 4: Pi restriction does not affect expression of proteins involved in renal 
calcium handling between genotypes. Renal protein abundance of Cabindin 28K (A), 
TRPV5 (B) and calcium sensing receptor (C) was assessed by Western blot in 
homogenates from kidneys of wild type (WT) and NaPi-IIb deficient animals (KO) 
after 14 days of Pi restriction. Corresponding densitometric analysis was normalized 
by the expression level of β-actin and data is shown as mean + SEM. Differences 
between genotypes were analyzed by unpaired t-test. 
Figure 5: Urinary excretion of deoxypyridionline (DPD) and chorticosterone as well 
as bone mineral density (BMD) are altered in Pi-restricted NaPi-IIb KO mice. Urinary 
DPD (A) levels were measured in samples from wild type (WT) and NaPi-IIb deficient 
mice (KO) mice fed 3 days high or low Pi diets as well as 14 days low Pi. 
Corticosterone levels in urine (B) were determined in both genotypes after 14 days of 
Pi restriction. Cortical (C) and trabecular (D) BMD were measured in femurs of mice 
after 14 days Pi restriction. Data is presented as mean + SEM and was analyzed by 
either ANOVA-Bonferroni (DPD) or unpaired t-test (corticosterone and BMD). 
Significant differences are indicated as: a/* p<0.05, ** p<0.01 and *** p<0.001, where 
69 
 
a represents the difference versus the corresponding high dietary group, whereas 
asterisks mark differences between genotypes under the same dietary conditions. 
Table 1: Metabolic data. Parameters were measured in wild type (WT) and NaPi-IIb 
deficient mice (KO) fed diets containing normal (N), high (H) and low (L) amounts of 
Pi. The high Pi diet was provided for 3 days (3d) whereas the low Pi diet was 
provided for 3 (3d) and 14 days (14d).  Data is presented as mean + SEM (n≥10) and 
was analyzed by ANOVA-Bonferroni. Significant differences are indicated as: a/* 
p<0.05, b/** p<0.01 and c/***p<0.001, where letters indicate significant changes 
versus normal diets (or versus the high Pi diet, if normal diet is not available), and 
asterisks mark differences between genotypes under the same dietary condition.  
Table 2: Additional urinary parameters measured in samples collected from wild type 
(WT) and NaPi-IIb deficient mice (KO) after 14 days Pi restriction. Data is presented 
as mean + SEM (n≥10) and was analyzed by unpaired t-test. 
Supplementary figure 1: Fecal Pi excretion in wild type (WT) and NaPi-IIb deficient 
mice (KO) after normal, 3 days high, 3 days low and 14 days low dietary Pi. Values of 
the KO mice were normalized to the mean of the dietary-matched WT. Data is 
presented as mean + SEM (n=10), and was analyzed by ANOVA-Bonferroni, with 
***p<0.001 versus the dietary-matched WT. 
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3.3 Preliminary results paracellular Pi permeability 
3.3.1 Summary 
In order to address the possible role of the paracellular pathway in the intestinal 
transport of Pi, dilution potential measurements in Ussing chamber were performed. 
Experiments in intestinal cell culture models and ex vivo preparations of intestinal 
segments of rats and mice showed that the tight junctions are permeable to Pi. 
Furthermore the paracellular pathway seems to discriminate between monovalent 
and divalent Pi in favor of the monovalent form. No differences in the paracellular 
permeabilities were found in NaPi-IIb KO mice suggesting that the existing 
permeability is either not regulated or sufficient to provide Pi under conditions of 
normal or high Pi availability. 
3.3.2 Methods 
Dilution potential measurement in cell culture models and rat intestine  
The permeabilities for Na+ (PNa), Cl
- (PCl) and Pi (PPi) of intestinal cell culture models 
and rat intestinal segments were determined by dilution potential measurements. 
Determinations were done in Ussing chambers modified for cell culture or tissue 
inserts, in which the basolateral and apical sides were independently perfused as 
previously described [207]. Experiments were performed at pH 6 (14 0mM NaCl, 5.4 
mM KCl, 1 mM MgCl2, 1.2 mM CaCl2, 10 mM glucose, 10 mM MES, pH 6 adjusted 
with NaOH) or pH 8.4 (140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 1.2 mM CaCl2, 10 
mM glucose, 10 mM TAPS, pH 8.4 adjusted with NaOH) in a bubble lift system, 
gassed with oxygen, that drives the circulation of the bathing solutions (10 ml) on 
each side. Temperature was maintained at 37°C with a water jacket. To determine 
Na+ and Cl- permeabilities 5 ml on either the basolateral or apical side were replaced 
by a 5 ml of a solution containing 280 mM mannitol instead of 140 mM NaCl. After 
equilibrating each side again, Pi permeability was assessed by replacing 5 ml on 
either side with a solution containing 140 mM NaH2PO4 (pH 6) or 70 mM Na2HPO4 
(pH 8.4, with additional 70 mM mannitol to maintain osmolality)  instead of 140 mM 
NaCl. Differences in transepithelial voltage (Vte) upon change of solution were 
corrected for previously defined liquid junction potentials.  The ratios PNa/PCl and 
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PNa/PPi obtained by the Goldman-Hodgkin-Katz equation and the transepithelial 
resistance (Rte) were used to calculate permeabilities. 
Dilution potential measurement in mouse intestine 
Freshly isolated intestinal segments from mouse were mounted into a modified 
Ussing chamber, with an exposed area of 0.8 mm2. The basolateral and apical side 
were independently perfused with a flow rate of 5-10 ml/min. The basolateral side 
was perfused with Ringer solution (145 mM NaCl, 0.4 mM KH2PO4, 1.6 mM K2HPO4, 
5 mM glucose, 1 mM MgCl2, 1.3 mM Ca-Gluconate, pH7.4). After equilibration of the 
mounted tissue the apical side was consecutively perfused with Ringer solution (pH 
6), a low NaCl Ringer (30 mM, isotonic with 230 mM Mannitol, pH 6), and a modified 
Ringer containing 140 mM NaH2PO4 (pH 6).  Differences in Vte upon change of 
perfusion solution were measured under open-circuit conditions with Vte referring to 
the basolateral side. Rte was assessed with short pulses (1s) of 1.41 µA, and the 
difference in Vte upon the pulse was used to calculate the Rte according to Ohm’s law 
(Rte=∆Vte/I) after correction for the resistance of the empty chamber. Relative and 
absolute permeabilities for Na+, Cl- and Pi were calculated using the Goldman-
Hodgkin-Katz equation and the Rte. 
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3.3.3 Results 
Passive absorption of Pi along the paracellular pathway requires a concentration 
gradient across the epithelium. Thus we measured Pi in the different segments of the 
gut. Our measurements indicate that luminal Pi concentration of Pi exceeds plasma 
levels by at least tenfold (Figure 8) providing a gradient to drive passive diffusion of 
Pi from the lumen to the blood. 
 
Figure 8: Pi concentration in different compartments of the intestine and in dissolved chow 
(measurement and theoretical). 
 
IPEC-J2 (swine small intestine), HT-29/B6, Caco2-bbe and T84 cells (the last three 
of human colon carcinoma origin) grown to confluency were analyzed in Ussing 
chambers to determine the permeability of the tight junctions to Pi. 
As shown in Figure 9, alkaline pH lowers transepithelilal resistance in all models and 
thereby affects the absolute permeability for all ions. Therefore results are shown as 
relative permeabilities PNa/PCl and PPi/PNa, since the ratio between the permeabilities 
of Cl- and Na+  seems to be unaffected by pH. The cell culture experiments indicate 
that the tight junctions are permeable to Pi and discriminate between Pi species. 
Monovalent Pi (H2PO4
-), the predominant species at pH 6, seems to pass the tight 
junctions more easily than its divalent form (HPO4
2-). The permeability for Pi 
observed at pH 6 was about 40-50% of the one of Na+. The permeability of the tight 
junctions is mostly dependent on the expression profile of claudins [208]. Claudins 
form pores that facilitate passive diffusion and thereby their transport characteristics 
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are symmetric, unlike transcellular transport. To test the symmetry of Pi transport, 
Na+ and Pi gradients were introduced from either the basolateral or the apical side: 
as expected, no differences in permeability were observed, confirming that transport 
was symmetric. Data presented in Figure 9 was obtained by pooling results from 
apical and basolateral applications. 
 
 
Figure 9: Relative permeabilities PNa/PCl and PPi/PNa and transepithelial resistance in different cell 
culture models under pH 6 (red) and 8.4 (blue). 
 
Introduction of the anion selective claudin17 [209] and tricellulin into renal MDCK 
cells did not affect PPi in dilution potential measurements (Figure 10). Introduction of 
claudin17 shifted the selectivity towards Cl- (compare decreased PNa and increased 
PCl) as expected. 
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Figure 10: Permeability to Na
+
 (PNa), Cl
-
 (PCl) and Pi (PPi) in renal MDCK cells at pH 6 (red) and pH 
8.4 (blue). The left panels show MDCK II cells stably transfected with tricellulin (TRA47) and the 
corresponding control (CMV10). The right panels show MDCK C7 cells expressing claudin 17 (cldn17) 
and corresponding control (CMV4) 
 
The same experimental procedure was used to measure Pi permeability in different 
intestinal segments of rats (Figure 11).  Dilution potential measurements showed that 
the rat intestine is also permeable to Pi. Alkaline pH did not affect transepithelial 
resistance of the tissue, unlike in the cell culture experiments. The permeability to Pi 
was again higher at pH 6 than pH 8.4, though the difference was not as pronounced 
as in cultured cells. Instead, the permeabilities to Na+ and Cl- were not affected by 
pH. Monovalent Pi showed about half the permeability of Na+ or Cl- in all the 
segments analyzed. A higher transepithelial resistance was observed in preparations 
of colon tissue, which leads to an overall lower conductance of the tissue to ions (due 
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to Ohm’s law; the higher the resistance the lower the current). This is reflected in the 
lower permeability to Na+, Cl- and Pi all together, but comparatively the ratio between 
the ions stays the same. 
 
 
Figure 11: Permeability to Na
+
 (PNa), Cl
-
 (PCl) and Pi (PPi) observed in rat jejunum, ileum and colon, 
with recording of the corresponding transepithelial resistance. Dilution potential measurements were 
performed at pH 6 (red) and pH 8.4 (blue). 
 
Dilution potential measurements in mouse intestine were performed with a luminal pH 
of 6 and basolateral pH of 7.4 to achieve a more physiological condition (Figure 12). 
The pH difference across the epithelium did not alter the measurements (data not 
shown). Overall it looks like that the mouse intestine has a higher selectivity for Na+. 
Otherwise no major differences between species were observed, with PPi about half 
of PCl, and lowest permeability to all ions in the colon, due to high tissue resistance. 
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Figure 12: Permeability to Na
+
 (PNa), Cl
-
 (PCl) and Pi (PPi) observed in mouse duodenum, jejunum, 
ileum and colon, with recording of the corresponding transepithelial resistance. 
 
The absence of NaPi-IIb had no effect on the paracellular ion permeability. As shown 
in Figure 13, NaPi-IIb deficient mice show similar PNa, PCl and PPi along the intestine. 
 
Figure 13: Permeability to Na+ (PNa), Cl
-
 (PCl) and Pi (PPi) observed in NaPi-IIb deficient (f/f) and 
corresponding wild type mice (WT). 
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Abstract 
MCT14 is an orphan transporter belonging to the SLC16 transporter family mediating 
the transport of monocarboxylates, aromatic amino acids, creatine, and thyroid 
hormones. The expression, tissue localization, regulation, and function of MCT14 are 
unknown. In mouse MCT14 mRNA abundance is highest in kidney. Using a newly 
developed and validated antibody, MCT14 was localized to the luminal membrane of 
the thick ascending limb of the loop of Henle colocalizing in the same cells with 
uromodulin and NKCC2. MCT14 mRNA and protein was found to be highly regulated 
by dietary phosphate intake in mice being increased by high dietary phosphate intake 
at both mRNA and protein level. In order to identify the transport substrate(s), we 
expressed MCT14 in Xenopus leavis oocytes where MCT14 was integrated into the 
plasma membrane. However, no transport was discovered for the classic substrates 
of the SLC16 family nor for phosphate. In summary, MCT14 is an orphan transporter 
regulated by phosphate and highly enriched in kidney localizing to the luminal 
membrane of one specific nephron segment. 
Key words: Slc16a14/MCT14, renal expression, dietary regulation 
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Introduction 
Inorganic phosphate (Pi) is a molecule involved in energy metabolism and signaling 
as well as essential for structural molecules in cells and bone. Phosphate excess 
triggers ectopic calcifications and is associated with increased cardiovascular 
mortality. Therefore, the plasma levels of phosphate are kept in a close range; this is 
achieved by a variety of compensatory and highly regulated mechanisms. Phosphate 
deficiency leads to increased levels of plasma active vitamin D, which promotes 
intestinal phosphate absorption at least in part by stimulating the expression of the 
Na+-dependent phosphate transporter NaPi-IIb [1]. Additionally, hypophosphatemia 
blunts the production of parathyroid hormone (PTH) [2]  and fibroblast growth factor 
23 (FGF23) [3], releasing the inhibitory effect of both hormones on renal phosphate 
cotransporters (NaPi-IIa, NaPi-IIc and PiT-2), thus enhancing renal reabsorption of 
phosphate. On the other hand hyperphosphatemia leads to an increased renal 
excretion of phosphate, an effect mediated at least in part by PTH [2]  and FGF23 [4-
6] . Both hormones reduce the renal expression of NaPi-IIa NaPi-IIc and PiT-2 in the 
proximal tubule [2], and FGF23 additionally suppresses the production of vitamin 
D[7]. But beyond these effects directly linked to phosphate metabolism, alterations in 
phosphate intake affect, among other effects, glycogenolysis and glucose production 
[8], indicating broader systemic changes in response to phosphate status.  
The SLC16 gene family comprises 14 members collectively called MCTs 
(monocarboxylate transporter) due to the fact that the first 4 members to be 
characterized mediate transport of monocarboxylates such as lactate, pyruvate and 
ketone bodies, in a proton dependent manner [9]. MCT1, 3 and 4 associate with 
CD147 (basignin) [10], an immunoglobulin-like protein, that acts as a chaperone for 
these MCTs. The interaction of MCT1 and CD147 has been extensively studied and 
it was shown that sorting of MCT1 to the right pole of an epithelial cell relies on 
CD147 [11]. MCT1 and 2 are both expressed in kidney where they are involved in 
reabsorbing lactate. MCT1 is localized to the basolateral membrane of the renal 
proximal tubule together with CD147 [12], whereas MCT2 is found in the basolateral 
membrane of cells in the thick ascending limb of the loop of Henle [13]. 
The characterization of further members of the SLC16 family revealed that transport 
by MCTs is not limited to monocarboxylates. MCT8 transports thyroid hormone [14] 
and mutations of MCT8 associate with elevated levels of triiodothyronine (T3) and 
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psychomotor retardation [15]. MCT10 is an aromatic amino acid transporter, also 
known as TAT1 (T-type amino acid transporter 1). Both transporters mediate 
transport in a proton (and sodium) independent manner [16], unlike the first 4 
members. Recently MCT12, associated with juvenile cataract, was characterized as 
a creatine transporter [17], further widening the substrate spectrum of the MCT 
family. MCT12 localizes to the basolateral membrane of proximal tubules in kidney, 
and patients with mutated MCT12 excrete increased amounts of guanidinoacetate, 
but functional studies did not show transport of the creatine precursor [18]. The other 
members of the family remain orphan transporters, and although it has been 
suggested that they might act as drug transporters (as demonstrated with 
bumetanide transport for MCT6 [19]) their endogenous transport substrates are still 
elusive. A renal transcriptome study detected mRNA of MCT1, MCT2, MCT5, MCT6, 
MCT7, MCT8, MCT9, MCT10 (TAT1), MCT13 and MCT14 in kidney [20], and the 
renal localization of MCT1, 2, 7, 8 and 10 has been described [12,21].   
MCT14, encoded by the SLC16A14 gene, is an orphan member of the family that has 
been shown to be expressed in the bovine intestinal tract [22] and the mammary 
gland of lactating cows [23]. A recent study also mapped the expression of MCT14 in 
the mouse brain and provided a relative expression of this transporter in several 
tissues [24]. Of interest, among all the tissues tested renal mRNA abundance was 
the highest (by about 20 fold). This report also provides a phylogenetic analysis of 
the MCTs, which shows that MCT14 is closest related to MCT8, 9 and 10 [24], the 
non-classical members of the family. 
Here we report that the renal expression of MCT14 is regulated by the dietary content 
of phosphate, the generation and validation of a polyclonal antibody to analyze its 
segmental distribution in kidney as well as our attempts to identify substrates. 
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Experimental procedures 
Animals 
All experiments with animals were performed according to Swiss Animal Welfare 
laws and were approved by the local veterinary authority (Veterinäramt Zürich). Male 
mice (C57BL/6) 10 to 13 weeks old were fed for 14 hours or 5 days with either high 
(1.2%) or low (0.1%) phosphate diet (Kliba Promivi AG, Switzerland). Food was 
provided ad libitum and animals had free access to water. After the adaptation, mice 
were anesthetized with a mixture of ketamine and xylazine. Venous blood was 
collected from the vena cava and centrifuged (8 min at 8’000rpm at 4°C) in tubes 
containing heparin. After centrifugation the plasma was aliquoted and snap frozen in 
liquid nitrogen. Organs were extracted and snap frozen. All samples were stored at  -
80°C until further use.  
 
RNA isolation and semi-quantitative real-time PCR (RT-qPCR) 
Snap frozen kidneys were homogenized in RLT buffer (Qiagen, Germany) containing 
1% β-mercaptoethanol. Total RNA was purified from these homogenates using the 
Qiagen RNeasy Mini Kit following the manufacturer’s protocol. Isolated RNA was 
reverse transcribed to cDNA with the TaqMan Reverse Transcription Kit (Applied 
Biosystems), following the manufacturers protocol. 
Specific primers for Slc16a14/MCT14 and Cyp27b1 and the corresponding probe 
labeled with FAM/TAMRA (Mm01272722_m1, Mm01165918_g1; Applied 
Biosystems) as well as for β-actin (Microsynth, Switzerland) used as a control gene 
were purchased. TaqMan universal PCR master mix (Applied Biosystems) containing 
primers and probes in concentrations of 5 μM and 25 μM, respectively, was used to 
amplify cDNA. Relative mRNA expression levels were measured on a 7500 Fast 
Real Time PCR System (Applied Biosystems). The cycle number at a given threshold 
(Ct) was determined, and the relative expression (R) was calculated according to the 
formula R=2^((CT– β-actin) – (CT-MCT14), where R represents the expression of 
MCT14 relative to the housekeeping gene (β-actin). 
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Western blot analysis 
Frozen kidneys were homogenized in homogenization buffer (300 mM Mannitol, 5 
mM EGTA, 12 mM Tris/HCl, pH 7.1) for 2 min on ice using a Polytron homogenizer 
(PT 10-35, Kinematica GmbH, Lucerne). The homogenates were then centrifuged for 
5 min at 2’000 rpm at 4°C. Supernatants were collected and protein concentrations 
were determined with the BioRad DC protein assay, based on the Lowry method 
(44). Aliquots of 50 μg of renal homogenates were mixed with Laemmli sample buffer 
(0.38 M Tris base, 8% SDS, 4 mM EDTA, 40% (v/v) glycerol, pH 6.8 with HCl, 4 
mg/ml of Bromphenol Blue) and loaded on a 10 % acrylamide SDS gel for SDS-
PAGE. Proteins were transferred from gel onto polyvinylidene difluoride membranes 
(PVDF; Immobilon-P, Millipore) in a standard tank system (Mini Trans- Blot, Bio-
Rad). PVDF membranes were blocked with TBS containing 5 % fat-free powder milk 
at room temperature and incubated with primary antibodies over night at 4°C. 
Membranes were then washed with TBS and blocked again before incubation with 
secondary antibodies for 2 hours at room temperature. Horseradish peroxidase-
coupled secondary antibodies (GE Healthcare, United Kingdom) were used to detect 
primary antibody binding. Chemiluminescence was detected upon incubation with 
HRP substrate (Western Chemiluminescence HRP Substrate, Millipore) for 5 
minutes, using a LAS-4000 camera system (Fujifilm). 
An antibody targeting a predicted extracellular loop (Uniprot) of MCT14 was raised by 
immunizing rabbits with an antigenic peptide (NH2-
KSGGPLGMAEEQDRRPGNEEMVC-COOH) linked to KLH (Pineda, Berlin, 
Germany). The anti-serum was affinity purified using protein A/G chromatography. 
 
Immunofluorescence 
Animals were perfused through the left cardiac ventricle with a pre-fixative solution 
(1000 U/ml Heparin, 0.2 % procain-HCl, 3.2 % CaCl2 and 0.18 % NaCl) followed by 
the fixative (3 % Paraformaldehyde (PFA)/PBS). After incubation in PFA for one hour, 
kidneys were placed overnight in 32 % sucrose/PBS and subsequently embedded in 
OCT embedding Matrix (Cell Path, Newtown, Wales, United Kingdom) and frozen in 
liquid propane. Cryosections of 5 μm were mounted on slides (Superfrost Plus, 
Thermo Scientific) and blocked with 3 % bovine serum albumin/PBS; the primary 
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antibodies against MCT14 (1/1000), NKCC2 [25] (1/1000), Uromodulin [26] (1/400), 
NCC [27] (1/500) or NaPi-IIa [28] (1/400) were diluted in PBS and added to the 
cryosections for incubation over night at 4°C. Then, samples were washed twice with 
hypertonic PBS (18g NaCl/PBS), once with PBS and incubated with the secondary 
antibodies donkey anti-rabbit Alexa594, donkey anti-sheep Alexa 488 and goat anti-
guinea-pig Alexa 488 (1/1000, Invitrogen) during 2 hours at room temperature. After 
two consecutive washing steps with hypertonic PBS and once with PBS, cover slips 
were mounted with Glycergel (DakoCytomation, Baar, Switzerland). Fluorescence 
was detected with a Leica fluorescence microscope (Leica CTR600). Leica AF lite 
and Image J freeware programs were used to process the pictures. 
 
Expression of MCT14 in Xenopus laevis oocytes 
An Escherichia coli clone containing the cDNA of murine Slc16a14 inserted into the 
pCMV-Sport6 expression vector downstream of the SP6 promotor 
(IRAVp968E0963D) was purchased from imaGenes (Berlin, Germany). Bacterial 
clones were selected and expanded using standard procedures. The expression 
vector was isolated using the QIAprep Spin Miniprep Kit (QIagen) and was linearized 
with the restriction enzyme NotI. The restriction product was purified with the 
QIAquick gel extraction kit (Qiagen) following the manufactures protocol. Linearized 
plasmid was used as template to synthesize cRNA using the mMessage mMachine 
SP6 kit (Ambion) with addition of a 5’-cap analogue (m7G(5')ppp(5')G RNA Cap 
Structure Analog (New England BioLabs inc., Allschwil, Switzerland). Upon 
purification, 10 ng of MCT14 cRNA were injected into oocytes isolated from female 
Xenopus laevis. Three days after cRNA injection, oocytes were used for experiments. 
Non-injected oocytes served as control. 
 
Oocyte preparation for immunodetection of MCT14 
Xenopus laevis oocytes were placed in 20 μl lysis buffer (100 mM NaCl, 20 mM Tris 
HCl (pH 7.6) and 1% Igepal CA 630 (Sigma Aldrich, Buchs, CH)) and lysed by 
pipetting up and down. Lysates were then centrifuged for 3 minutes at 16000g at 
22°C. Yolk-free supernatants were collected avoiding contamination with floating 
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lipids and mixed with Laemmli sample buffer. A volume corresponding to 1/3 of an 
oocyte/lane was loaded on an acrylamide SDS gel and protein expression was tested 
following the Western blot protocol described above. 
To prepare Xenopus laevis oocytes for immunohistological detection, cells were 
incubated in 3% PFA in PBS for 4 hours at 4°C. After washing with PBS, oocytes 
were placed in 30 % sucrose/PBS over night at 4°C for cryoprotection. Oocytes were 
then transferred to cryomolds (Cryomold Biopsy, Sakura Finetek Germany GmbH, 
Staufen, Germany) containing embedding medium (OCT embedding Matrix, Cell 
Path, Newtown, Wales, United Kingdom) and were immediately frozen in liquid 
propane. Frozen oocytes were stored at -80°C and processed for 
immunofluorescence experiments as described above. 
 
Transport studies in Xenopus laevis oocytes expressing MCT14 
Ten oocytes were transferred into plastic vials containing ice cold ND96 (96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM Hepes, pH 7.4 adjusted with 
Tris). ND96 was replaced with ND96 containing the desired uptake substrate in 100 
μM concentration and traces of radioactively labelled substrate (5 μCi/ml). Upon 10 
minutes incubation at room temperature, substrate solution was removed and 
oocytes were subsequently washed 4 times with ice cold ND96. Single oocytes were 
transferred to a scintillation vial containing 200 μl of 2% SDS and lysed by shaking. 
Upon addition of Emulsifier-Safe (PerkinElmer), radioactivity accumulated in each 
oocyte was measured in a -counter (Packard BioScience) and total uptake was 
calculated. 
 
Statistical Analysis 
Unpaired students t-test was used to analyze expression level comparisons. P-values 
> 0.05 were considered as significant. Data is presented as Mean + SEM. 
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Results 
Dietary phosphate content regulates Slc16a14 mRNA  
A transcriptome analysis using a GeneChip Mouse Genome 430 2.0 arrays 
(Affymetrix, Santa Clara, CA) was performed on kidneys from mice adapted to high 
(1.2 % Pi, HPD) or low (0.1 % Pi, LPD) dietary phosphate for either 14 hours or 5 
days, conditions that are considered as acute or chronic adaptation, respectively. 
Adaptation to the diets was validated by quantifying the renal protein expression of 
the Na+/phosphate cotransporter NaPi-IIa [29]. As expected, acute (Figure 1A) and 
chronic (Figure 1B) LPD diets increased the abundance of NaPi-IIa protein compared 
to HPD. The microarray detected more than 12’000 protein coding transcripts. Only 
transcripts with at least 1.5 fold change and p-values <0.05 were considered for 
further analysis. Under LPD conditions 50 transcripts were found to be upregulated 
acutely and 1259 under chronic adaptation. LPD further decreased the expression of 
93 transcripts acutely and 631 chronically (detailed data to be reported elsewhere). 
The mRNA expression of Cyp27b1 was used as a marker to validate data obtained 
by the microarray by RT-PCR. Cyp27b1 did not show any different expression after 
acute changes in dietary Pi (Figure 1C), but chronic adaptation led to a 10 fold 
increase of Cyp27b1 under LPD conditions compared to HPD (Figure 1D). 
In both, acute and chronic adaptation experiments, transcriptome analysis revealed 
that the mRNA of Slc16a14 (the gene encoding the monocarboxylate transporter 
MCT14) was strongly regulated. SLC16a14 mRNA appeared among the SLC 
transporter transcripts to be the most highly affected transcript. In fact Slc16a14 
mRNA abundance was decreased by a factor of 4.3 in mice acutely fed a LPD as 
compared with mice fed a HPD, whereas the reduction was by a factor of 5.0 in 
chronically adapted mice. The microarray data was confirmed by semi-quantitative 
real time RT-PCR with renal mRNA extracted from the same group of mice as well as 
from an independent group of animals. Already 14 hours after the start of the dietary 
adaptation renal Slc16a14 mRNA expression was drastically decreased in animals 
under LPD condition compared with HPD (Figure 1E). This effect was further 
enhanced after chronic adaptation for 5 days (Figure 1F).  
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Antibody generation and validation of specificity 
To investigate if the changes in mRNA expression were paralleled by altered protein 
levels, a polyclonal antibody was raised in rabbits against a peptide located in a 
predicted extracellular loop of MCT14. Western blot analysis with renal homogenates 
was performed in the presence and absence of the antigenic peptide to confirm 
specific binding of the antibody to its epitope. The anti-MCT14 antibody detected 
several bands in renal homogenates at approximately 40 and 50 kDa (Figure 2A). 
Preincubation with the antigenic peptide abolished detection of these bands. The 
expected size of the MCT14 transporter is estimated to be around 50 kDa (510 amino 
acids). The MCT14 antigenic peptide did not affect the binding of the NaPi-IIa [28] 
antibody in the same homogenates (Figure 2B). Further proof of binding specificity 
was achieved by western blots of lysates from Xenopus laevis oocytes injected with 
Slc16a14/MCT14 cRNA or left non-injected. In lysates of oocytes injected with 
Slc16a14/MCT14 cRNA, the antibody detected two bands with molecular sizes of 
about 40 and 50 kDa corresponding to the major bands protected by the antigenic 
peptide in renal homogenates. These bands were absent from non-injected oocytes 
(Figure 1C).  
Renal localization of MCT14 
Real time PCR on mRNA samples extracted from several mouse tissues indicated 
that the kidney expresses the highest levels of Slc16a14/MCT14 mRNA, folpancreas 
and testis where the mRNA expression levels are about ten times lower than in 
kidney (data not shown) confirming a previous report [24]. In immunofluorescence 
experiments on murine kidney cryosections using the newly generated MCT14 
antibody, staining was observed mainly in the luminal membrane of nephron 
segments located in the outer renal medulla and to a lesser extent in the cortex 
(Figure 2D). Upon co-incubation of the antigenic peptide with the anti-MCT14 
antibody, tubular staining was abolished (figure 2D). These findings indicate specific 
staining of MCT14 in kidney sections using a standard immunofluorescence protocol. 
In order to further characterize the segmental distribution of MCT14 in the murine 
kidney, (co)immunostainings were performed in single or consecutive renal sections 
using the MCT14 antibody as well as antibodies against proteins with well-
established patterns of renal expression. Incubation of consecutive sections with 
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antibodies against MCT14 and NaPi-IIa, a marker for the proximal tubule [28], 
showed that both proteins labelled different nephron segments, with the MCT14 
related signal mostly detected in the outer medulla whereas NaPi-IIa showed the 
expected cortical expression (Figure 3A), thus indicating that MCT14 is not 
expressed in proximal tubule. Instead, immunostainings on consecutive sections with 
antibodies against MCT14 and NKCC2, a marker for the thick ascending limb of the 
loop of Henle, showed that both proteins are present in the same cells, in cortex and 
outer medulla (Figure3B and 3C). Moreover, coincubation of renal slices with 
antibodies against MCT14 and uromodulin, all cells positive for MCT14 stained also 
for uromodulin (Figure 3D). Uromodulin staining was present within the whole cell as 
well as on the luminal membrane of those cells, whereas MCT14 signal was 
restricted to the apical membrane. Costainings with antibodies against MCT14 and 
NCC, exclusively expressed in distal convoluted tubules [27] resulted in labeling of 
different tubular segments (Figure 3E).  
 
Dietary Pi content regulates renal MCT14 protein abundance 
Western blot analysis of renal homogenates from animals used previously for 
transcriptome analysis showed that MCT14 protein abundance followed the 
regulation of mRNA by dietary Pi. Reduced amounts of MCT14 protein was detected 
after 14 hours and 5 days LPD compared to HPD (Figures 4A and 4B). 
Immunostainings on renal cryosections of mice chronically adapted to HPD and LPD 
did not show a change of expression pattern as already observed in the initial 
localization experiments (Figure 4C). 
 
Functional studies in Xenopus laevis oocytes 
We used Xenopus oocytes to search for transport substrates of MCT14. Western blot 
analysis confirmed that the protein was produced by the oocytes (see Figure 2C). For 
transport studies in oocytes it is required that the expressed protein is incorporated 
into the cell membrane. Trafficking of MCT14 to the membrane was ascertained by 
immunostaining experiments. Oocytes injected with Slc16a14/MCT14 cRNA showed 
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a signal framing the cell body, which was absent from non-expressing cells (Figure 
2E), indicating insertion of MCT14 into the oocyte cell membrane. 
Next, oocytes expressing MCT14 and non-injected oocytes were incubated with 
several substrates previously shown to be transported by different members of the 
MCT family. However, oocytes injected with Slc16a14/MCT14 mRNA did not show 
any significant transport activity for lactate compared to non-injected oocytes, neither 
at substrate concentrations of 3 mM (Figure 5A) or at 100 μM (Table 1). 
Coexpression of MCT14 with CD147 also failed to induce lactate transport. Similarly, 
inorganic phosphate was not accumulated in oocytes expressing MCT14 (Table 1). 
Also creatine was not transported by oocytes injected with MCT14, whereas this 
substrate was incorporated by MCT12 expressing oocytes (Figure 5B).  Introduction 
of CD147 had again no effect in Slc16a14/MCT14 expressing oocytes regarding their 
failure to transport creatine. Further uptake experiments were performed in which 
oocytes were incubated with different amino acids (alanine, glutamine, cysteine, 
asparagine, serine, methionine, tyrosine and glutamate) in 100 μM concentrations. 
No significant differences were observed comparing oocytes expressing MCT14 and 
the corresponding non-expressing cells (Figure 5C, Table 1). Similarly, MCT14 failed 
to induce transport of tryptophan, phenylalanine, valine, leucine and isoleucine, with 
substrates present at 3 mM concentrations (Table 1). 
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Discussion 
Phosphate plays an essential role in a large variety of vital functions ranging from cell 
signaling and energy metabolism to structural purposes. Hence, it is not surprising 
that changes in phosphate status, as those induced by alterations in dietary 
phosphate intake, have a broader impact on systemic homeostasis than just 
adjusting intestinal and renal (re)absorption of phosphate. Thus, dietary alterations in 
phosphate supply cause a fast response in PTH and later on in vitamin D and FGF23 
[4,5], but also promote changes in other metabolic pathways such as  
gluconeogenesis,  or altered insulin sensitivity [8], indicating the importance of 
phosphate in energy metabolism.  
By performing a transcriptome-wide analysis on kidneys from mice fed on diets with 
high or low phosphate content we identified Slc16a14/MCT14 as one of the 
transcripts more strongly down-regulated under acute and chronic dietary phosphate 
restriction. Altered expression of NaPi-IIa protein and Cyp27b1 mRNA confirmed the 
adaptation of the mice to the dietary content of Pi, where NaPi-IIa is regulated acutely 
and chronically as described before [30]. Cyp27b1 on the other hand was only 
regulated after chronic adaptation, in agreement with previous observations, 
indicating that the activation of vitamin D3 is not affected acutely by Pi restriction [31]. 
It was recently reported that MCT14 mRNA shows the highest abundance in the 
kidney [24], which is in agreement with our own observations (data not shown). The 
fact that MCT14 abundance decreases drastically in kidney after only 14 hours of 
LPD might suggest that this transporter is directly involved in an immediate metabolic 
response to phosphate deprivation, but without identification of its substrate it is 
impossible to draw conclusions as to its functional relevance.  
MCT14 consist of 510 amino acids and, as for other members of this family, 
hydropathy plots predict 12 transmembane domains with cytoplasmic N and C-
termini [32]. The predicted topology of MCT1 was experimentally confirmed in 
proteolytic cleavage experiments in red blood cells, where the big intracellular loop 
and the N- and C-termini were only accessible for cleavage in leaky ghosts [33]. In 
order to analyze MCT14 at the protein level and to localize its expression in kidney, a 
polyclonal antibody was raised against a predicted extracellular loop. We provide a 
careful validation of the specificity of this antibody by showing peptide protection of 
antibody binding to renal samples (western blot and immunofluorescence) as well as 
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specific antibody binding to cell lysates overexpressing  MCT14 (western blot in X. 
laevis oocytes).  On Western blots, the antibody detected one band of about 50 kDa 
that is in good agreement with the expected size of the full length protein as well as 
smaller bands at about 40 kDa that may represent either degradation products or 
unglycosylated proteins, since they were mostly detected in boiled samples, whereas 
in unboiled samples they became fainter with and a stronger representation of the full 
length MCT14.   A similar pattern of bands was reported in a recent publication using 
a commercial antibody [24].  
Initial immunofluorescence experiments on renal sections indicated that the 
expression of MCT14 is restricted to apical membrane of renal tubules, with higher 
levels in the outer medulla than the cortex. To identify its precise segmental 
distribution, we compared the pattern of expression of MCT14 with that of several 
other proteins with well characterized renal location.  Expression in proximal tubules 
was ruled out based on the observation that MCT14 did not colocalize with NaPi-IIa, 
the major Na+-dependent phosphate transporter expressed in the apical membrane 
of the renal proximal tubule [29]. NKCC2 was used as a marker for the thick 
ascending limb of the loop of Henle (TAL) [34]. Immunostaining of consecutive 
sections with both antibodies suggest that MCT14 and NKCC2 are present in the 
same cells. TAL expression of MCT14 was further supported by co-staining of 
MCT14 and uromodulin (Tamm-Horsfall protein). Uromodulin is exclusively 
expressed in cells of the TAL and excreted into the urine [35]. On renal slices all cells 
positive for MCT14 did also show a signal for uromodulin. Uromodulin staining was 
present within the whole cell as well as on the luminal membrane of those cells, 
whereas the MCT14 signal was restricted to the apical membrane of TAL cells. In 
order to investigate if MCT14 is exclusively expressed in the TAL or its expression 
extends into the adjacent distal convoluted tubule (DCT), further co-stainings were 
performed with a marker of the DCT, namely the Na+/Cl- cotransporter NCC [36]. As 
no coexpression of MCT14 with NCC was detected, we conclude that expression of 
MCT14 is restricted to the apical membrane of the TAL. Of note, despite the strong 
regulation of RNA/protein abundance caused by dietary phosphate, no changes were 
detected in the distribution pattern of MCT14 in renal sections from mice fed high or 
low phosphate. 
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The physiological role of the classical monocarboxylate transporters MCT1-4 is the 
import and export of lactate as a substrate of oxidation or end product of glycolysis. 
MCT1, 3 and 4 interact with the accessory protein CD147 and for MCT1 it is well 
documented that association with CD147 is required for proper targeting to the 
basolateral membrane of the proximal tubule [11]. We could demonstrate that 
transport of lactate is not facilitated by MCT14, and introduction of CD147 did not 
show any effect. In fact expression and incorporation of MCT14 into the Xenopus 
laevis oocyte membrane in the absence of CD147 was confirmed by western blot and 
immunofluorescence experiments. Expression of MCT14 in Xenopus laevis oocytes 
did not support either transport of phosphate, suggesting that that MCT14 is not 
directly involved in renal Pi transport. Previous experiments detected CD147 at the 
basolateral membrane of TAL cells [12] whereas MCT14 appears to be restricted to 
the apical membrane of these cells making a relevant direct interaction between 
these two proteins in vivo rather unlikely. 
Phylogenetically MCT14 is closer related to MCT8 and MCT10, than to the classical 
monocarboxylate transporters. MCT8 and MCT10 transport thyroid hormone [14] and 
aromatic amino acids [16] respectively. A recent study suggested that MCT14 might 
be involved in transport of amino acids, rather  than in the shuttling of 
monocarboxylates [24]. However, our transport studies do not support this hypothesis 
since they failed to show any significant transport of any of the tested amino acids. 
There might be a tendency of slightly higher import of serine and glutamate, which 
could be due to structural homologies to endogenous substrate. However, the rate of 
induction was very small and may represent rather the stimulation of an endogenous 
Xenopus transport system than transport by MCT14 itself. Since most amino acids 
are already absorbed in the proximal tubule, very low concentrations are reaching the 
TAL; therefore, amino acid transporters located in the TAL must have the properties 
of a high affinity transporter. Another member of the MCT family, which has been 
recently characterized, is MCT12. MCT12 has been shown to be a creatine 
transporter [17]. However, compared to MCT12, MCT14 did not show any transport 
for creatine. Interestingly MCT7, which is another orphan member of the family, is 
expressed at the basolateral membrane of the TAL [12]; thus we can speculate that 
MCT7 might work in tandem with MCT14 for vectorial shuttling of metabolites across 
the epithelium. 
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In summary, we showed that the renal abundance of MCT14 is highly regulated by 
the dietary content of phosphate and that its expression in kidney is restricted to the 
luminal side of the TAL.  However, MCT14 seems to transport neither phosphate nor 
several other substrates of different members of the MCT family. 
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Figure legend 
Figure 1: Renal adaptation to low (LPD) and high (HPD) dietary phosphate. 
Adaptation was confirmed by the expression of NaPi-IIa protein abundance in 
kidneys of mice fed 14 hours (A) and 5 days (B) with both diets. β-actin was used as 
a loading control. Renal mRNA expression of Cyp27b1 and MCT14 after either 14 
hours (C and E) or 5 days (D and F) of LPD respectively HPD, n = 5-6 animals/group.  
Statistical differences were calculated with t-test: *p<0.05, **p<0.01 and ***p<0.001. 
Figure 2:  Validation of a newly generated MCT14 antibody. Renal homogenates 
were incubated with antibodies against MCT14 (A) and NaPi-IIa (B) in the presence 
and absence of the antigenic peptide as indicated. Lysates of Xenopus laevis 
oocytes injected with MCT14 cRNA and non-injected oocytes (n.i.) were incubated 
with the MCT14 antibody (C); renal homogenate was loaded in the last lane (+). 
Immunofluorescence was performed on kidney cryosections in the presence and 
absence of the antigenic peptide (E). Immunofluorescence in oocytes expressing 
MCT14 and corresponding non-injected oocytes (F). 
Figure 3: MCT14 renal localization. Consecutive sections showing MCT14 and NaPi-
IIa localization (A). Cortical (B) and outer medullary (C) staining patterns of MCT14 
and NKCC2 on consecutive sections. Costainings performed with MCT14 and 
uromodulin (D) or NCC (E) on renal sections. MCT14 is shown in red, NaPi-IIa, 
NKCC2, uromodulin and NCC are represented in green and blue indicates nuclear 
fluorescence (DAPI). 
Figure 4: Regulation of MCT14 protein abundance by dietary phosphate. Western 
blotting with MCT14 antibody was performed on renal homogenates from animals fed 
14 hours (A) and 5 days (B) with either low (LPD) or high (HPD) phosphate. 
Expression levels were normalized to corresponding β-actin levels. MCT14 protein 
abundance was significantly increased in animals fed a HPD compared to LPD as 
indicated in the corresponding densitometric analysis. Statistical differences were 
calculated with t-test: *p<0.05 and ***p<0.001. Immunofluorescence staining against 
MCT14 was performed in kidneys of mice fed HPD or LPD for 5 days (C). 
Figure 5: Uptake in X. laevis oocytes. Lactate transport was assessed in Xenopus 
laevis oocytes injected with cRNA of MCT14 and CD147, in oocytes injected with 
MCT14 or CD147 alone and non-injected oocytes (NI) (A). Oocytes expressing 
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MCT12 and CD147, MCT14, MCT14 and CD147 and non-expressing oocytes (N.I.) 
were used to perform creatine uptake (B). Transport of the indicated amino acids into 
oocytes expressing MCT14 is given in relation of uptakes into non-injected oocytes 
(NI) (C). Each experiment was performed with at least n = 7-10 oocytes. 
 
Table 1: Transport studies in Xenopus laevis oocytes [pmol/10min] 
Substrate MCT14 Non injected 
  
Lactate 7.593 ± 0.600 7.174 ± 1.620  
Pyruvate 0.300 ± 0.063 1.177 ± 0.169 * 
Alanine 4.430 ± 0.702 5.135 ± 2.803  
Methionine 4.784 ± 0.906 4.863 ± 1.789  
Cysteine 0.635 ± 0.177 0.489 ± 0.076  
Cystine 6.601 ± 1.419 7.866 ± 0.962  
Glutamine 2.676 ± 0.274 6.053 ± 2.502 * 
Serine 12.29 ± 7.19 7.52 ± 4.49  
Tyrosine 11.44 ± 1.05 12.69 ± 1.32  
Glutamate 0.882 ± 0.685 0.628 ± 0.278  
Aspartate 1.770 ± 0.327 1.625 ± 0.176  
Isoleucine 4.955 ± 6.238 1.997 ± 2.152  
Valine 25.70 ± 1.97 24.70 ± 3.23  
Tryptophane 90.97 ± 14.58 100.93 ± 8.41  
Phenylalanine 81.18 ± 23.12 86.28 ± 15.39  
Phosphate 1.384 ± 0.479 1.376 ± 0.377  
Urate 0.0039 ± 0.0015 0.0087 ± 0.0039 * 
Citrate 6.442 ± 3.022 5.452 ± 0.462  
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Chapter 4 
4. Discussion 
Pi is an essential nutrient and the maintenance of its homeostasis is vital for several 
biological functions in the mammalian body. The impact of dietary Pi content has 
been granted little attention until recently, when Pi was associated with premature 
aging, vascular calcifications, cardiovascular mortality, risk for renal failure, and bone 
damage [210,211]. Therefore it is of importance to get a better understanding of the 
mechanisms underlying intestinal Pi absorption. Especially since some novel 
therapeutic approaches to decrease pathologically high Pi levels in CKD patients 
involve intestinal NaPi-IIb inhibition. Though animal models suggest that NaPi-IIb is 
the major if not only transporter for transcellular Pi transport in the intestine [43,52], 
the relative contribution of transcellular versus paracellular absorption of Pi is not 
clear yet. 
NaPi-IIb deficient animals fed normal chow show a rather mild phenotype regarding 
Pi homeostasis. Whereas intestinal ablation of NaPi-IIb abolishes Pi uptake into ileal 
BBMV, the associated increase in fecal Pi excretion is very moderate. As a 
compensatory mechanism the expression of the renal NaPi-IIa is upregulated, which 
is reflected by increased Pi uptakes into renal BBMV. Consistently NaPi-IIb deficient 
mice excrete less Pi in urine. The reduced intestinal absorption seems to be fully 
compensated by the concomitantly reduced renal excretion of Pi, since plasma levels 
of Pi and its regulatory hormones remain constant in those animals [43]. Those 
findings were similar in intestinal specific as well as in inducible NaPi-IIb deficient 
mouse models [43,52]. Furthermore, this moderate contribution of NaPi-IIb may also 
apply to patients suffering from pulmonary alveolar microlithiasis, caused by 
mutations in NaPi-IIb [44]. Despite calcifications in lung no impact on Pi homeostasis 
is reported, and, if mentioned, plasma levels of Pi are normal [44]. Together, the 
above observations strongly suggest an alternative pathway for Pi across the 
intestinal epithelia. Since uptake into BBMV from ileum [43] and transport studies in 
everted gut sacs [52] showed an abolished transcellular transport of Pi in mice 
lacking NaPi-IIb, it may be hypothesized that the paracellular pathway plays an 
important role in those animals, and possibly even in non-mutated mammals. Of 
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note, the transport studies in everted gut sacs were performed with equimolar Pi 
concentrations on both sides of the epithelium, neglecting any possible contribution 
of the paracellular pathway, since paracellular transport requires a concentration 
gradient [52]. In fact Pi concentrations in the intestinal lumen exceed plasma levels of 
Pi more than tenfold [53]. Additionally, upon Pi depletion the absorptive rate is about 
50% higher in WT animals than in NaPi-IIb deficient animals [52], suggesting a 
contribution of NaPi-IIb in the same margin. Instead nothing is known about the 
molecules allowing for paracellular Pi transport and possible adaptive mechanisms. 
Since NaPi-IIb is upregulated upon dietary Pi restriction, this rather highlights the 
maximal contribution of NaPi-IIb, than reflecting the physiological relevance under 
normal dietary conditions. 
Upon dietary Pi restriction a strong increase of intestinal NaPi-IIb abundance is 
observed [212], consistent with higher uptakes into ileal BBMV. Furthermore NaPi-IIb 
has an apparent Km >10µM [16], thus it is a high affinity transporter that is expected 
to be saturated already at very low luminal Pi concentrations. This might suggest that 
the role of NaPi-IIb is critical once dietary Pi supply is low. In order to investigate this 
hypothesis we challenged NaPi-IIb deficient animals with either high or low Pi diets. 
We found that similarly to WT mice, NaPi-IIb deficient mice also increase urinary and 
fecal Pi excretion when fed with a high Pi diet. On the contrary, dietary Pi restriction 
decreased fecal and urinary Pi excretion in both groups. Though urinary excretion 
was decreased under low dietary Pi conditions, it does not seem to be sufficient to 
match the lack of intestinal absorption in NaPi-IIb deficient mice, resulting in a 
transient hypophosphatemia. Considering that in response to low Pi WT animals 
increase their renal Pi reabsorption to a point where almost no Pi is excreted (after 14 
days), it is not surprising that NaPi-IIb deficient mice are unable to further adapt 
through renal Pi transport rates. Interestingly, the circulating levels of vitamin D3, PTH 
and FGF23 are comparable in both groups, even when intestinal ablation of NaPi-IIb 
leads to a transient hypophosphatemia during low dietary supply of Pi. However, 
upon prolonged Pi deprivation NaPi-IIb deficient mice show increased urinary levels 
of deoxypyridinoline (DPD), a marker for bone resorption, indicating that mutant mice 
release Pi from bones to maintain its circulating levels constant. The concomitant 
mobilization of Ca2+ from bones is refleceted by the increased amount of Ca2+ 
excreted in urine. NaPi-IIb deficient mice also show higher urinary excretion of 
corticosterone and two of its metabolites 5α-dihydrocorticosterone and 11-
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dehydrocorticosterone, which together reflect higher plasma levels of corticosterone. 
Glucocorticoids have been shown to be potent stimulators of bone catabolism and 
osteoclast activity [154], which is consistent with the observed Ca2+ loss and elevated 
DPD in urine, thus supporting the hypothesis of the bone as a source of Pi of NaPi-IIb 
deficient mice under Pi depletion. As a consequence, we found that bone mineral 
density under low Pi diet was decreased in NaPi-IIb deficient mice. Thus, NaPi-IIb 
mediated Pi absorption during low Pi availability is important to protect bone from 
demineralization and to maintain systemic Pi balance.  
Our observations in dilution potential measurements in intestinal and renal cell 
culture models suggest that the tight junctions are permeable to Pi. Because under 
physiological conditions Pi is present in monovalent and divalent forms and claudins 
are charge and size selective, experiments were initially performed at pH 6 and pH 
8.4, to investigate if claudins discriminate between the two Pi species. Additionally, 
claudins form pores that facilitate diffusion selectively, and their transport is supposed 
to be symmetric, unlike transcellular transport. Therefore experiments were 
performed with apical and basolateral application of Pi and permeability was 
normalized to that of Na+. In intestinal cell culture models we observed a strong 
preference of the paracellular pathway for monovalent Pi, with a relative permeability 
of about 40% versus a maximal permeability of 20% for divalent Pi. The relative 
permeability to Cl-, was unaffected by pH, suggesting that the differences observed 
are truly due to Pi species selectivity. Moreover, permeabilities were symmetric, 
indicating that potential changes were indeed due to ion flux through the paracellular 
pathway. Overexpression of either claudin 17 (cldn17) or tricellulin in MDCK cells had 
no effect on Pi permeability, whereas as expected cldn17 strongly increased the 
paracellular permeability to Cl-. This suggests that the anion selective cldn17 [209] is 
not involved in mediating Pi passage through the tight junctions. Similar experiments 
were also performed in different segments of rat and mouse intestine. Duodenum 
(done only in mice), Jejunum, ileum and colon all conducted Pi across their 
epithelium, with the small intestine having a higher absolute permeability than the 
colon, due to higher transepithelial resistance. The same was true for Na+ and Cl-. 
Following Ohm’s law (I=V/R), the higher the resistance of the tissue the lower is the 
flux of ions (current) observed across the epithelium. As for the cell culture models 
the tight junctions of the intestine also show a preference for monovalent Pi, though 
the effect of pH was not as strong as observed in cultured cell. Again pH did not 
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affect transport of Na+ or Cl-.  The permeability for Pi was symmetric and about half of 
the permeability of Na+ and Cl-. In our experimental setup the colon paracellular 
pathway is permeable to Pi. Moreover, hyperphospatemia develops after enemas 
containing Pi concentrations exceeding blood levels, highlighting the capacity of the 
colon to absorb Pi [31]. However, the role of the colon in intestinal Pi absorption 
might be minor, due to increasing solidity of the content. Paracellular Pi permeability 
in NaPi-IIb deficient mice fed a normal diet is comparable to the one observed in WT 
mice. These findings strongly support the hypothesis that the paracellular transport is 
involved in intestinal Pi absorption and is sufficient to provide enough Pi to maintain 
Pi homeostasis in NaPi-IIb deficient mice (and eventually PAM patients) under 
normal dietary Pi supply. 
The confirmation of paracellular Pi transport in intestine might also help to explain the 
observations in NaPi-IIb deficient mice adapted to different dietary Pi content. 
Assuming that the luminal Pi content somehow reflects the dietary content, the higher 
the dietary Pi content the higher the amount of Pi absorbed through paracellular 
diffusion. Thus the urinary Pi excretion in NaPi-IIb deficient animals should reflect the 
efficiency of this concentration dependent mechanism. In the absence of an active 
transport mechanism, NaPi-IIb mice excrete higher levels of Pi with increasing 
amount of Pi in the diet, and even under normal dietary conditions more Pi is 
absorbed than necessary since there is still a large proportion excreted in urine. Only 
when dietary Pi is restricted and presumably the concentration gradient is not high 
enough to drive passive diffusion, NaPi-IIb deficiency proofs to be critical. These 
findings suggest that active transport mediated by NaPi-IIb is there to cope with low 
luminal Pi concentrations, while under normal dietary conditions paracellular 
transport may be the major component. Also from an energetic point of view, it would 
make sense to utilize a passive diffusion gradient for absorption, because every Pi 
imported via NaPi-IIb requires one ATP since the Na+/K+-ATPase to remove the three 
imported sodium.  
Hyperphosphatemia promotes secondary hyperparathyroidism and is a risk factor for 
cardiovascular disease, soft tissue calcification and is the major cardiovascular risk 
factor in CKD patients, increasing cardiovascular morbidity [1]. Still, daily intake of Pi 
exceeds recommended amounts. For instance a daily intake of 1500 mg Pi is 
reported for American males, whereas 700 mg is recommended [213]. The increased 
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dietary intake of Pi is partially attributed to the consumption of processed food and 
soft drinks. Preservatives in these products contain a high amount of Pi salts. In 
contrast to Pi naturally present in the food, these additives have a much higher 
availability for absorption [214].  This high amount of Pi in our nutrition is expected to 
provide a strong diffusion gradient across the intestinal epithelium, triggering the 
passive absorption of Pi, which does not show any saturation and linearly increases 
with luminal Pi content. Luminal Pi concentration in human jejunum has been 
reported to be between 0.7 and 12.7mM [215] depending on dietary conditions, thus 
NaPi-IIb might transport already close to the maximal capacity considering its KM or 
may even be downregulated. Therefore the excessive amount of Pi causing adverse 
effects, including renal damage and vascular calcification might be eventually 
attributed to the passive absorption in the intestine. Thus our dietary habits might be 
reflected by the experiments presented in this study, in which mice were fed high Pi 
diet: even in the absence of NaPi-IIb, Pi supply was excessive and led to 
phosphaturia. 
Hyperphosphatemia is observed in CKD patients due to renal failure and worsens the 
patients` outcome. Dietary Pi restriction, the inhibition of intestinal NaPi-IIb, or the 
use of Pi binders have been suggested as an approach to treat hyperphosphatemia 
in CKD patients. However, a combination of at least two might be necessary, since 
NaPi-IIb independent mechanisms, i.e. paracellular transport may be sufficient to 
drive the intestinal absorption of dietary Pi supply. Furthermore NaPi-IIb might 
already be down regulated due to hyperphosphatemia and its relative contribution 
already blunted. In contrast, lowering luminal Pi concentrations by Pi binders might 
induce NaPi-IIb upregulation. Indeed experiments in mice with adenine induced CKD 
show that administration of sevelamer (a Pi binder) stimulates the expression of 
NaPi-IIb, despite high levels of serum Pi in adenine treated and untreated mice [216]. 
Thus sevelamer was not able to correct hyperphosphatemia in this CKD mouse 
model. NaPi-IIb deficiency alone decreased serum Pi levels in adenine induced CKD, 
but was not able to completely correct the hyperphosphatemia. However sevelamer 
was able to reduce serum Pi levels to normal values in adenine treated NaPi-IIb 
deficient mice, supporting the notion that both pathways contribute to intestinal 
absorption of Pi [216].  
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In summary we could show that under normal and high dietary Pi conditions the 
ablation of intestinal NaPi-IIb can be compensated by the kidney and does not alter 
overall Pi homeostasis. Pi seems to be sufficiently/excessively supplied by the 
paracellular pathway. However the role of NaPi-IIb appears to be crucial as soon as 
dietary Pi is restricted. In this case NaPi-IIb deficient mice compensate impaired 
intestinal Pi absorption by resorbing bone to release Pi. Furthermore we demonstrate 
that the tight junctions in the intestine are permeable to Pi, providing the 
requirements for paracellular diffusion of Pi.  
Additionally, we showed that the renal abundance of MCT14, an orphan member of 
the monocarboxylate transporter family, is highly regulated by the dietary content of 
Pi and that its expression in kidney is restricted to the luminal side of the TAL.  
However, MCT14 seems to transport neither Pi nor several other substrates of 
different members of the MCT family. 
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Chapter 5 
5. Outlook 
1. The permeability of the intestinal paracellular pathway to Pi, assessed by 
dilution potential measurements in Ussing chambers, needs to be confirmed, 
for example with radioactive flux experiments. Furthermore the 
responsiveness of the paracellular pathway for Pi to alterations in dietary Pi 
content or other regulators of Pi homeostasis like vitamin D3, PTH and FGF23 
should be addressed. Of interest some claudins are regulated by vitamin D3. 
Moreover, it was reported that passive Pi transport in small intestine was 
stimulated by the glucocorticoid cortisone [217]. The increase in 
glucocorticoids observed in NaPi-IIb deficient mice might not only be involved 
in increased bone resorption, but also provide another mechanism to increase 
intestinal reabsorption. 
2. Comparing possible regulatory mechanisms with transcriptome data on Pi 
regulated transcripts in intestine might give insight into the molecular 
mechanism behind paracellular Pi permeability. So far there is no association 
of any tight junction component and intestinal Pi absorption. Preliminary 
results indicate that the anion selective claudin 17 and tricellulin are not 
participating in this gating of Pi.  
3. Final aspect to be addressed is the relative contribution of active and passive 
transport in the intestine to understand the relevance of each pathway. From 
an energetic point of view this would be of interest, because for active 
transport intestinal cells have to spend ATP through the Na+/K+-ATPase, to 
maintain the membrane potential and the Na+ gradient for secondary active 
transport. Also from an evolutionary point of view it would not make sense to 
spend energy as long as there is a passive pathway providing the body with 
Pi. 
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Chapter 6 
6. Publications that did not contribute 
to the thesis 
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Published in:  
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Structural Fold and Binding Sites of the Human NaD-Phosphate
Cotransporter NaPi-II
Cristina Fenollar-Ferrer,† Monica Patti,‡ Thomas Kno¨pfel,‡ Andreas Werner,§* Ian C. Forster,‡*
and Lucy R. Forrest†*
†Computational Structural Biology Group, Max Planck Institute of Biophysics, Frankfurt amMain, Germany; ‡Institute of Physiology and Zurich
Center for Integrative Human Physiology, University of Zurich, Zu¨rich, Switzerland; and §Epithelial Research Group, Institute for Cell and
Molecular Biosciences, Newcastle University, Newcastle upon Tyne, United Kingdom
ABSTRACT Phosphate plays essential biological roles and its plasma level in humans requires tight control to avoid bone loss
(insufficiency) or vascular calcification (excess). Intestinal absorption and renal reabsorption of phosphate are mediated by
members of the SLC34 family of sodium-coupled transporters (NaPi-IIa,b,c) whose membrane expression is regulated by
various hormones, circulating proteins, and phosphate itself. Consequently, NaPi-II proteins are also potentially important phar-
maceutical targets for controlling phosphate levels. Their crucial role in Pi homeostasis is underscored by pathologies resulting
from naturally occurring SLC34 mutations and SLC34 knockout animals. SLC34 isoforms have been extensively studied with
respect to transport mechanism and structure-function relationships; however, the three-dimensional structure is unknown.
All SLC34 transporters share a duplicated motif comprising a glutamine followed by a stretch of threonine or serine residues,
suggesting the presence of structural repeats as found in other transporter families. Nevertheless, standard bioinformatic
approaches fail to clearly identify a suitable template for molecular modeling. Here, we used hydrophobicity profiles and hidden
Markov models to define a structural repeat common to all SLC34 isoforms. Similar approaches identify a relationship with the
core regions in a crystal structure of Vibrio cholerae Naþ-dicarboxylate transporter VcINDY, from which we generated a homol-
ogy model of human NaPi-IIa. The aforementioned SLC34 motifs in each repeat localize to the center of the model, and were
predicted to form Naþ and Pi coordination sites. Functional relevance of key amino acids was confirmed by biochemical and
electrophysiological analysis of expressed, mutated transporters. Moreover, the validity of the predicted architecture is corrob-
orated by extensive published structure-function studies. The model provides key information for elucidating the transport mech-
anism and predicts candidate substrate binding sites.
INTRODUCTION
Cells depend on inorganic phosphate (Pi) to ensure growth
and structural integrity, maintain energy balance, and
communicate with their environment. In mammals, Pi trans-
port across the cell membrane is mediated by secondary
active transporter proteins that use the free energy from
the Naþ gradient and transmembrane (TM) electrical poten-
tial to catalyze uphill Pi transport. Multicellular organisms,
especially vertebrates, face a particular challenge in main-
taining whole body Pi homeostasis: the solubility of Pi is
limited in the presence of divalent cations, especially cal-
cium, and excess of Pi in bodily fluids promotes Ca-Pi pre-
cipitation. This is of particular concern in patients with
chronic kidney disease who tend to retain excessive levels
of Pi (hyperphosphatemia), which leads to vascular calcifi-
cation (1).
A family of Naþ-coupled Pi transporters belonging to the
solute carrier family SLC34 (NaPi-II), is central to main-
taining whole body Pi homeostasis (2). All vertebrates
express up to three isoforms of NaPi-II in organs that
contribute to maintaining Pi balance. Mammals express
NaPi-IIb (SLC34A2) in the intestine to mediate dietary Pi
absorption and express NaPi-IIa (SLC34A1) together with
NaPi-IIc (SLC34A3) in the renal proximal tubule to mediate
reabsorption of Pi from the glomerular filtrate (2–4). The
central role of NaPi-II proteins emerged when hormones
and metabolic factors known to influence body Pi levels,
such as parathyroid hormone, calcitonin, growth hormones,
or Pi availability, were found to regulate NaPi-II membrane
expression (reviewed in (5,6)). Their homeostatic role was
further corroborated by NaPi-II knockout mice, which dis-
played organ-specific perturbations of Pi handling (7). Of
importance, in humans, dysfunction in renal Pi handling
can be attributed to naturally occurring mutations in NaPi-
IIa (8,9); NaPi-IIc (10), and to Pi-related pathologies for
NaPi-IIb in lung and testes (11), further underscoring the
importance of these proteins.
Functional analyses of wild-type (WT) and mutant trans-
porters expressed in Xenopus laevis oocytes have allowed a
detailed characterization of each isoform. The NaPi-II pro-
teins transport one divalent Pi ion with an apparent affinity
(K0.5
Pi) of 10–70 mM, together with two (NaPi-IIc) or three
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Naþ ions (NaPi-IIa and NaPi-IIb) with an apparent affinity
(K0.5
Na) of 25–50 mM (reviewed in (12)). The experi-
mental evidence supports the notion that NaPi-II proteins
mediate transport according to the canonical alternating
access mechanism (13–15). In the normal transport cycle
(Fig. 1 A), substrate binding at the external side is ordered,
with 2 Naþ ions binding before Pi. These cation interactions,
together with intrinsic mobile charges that are postulated to
alter the empty carrier orientation between inward and out-
ward facing conformations (states 0 and 1, Fig. 1 A), effec-
tively couple membrane potential to the NaPi-IIa/b transport
cycle to act as a transport driving force (12). In contrast, the
electroneutral NaPi-IIc cycle is insensitive to membrane
voltage and only one of the Naþ ions preceding Pi binding
is translocated. However, for all three isoforms, binding
of the last Naþ is a rate-determining partial reaction
(Fig. 1 A, transition 4/ 5) (16,17) and moreover, the sim-
ilarity of apparent substrate affinities suggests that they
share the same substrate recognition and translocation struc-
tural unit.
All vertebrate NaPi-II homologs identified and studied
to date are assumed to have identical TM topologies (12)
(Fig. 1 B). Specifically, the protein contains two sets of TM
helices, each containing a copy of a conserved sequence
motif, separated by a large extracellular loop. Epitope
tagging and cysteine scanningmutagenesis experiments sug-
gest that these repeated units have inverted TM topologies
and that both termini are cytosolic (12,18). However, a
three-dimensional structural model of NaPi-II proteins that
integrates these functional and structural data is still lacking,
preventing further understanding of the transport mechanism
and limiting the interpretation of structure-function data.
The inverted-topology repeat architecture represents a
common structural leitmotif displayed by a number of
FIGURE 1 Kinetic and structural features of
NaPi-IIa. (A) The transport cycle is depicted as a
sequence of partial reactions between conforma-
tional states, numbered 0–7 (reviewed in (12)).
Cartoons illustrate the ordered nature of protein-
substrate interaction based on experimental evi-
dence. Partial reactions on the cytosolic side have
not been explicitly identified except the last Naþ
release (transition 7 / 0) (68). Red arrows:
electrogenic partial reactions (involving charge
movement); black arrows: electroneutral partial
reactions. In the absence of external Pi, Na
þ ions
can also translocate via a leak transition (24 7)
(66). For the electroneutral cycle (of NaPi-IIc),
all transitions are electroneutral and the first
Naþ ion to bind (transition 1/ 2) is hypothesized
not to translocate (58). (B) Secondary topology of
NaPi-IIa based on previous experimental evidence
and bioinformatic predictions (12). The assumed
boundaries of repeat regions (rat sequence) are
indicated (52); colored symbols indicate identical
or conserved residues in each repeat. A disulfide
bridge links the two halves of the protein in the
large extracellular loop. (C) Hydropathy plots of
the regions predicted to contain the structural re-
peats in NaPi-II, averaged over a set of sequence
homologs and aligned using AlignMe. Region 1,
containing residues 86–256 of the human NaPi-
IIa (RU1, black) is aligned to region 2 plus C-ter-
minus consisting of residues 335–564 (RU2þC,
red). Gaps in the alignment are indicated by dashes
along the base of the plot. To see this figure in
color, go online.
Biophysical Journal 106(6) 1268–1279
Structural Model of NaPi-II 1269
secondary active transporters for which crystal structures
have been determined recently (see e.g. (13,19,20).). Such
repeats provide a pseudosymmetry to the fold that has a
number of important implications for function. For example,
these transporters frequently harbor a central substrate bind-
ing site at the axis of pseudosymmetry. This site is then
accessed alternately via two pseudosymmetric pathways,
each constructed from equivalent elements from the two re-
peats (21,22). Interestingly, binding sites for sodium ions
have also been identified by studying pseudosymmetric po-
sitions in structures of a sodium-coupled transporter, BetP
(23). Thus, although many transporters have evolved signif-
icant breaks in this pseudosymmetry, presumably as a means
to introduce specificity and variety, consideration of the re-
peats and their symmetry can be a useful starting point for
structure-function studies of secondary transporters.
The recognition of the conserved inverted-topology
sequence repeat in NaPi-II prompted us to search for a suit-
able template among the crystal structures of solute trans-
porters reported to date, from which a homology model
could be generated, compared with a wealth of experimental
evidence, and used to predict putative binding site regions.
METHODS
Computational methods
Full details of the computational procedures are provided in the Supporting
Material. A brief description follows. Sequences of NaPi-II transporters
were identified using HMMER (24) from the National Center for Biotech-
nology Information (NCBI) nonredundant (nr) database, clustered using
UCLUST (25), and aligned with MSAProbs (26). Segments of the multiple
sequence alignments were converted to averaged hydropathy profiles
and aligned with the AlignMe web server (27). Hidden Markov-models
(HMMs) of the same segments were constructed after identifying homologs
from the NCBI nr20 database using HHblits (28). HMMs were aligned
using HHalign (29).
Template structures were searched for using PSI-BLAST (30), Phyre2
(31), COMA (32), and HHpred (29). Template-target alignments of
either full-length proteins or individual repeats were generated with
either ProfileþSecondary-Structure (AlignMePS) or þTransmembrane
(AlignMePST) modes on the AlignMe server (27), or with HHalign.
A homology model was constructed using Modeler (33) based on the
structure of VcINDY (PDB identifier 4F35). After refinement and guided
by conservation patterns from the ConSurf server (34), the percentage of
identical residues between VcINDY and NaPi-II was ~15% in repeat unit
1 (RU1) and 11% in repeat unit 2 (RU2). A single model was selected after
2000 Modeler attempts, with two sodium ions and a phosphate molecule
modeled in putative binding sites. The model was evaluated using ProQM
(35) and PROCHECK (36).
Functional expression in oocytes and transport
assays
Reagents and solutions
Oocytes were incubated in Modified Barth’s solution that contained
(in mM): 88 NaCl, 1 KCl, 0.41 CaCl2, 0.82 MgSO4, 2.5 NaHCO3,
2 Ca(NO3)2, 7.5 HEPES, adjusted to pH 7.5 with TRIS and supplemented
with antibiotics doxycyclin and gentamicin (5 mg/l). The solution compo-
sitions were as follows: Control superfusate (100 Na) (in mM): 100 NaCl,
2 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, adjusted to pH 7.4 using TRIS.
Choline solution (100 Ch): as for 100 Na with isosmotic substitution of
100 mM choline chloride. Pi was added to the required substrate concentra-
tion from 1 M K2HPO4 and KH2PO4 stocks premixed to give the required
pH (7.4).
Molecular biology and single point mutations
cDNA encoding WT human NaPi-IIa was subcloned into a vector contain-
ing the 50 and 30 UTRs from Xenopus b-globin to improve its expression in
oocytes. Mutations were introduced using the Quickchange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). The sequence was verified by
sequencing (Microsynth, AG, Balgach, Switzerland), plasmids were linear-
ized with XbaI and cRNAwas synthesized in presence of Cap analog using
the T3 Message Machine kit (Ambion, Austin, TX).
Functional expression and transport assays
X. laevis frogs were purchased from Xenopus Express France (Vernassal,
France). Ovarian lobes were surgically removed and the oocytes isolated
following standard protocols (e.g. (37)). Animal procedures were per-
formed according to Swiss Cantonal and Federal legislation. Injected
oocytes (50 nl of cRNA (0.2 mg/ml)) were incubated for 3–5 days in modi-
fied Barth’s solution. Radioisotope uptake assays were performed using
standard procedures as described elsewhere (e.g. (38)) using 100 Na solu-
tion and 1 mM cold Pi to which
32Pi (specific activity 10 mCi/mmol Pi)
was added. Standard two-electrode voltage clamp hardware was used for
electrophysiology (GeneClamp, model 500, Molecular Devices, Sunnyvale,
CA) and controlled using pClamp 8-9 software (Molecular Devices).
Clampfit (Molecular Devices) was used for postacquisition analysis.
Immunostaining
After 3 days of expression, oocytes were fixed according to standard proce-
dures (e.g. (39)). Further details are given in the Supporting Material.
RESULTS
Identifying the repeated elements and peripheral
TM helices in NaPi-IIa
Modeling the structure of a protein is aided by knowledge of
the conserved and repeated structural elements within its
fold. Although it was clear from earlier studies, and from
the presence of a repeated conserved motif (Fig. S1), that
NaPi-II transporters contain a structural repeat with inverted
topology, it was not obvious where the boundaries of the
repeat units lay, or was it clear whether their overall fold
had an equivalent already reported. Aligning family-
averaged hydropathy profiles of different fragments of the
sequence clearly shows that the structure comprises two
repeat units (RU1, RU2) plus a C-terminal extension of
two additional TM helices (Fig. 1 C). These segments corre-
spond to TMs 1–5, TMs 6–10 and TMs 11–12, respectively,
of the published topology (Fig. 1 B).
A similar result was obtained by aligning HHalign hidden
HMMs of region 1 with region 2 or with region 2þC (see
Methods; Fig. S1, Fig. S2). This confirmed that regions 1
and 2 have similar secondary structures and further indi-
cated that they have ~27% identical residues. We concluded
that RU1 and RU2 in NaPi-II comprise residues 86–256 and
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335–489, respectively, and residues 504–564 form periph-
eral TM helices that are not part of the core fold.
Identifying a structural homolog of NaPi-IIa
To identify whether any available structure would be a suit-
able template for NaPi-IIa, several approaches were attemp-
ted (see Methods), of which HHpred provided the most
promising clue. Specifically, among the top five hits was a
Naþ-coupled dicarboxylate transporter from Vibrio cholera
(VcINDY) (40), also known as NaDC, a member of the
Divalent Anion:Naþ Symporter (DASS, 2.A.47) (41) or
SLC13 family (42), which also includes Naþ-coupled inor-
ganic anion (sulfate and phosphate) transporters (41). The
VcINDY structural fold belongs to the ST[3] class (43)
and contains an inverted-topology repeat fold (40). The
E-values of the top 10 hits were rather large (>2  102),
indicative of low confidence levels. Among those top 10
were three aquaporins, a GlpG protease, a KQT potassium
channel, and a disulphide reductase, DsbD, as well as
three water-soluble proteins. Pairwise alignments of NaPi-
IIa with four of the five highest-scoring membrane pro-
teins (aquaporin-4, GlpG protease, AQY1 aquaporin, and
VcINDY) using AlignMe in PS mode indicated that the
template with the greatest fold similarity among these hits
was VcINDY, with 62% sequence coverage and 7% iden-
tical residues, compared to%40% coverage and%4% iden-
tity for the other four proteins. (The other HHpred hit in the
top five, the KQT potassium channel was excluded because
the region matched to NaPi-II comprised unconserved
residues.)
The high E-value and small percentage of identical resi-
dues in VcINDY and NaPi-II suggested significant differ-
ences between their sequences, though these properties do
not preclude them from sharing a common core fold given
that structure is much more conserved during evolution
than sequence. Indeed, the two repeats in inverted-topology
membrane proteins can contain <10% identical residues,
despite being structurally related (14,40,44). In the afore-
mentioned search, HHpred matched the conserved QSSS
NaPi-II motif to a SNT motif that contributes to Naþ and
dicarboxylate binding in VcINDY (Fig. S4 B), which sug-
gested that the binding site regions at least are conserved.
To assess whether the similarities between VcINDY and
NaPi-II extend beyond function, the presence of inverted
repeats and hydrophilic binding motifs, we used a number
of other bioinformatic approaches (see Methods) culmi-
nating in homology modeling and comparison with experi-
mental data.
An important factor complicating the detection of distant
sequence relationships between transporter proteins has
been the presence of additional structurally-peripheral TM
helices that confound the alignment algorithms. A case in
point is the BCCT and NSS families (14,20,40,44,45),
which contain two additional TM helices either before or
after, respectively, the core inverted-topology fold. The
structural similarity between these families is clear using
hydropathy profile alignments, especially after separating
out the repeats of each protein, because that reduces the
chances of core helices aligning to peripheral helices (46).
In a family-averaged hydropathy profile alignment of
full-length NaPi-IIa and VcINDY, RU1 of NaPi-IIa was
aligned with several helices in the first repeat of VcINDY
(Fig. S4 A, green dashed box). That segment of the align-
ment resembled the NaPi-II repeat alignment (Fig. 1 B),
suggesting a relationship between the two proteins. How-
ever, RU2 was not aligned to the second repeat of VcINDY
in this global alignment, due to a shift of one TM segment
(Fig. S4 A, orange dashed box). Therefore, to identify puta-
tive corresponding helices in both VcINDY and NaPi-II re-
peats, we separately aligned hydropathy profiles of RU1 or
RU2 from the two proteins (Fig. 2 A), as well as HMMs of
these repeat units (Fig. S4 C and D). These alignments from
both methods, as well as alignments obtained using
AlignMe in PST mode, clearly indicated that the first two
TMs of each of the repeats of VcINDY (Fig. S3 A) has no
equivalent in NaPi-IIa.
In VcINDY, these additional helices (TMs 2, 3, 7, and 8)
are located at the periphery of the VcINDY monomer
(Fig. S3 A), and therefore could be omitted from the NaPi-
IIa model without affecting the integrity of the core transport
unit. Indeed, in the case of citrate carrier (CitS), which was
recently shown to share a similar architecture with VcINDY,
substrate-activated structural changes observed in electron
microscopy projection maps include no conformational
changes in these helices. This indicated that they act as a
stator with little or no functional role (47). The fact that
both NaPi-IIa repeats align to the equivalent structurally
repeated regions in VcINDY (i.e., the C-terminal segment
of each repeat, Fig. 2 A) gave support to the proposed rela-
tionship between the two proteins. At the same time, the
significant number of additional helices in VcINDY com-
pared to NaPi-IIa, before, between, and after the repeats
(Fig. S3 A) indicated why the alignments of the full-length
sequences were poor and the scores were low.
According to HHalign and AlignMePSTalignments of the
individual repeats the proposed Naþ and substrate binding
site residues of both RU1 and RU2 of VcINDY were aligned
to themost conserved regions of NaPi-IIa (Fig. 2B, Fig. S4B,
and Fig. S4C). Thismatching of conserved residues, the con-
sistency of the alignments using three different alignment
methodologies, i.e., AlignMePST, HHalign, and hydropathy
profile alignment, and the equivalency of thematched helices
in both repeats, together provided support for the choice of
VcINDYas a template for NaPi-II transporters.
A structural model of human NaPi-IIa
Although the expected accuracy of a model with this level
of sequence similarity is modest, it should suffice for
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comparison with topological and accessibility data even
if individual TM segments are misaligned by one or two
helical turns (48). An initial model of human NaPi-IIa
comprising residues 97–249 (RU1) and 341–505 (RU2)
was constructed (Fig. 3 and Fig. 4, A–C), whose topology
differs in some aspects from earlier proposals (Fig. 1 B).
The earlier, simpler proposal, based on the assumption of
membrane-spanning segments, agrees with the present
model on the nature of TMs 1 and 3 (previously 1 and 5)
and TMs 4 and 6 (previously 6 and 10). In addition, the
overall topology, in the sense of the accessibility of
the loops, is unchanged. However, in its oversimplicity,
the earlier model did not satisfactorily explain the unusual
hydropathic nature of the segments between TMs 1 and 3,
and between TMs 4 and 6 (Figs. 2 B, 3 A, and 4 C). Because
these segments in VcINDY consist of helical hairpins that
do not fully span the membrane, as well as long nonhelical
elements within TM segments, the model based on VcINDY
therefore makes sense of the hydropathy plots. At the
same time, the updated topology based on VcINDY agrees
well with results from studies using in vitro glycosylation
(49) and cysteine scanning mutagenesis and accessibility
measurements (SCAM -substituted cysteine accessibility
method (50)), e.g. (51–55).), as shown mapped onto the
model (Fig. 3 B, Fig. 4 C).
First, SCAM in the linker between TM1 and TM2 of RU1
(see Fig. 3 B) established that this region is accessible to the
external medium (56), consistent with its position at the
exposed external surface of our model (helix 1c, Fig. 4 C).
Second, SCAM in RU2 identified an externally accessible
region in loop L5ab between TM5a and TM5b (Fig. 3 B)
(53). In our model (Fig. 4 C), this linker is now localized
at the same depth as the proposed substrate coordination
sites (see below). Nevertheless, it should be accessible to
cysteine modifiers via the same aqueous pathway as that
of the substrates. Our original topology (Fig. 1 B) also
implied that helix 1c should be more accessible from the
external medium than loop L5ab, whereas SCAM studies
(56) indicate that both regions have similar apparent acces-
sibilities, which is in better agreement with their positioning
relative to the external medium depicted in our three-dimen-
sional model (Fig. 4 C). Finally, a cysteine at position S424,
which was considered accessible based on the original
topology, did not give resolvable fluorescence upon attempts
to label the equivalent site in the flounder isoform (57).
In better agreement with that data, the updated model
(Figs. 3 and 4 C) places this residue deeper in the structure
within HP2b.
Third, thiol modification from the external medium of a
Cys substituted at S183 in NaPi-IIa or at the equivalent
site in flounder NaPi-IIb (S155) at the top of helix 2a in
RU1 (Fig. 3 B) is possible, with minimal functional conse-
quences (49,57,58). These findings are consistent with the
relatively exposed position of this site, far from the central
binding region in the new fold (Fig. 4 C).
Fourth, SCAM revealed four sites that are accessible
only from the cytosol: N199 at the end of TM2a, together
with V202, A203, and M205 from L2ab (49,52,57,58)
FIGURE 2 Comparison of repeat units in NaPi-
II and the sodium-carboxylate transporter VcINDY
suggests that they share a common fold. (A) Hy-
drophobicity profiles of the two repeat units in
NaPi-II (red line) and VcINDY (black line).
Hydropathy plots averaged over a set of sequence
homologs of human NaPi-IIa or of VcINDY were
aligned using AlignMe for repeat unit 1 (left) and
repeat unit 2 (right). (B) Sequence alignment be-
tween VcINDY and the core region of human
NaPi-IIa used for modeling. The helices assigned
from the structure of VcINDY (Known SS) and
the PSIPRED predictions for helices in NaPi-IIa
(Pred SS) are shown as blue bars above and below
the sequences, respectively. Residues whose side
chains contribute to site Na2 (red triangles) or
Na3 (green triangles) are indicated. To see this
figure in color, go online.
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(Fig. 3 B). By contrast, the model suggests that these sites
are buried. However, it should be noted that our model
corresponds to an outward-open state, in which only the
extracellular pathway should be accessible. Transporters
containing pseudosymmetric repeats typically have pseudo-
symmetric pathways, which become exposed in a given
state, whereas their counterparts in the other repeat are not
(13,14). In NaPi-II, residues from TM5a and loop L5ab—
the symmetry equivalents of TM2a and L2ab—are acces-
sible in the modeled outward-open state (Fig. 4), and so it
is plausible that L2ab and TM2a are accessible from the
internal medium in cytosolic-open conformers of the pro-
tein. However, we cannot completely rule out an error in
the choice of template or sequence alignment used for the
modeling.
Fifth, SCAM in TM3 of human NaPi-IIa indicated that
this helix was inaccessible from the external medium,
with the exception of A240 at its extracellular end (55)
(Fig. 3 B). This pattern fits well with our model, wherein
TM3 acts as a buried scaffold with A240 exposed at the
extracellular side (Fig. 3 C).
We note that the proposed NaPi-IIa model has the oppo-
site TM topology from the core of VcINDY (Fig. S3), with
the first helix of RU1 in NaPi-II originating in the cytoplasm
(54). As a consequence, our NaPi-IIa model corresponds to
an extracellular-facing state.
Predicting substrate coordination sites
As indicated previously, the Naþ and citrate coordinating
residues located in the loops of the hairpins (HPin and HPout)
in VcINDY have conserved polar counterparts in hairpins
HP1 and HP2 of the NaPi-IIa model (Figs. 2 B and 4 C).
In addition, after comparing the structures, we observed
that the Ca atom of N199 from TM2a of NaPi-IIa
(Fig. 4 D) is located ~5 A˚ from the Ca atom of the Naþ-
binding residue N151 in VcINDY (40) even though they
originate from different helices. Although the accuracy of
the binding-site region in the model (Fig. 4 D) is highly
dependent on the correctness of the sequence alignment,
we considered the possibility that residue N199 in NaPi-II
plays a similar role to N151 in VcINDY; this possibility
would be consistent with an earlier finding that Cys substi-
tution of N199 in NaPi-IIa reduces the apparent Naþ affinity
40-fold (52). We therefore reasoned that other residues in
this region might coordinate the substrates or cosubstrates.
To identify such residues, we tentatively modeled an ion
into this region (see Methods), designated the Na2 site.
We observed that three other highly conserved hydroxyl-
containing residues lay nearby (Ca atoms within 6 A˚ of
the ion), namely S164 from HP1b, and T195 and S196
from TM2a (Fig. 4 D), which could provide suitable sodium
coordinating residues.
Assuming direct coupling between the substrate and Naþ,
as observed in LeuT (20) and in VcINDY (Fig. S3 B), a Pi
ion was tentatively placed at a position equivalent to that
of bound citrate (Fig. 4 D). The citrate density was observed
at the axis of the twofold pseudosymmetry between the
structural repeats, a common position for transporter sub-
strate binding sites (13). During the modeling, we imposed
coordination of the Pi by S164 and N199, such that they
each coordinate the ion at Na2 and the Pi (Fig. 4 D, see
also Fig S5 for coordination in the final model). This reflects
the observation that the nature of the side chain at site 199 is
a critical determinant of the mode of transport: small polar
and nonpolar residues do not alter the coupling mode, albeit
while causing a large increase in apparent sodium affinity
(see above), whereas large polar and charged residues at
FIGURE 3 Schematics of refined topology of NaPi-IIa. (A) Topological
elements are colored shades of green for RU1 and shades of red for RU2,
and the structural repeats (RU1, RU2) are indicated (shaded triangles).
Approximate positions of helical domains according to an earlier, simpli-
fied topology (gray boxes) are numbered according to the scheme in
Fig. 1 B for the human NaPi-IIa sequence. (B) Comparison with published
experimental data. The position of key residues is indicated. Residues that
are accessible based on cysteine scanning (SCAM) studies (black solid
circles); residues that are inaccessible based on SCAM (gray solid circles)
are highlighted. Sites accessible from the external milieu (red) or accessible
only from the internal milieu (blue) are labeled according to the organism:
flounder NaPi-IIb (f), human (h) or rat (r) NaPi-IIa. Positions on the
topology of residues mutated in this study are also shown (green and violet
solid circles for RU1 and RU2, respectively). To see this figure in color, go
online.
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this position lead to only the uncoupled leak mode being
observed (transition 2 4 7, Fig. 1 A) (52). Although we
cannot rule out a more indirect role for these mutations,
such an ability to affect the mode of coupling would be
consistent with a direct coordination of both substrates
(Fig. 4 D, Fig. S5).
In the model, residue S164 (at the start of HP1b) has a
symmetry equivalent position, namely S419 at the start of
HP2b, and so we speculated that S419 may also coordinate
Pi. Finally, beneath the binding site we identified a posi-
tively charged residue, R210 from TM2b, whose Ca atom
is ~8 A˚ from the substrate (Fig. 4 D), suitable for Pi coordi-
nation by the arginine side chain. R210 was therefore tested
as a putative Pi coordinating residue.
A second Naþ site, pseudosymmetric to that described
previously, could be hypothesized from our model—this
site would also involve direct coordination by the sub-
strate Pi. Assuming this pseudosymmetry predicts that
other residues in HP2ab and L4ab might coordinate an
ion in that site. In particular, according to the current
model, S462 lies at the start of TM5b, which after muta-
tion to Cys in flounder NaPi-IIb (S448) and in NaPi-IIc
(S437), can be modified by a thiol reagent and this modi-
fication abolishes transport (17,60,61). Under these condi-
tions, Naþ and Pi can still bind (partial reactions 1 4 2,
2 4 3, and 3 4 4, Fig. 1 A) (17,39,58,60), but either
the final Naþ binding step or the translocation step has
been compromised, consistent with the notion that S462
contributes to the third Naþ binding site, hereafter desig-
nated Na3.
Two other positions predicted to be in L5ab, correspond-
ing to A455 and L457 of NaPi-IIa, have been previously
mutated to Cys and subjected to thiol modification. Under
these conditions, not only was cotransport function compro-
mised, but the uncoupled leak (transition 24 7, Fig. 1 A)
significantly increased (53), which provided further confir-
mation of the importance of this loop in substrate transloca-
tion and cosubstrate coupling.
FIGURE 4 Structural model of human NaPi-IIa
based on VcINDY. (A–C) Overview of the pre-
dicted fold of the NaPi-IIa model represented by
cartoon helices. Two sodium ions (blue) and Pi
(yellow, red) are shown as spheres. The model is
viewed (A and C) from within the plane of the
membrane, or (B) from the extracellular side.
(A and B) Location of the structural repeats RU1
(green) and RU2 (pink), and the connecting long
extracellular loop (dashed lines). The transport
domain is highlighted by an orange circle, in B.
In C, individual helices are colored according to
Fig. 3 A. Regions for which experimental data
relating to the topology are highlighted: residues
accessible to the extracellular side (yellow) or
buried (blue) in helix 1c and 3, respectively; and
residues expected to be helical in TM5a, TM5b,
and the 5ab loop (red). The approximate extents
of the membrane are indicated by brown bars.
(D) The predicted binding site region in the model
of NaPi-IIa. The Ca-atoms of conserved and polar
residues close to the putative binding site are high-
lighted, as are bound Pi and sodium ions (spheres).
Residues N199 and S462 have previously been
implicated in substrate binding. Residues S164,
T195, S196, R210, Q417, S418, S419 are investi-
gated in this study. To see this figure in color, go
online.
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Finally, according to their proximity in the model (the Ca
atoms are within 6 A˚ of the ions), we identified residues
Q417 and S418 as potentially coordinating this ion in addi-
tion to S419 and S462.
Testing predictions by functional studies of
NaPi-IIa mutants
As mentioned previously, the minimal sequence identity
between VcINDY and NaPi-IIa limits the certainty with
which we can assign specific residues to the binding sites.
Therefore, to attempt to refine the structure of these sites
in atomic detail, for example using molecular dynamics
simulations, would not necessarily be informative. How-
ever, the predicted involvement of these residues in sub-
strate coordination requires experimental validation. We
therefore mutated S164, T195, S196, R210, Q417, S418,
and S419 to Ala or Cys, expressed the mutant constructs
in Xenopus oocytes, and performed standard radiotracer
and voltage clamp assays to compare their functional
behavior with that of WT NaPi-IIa (Table 1 and Fig. 5).
For constructs that displayed no measurable functional
behavior (namely S196C), we confirmed membrane expres-
sion by immunohistochemistry (Fig. S6). Furthermore, we
used presteady-state charge relaxation measurements to
ascertain if the mutagenesis had affected partial reactions
involving charge displacement arising from the empty car-
rier and the movement of Naþ ions to and from their binding
sites (Fig. 1 A) (12).
Two constructs (R210C and Q417C) displayed significant
32P uptake (Fig. 5 A), Pi-induced currents (data not shown)
and WT-like, resolvable charge relaxations in response to
voltage steps in the absence of Pi (Fig. 5 B). However, the
uptake levels of these two mutants were significantly
smaller than for the WT (Fig. 5 A). Because the uptake assay
was performed at only one Pi concentration (1 mM), the
lower transport rates could be ascribed to either altered
kinetics (apparent substrate affinity, reduced maximum
transport rate), or compromised membrane expression, or
a combination of both. Given the low transport activity of
R210C and Q417C and associated data uncertainties, we
did not perform standard dose dependence assays. Instead,
to assess whether the mutations had significantly altered
the apparent substrate affinities for Naþ and Pi, we deter-
mined activation indices defined as the ratio of Pi-induced
currents under defined conditions in which either Naþ or
Pi concentration was altered (see legend, Table 1) (56).
For R210C, the Naþ and Pi activation indices were both
close to those of the WT, whereas Q417C showed signifi-
cantly reduced indices (Table 1). These findings indicated
that transport and binding were unaffected by the R210C
mutation, but that the Gln-Cys substitution in the predicted
Na3 site (Fig. 4 D) reduced the apparent substrate affinities.
Nevertheless, for R210C, we noted that the presteady-state
relaxations showed a clear asymmetry compared with the
WT and other mutants (more charge movement for the
hyperpolarizing step compared to the depolarizing step)
(Fig. 5 B). This indicated that removal of this charge had
affected the voltage-dependent kinetics.
The replacement of S196 in RU1 with Cys did not prevent
surface expression (Fig. S6), but was considered lethal, as
the oocyte membranes became leaky after 2 days, pre-
venting further functional investigation. Nevertheless, this
behavior underscored the potentially critical role played
by this residue predicted to be at the Na2 site (Fig. 4 D).
The remaining six constructs (S164A, S164C, T195C,
S418C, S419A, and S419C) gave resolvable presteady-
state relaxations (Fig. 5 B), but insignificant 32P uptake or
Pi-induced current under voltage clamp (Table 1). The pres-
ence of presteady-state relaxations that are superimposed on
the background linear capacitive charge current of the
oocyte membrane (Fig. 5 B) provided strong experimental
evidence that, in the absence of Pi, one or more Na
þ ions
could still interact with these six mutants, in agreement
with our kinetic scheme for the WT (Fig. 1 A). However,
subsequent partial reactions required for cotransport, such
as association of Pi or the last Na
þ ion, were compromised
by these conservative, and yet apparently deleterious,
substitutions.
As described previously, the model predicts that S164 of
the first QSSS motif coordinates Na2 and/or Pi and that
T195 and S196 of TM2b contribute to the Na2 binding
site. The observation of presteady currents, combined with
the lack of uptake for both S164A and S164C supports the
TABLE 1 Functional properties of mutants
Repeat unit Construct 32P uptake
Presteady-state
Activation
indexa
100Na Pi
a Naa
WT þ þ 0.61 0.63
RU1 S164A  þ n.a. n.a.
S164C  þ n.a. n.a.
T195C  þ n.a. n.a.
S196C   n.a. n.a.
N199Cb þ n.d. 0.10 0.03
R210C þ þ 0.60 0.65
RU2 Q417C þ þ 0.46 0.39
S418C  þ n.a. n.a.
S419A  þ n.a. n.a.
S419C  þ n.a. n.a.
n.a.: not applicable; n.d.: not determined; : not detected; þ: detected.
Presteady-state relaxations suppressed () or left unchanged (þ) by
1 mM Pi.
Bold entries indicate constructs used for immunohistological confirmation
of membrane expression (Fig S6).
aActivation indices were defined as follows: the Pi index was the ratio of
Pi-induced current with 0.1 mM Pi to that with 1 mM Pi in 100 mM
Naþ and the Naþ index was the ratio of the response to 1 mM Pi with
50 mM Naþ to that with 100 mM Naþ. Both indices were determined
at 50 mV. These ratios give an approximate indication of shifts in the
apparent substrate affinity for screening purposes (e.g., (56)).
bFrom (52) for rat NaPi-IIa isoform, equivalent to N199 in human NaPi-IIa.
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proposal that S164 is critically required for later steps of
transport, consistent with a role in coordinating Na2 and/
or Pi.. Similar observations for T195C are consistent with
the proposal that it contributes to the Na2 binding site,
whereas the lethality of S196C indicates an important, albeit
less clearly defined, role for S196.
The model also predicts that Q417, S418, and S419 of
the second QSSS motif coordinate Na3, with the latter
also possibly coordinating Pi. The ~50% reduction in Na
þ
and Pi activation indices of Q417C (Table 1) indicates a
reduction in the apparent substrate affinities for both
substrates after modification, which is consistent with the
proposed role of Q417. Cys substitutions at neighboring
sites (S418, S419) resulted in similar properties to the
S164 and T195 mutants described above, i.e., the mutants
exhibited presteady-state currents while uptake was abol-
ished, consistent with a critical role in later steps in the
transport mechanism, most likely in Naþ and Pi coordina-
tion. Finally, based on the WT-like behavior of R210C
with respect to substrate activation, it is likely that R210
does not contribute to substrate coordination. Nevertheless,
the asymmetry of the presteady-state relaxations compared
with the WT (Fig. 5 B) suggests that R210 may play a crit-
ical role in defining the voltage dependence of the cotrans-
port cycle and therefore may be proximal to the binding
sites.
DISCUSSION
The structural repeat has emerged as a common architec-
tural leitmotif in all reported structures of secondary trans-
porters (e.g. (13,22), and in a majority of those, the
repeats have inverted TM topologies. The pseudosymme-
tries introduced by these repeats have functional implica-
tions that can include the location of binding sites and the
equivalency of repeated elements in defining pathways or
gating elements. In NaPi-IIa the repeated sequence of the
QSSS motif is particularly prominent and biochemical
studies suggested that these were accessible from opposite
sides of the membrane, consistent with the repeats exhibit-
ing inverted topologies (52,53). Inspired by the number of
new structures available, we used both statistical (using,
e.g., HHpred) and qualitative (using hydropathy profile
alignments) approaches to search for a putative template.
Notably, there is no similarity with the structure of a
recently reported fungal proton-dependent Pi transporter
(62), which is a member of the major facilitator superfamily
of transporters, with its characteristic fold of two lobes, each
containing 6 TM helices.
Hydropathy analysis was previously used to predict
fold similarity in the ST[3] class to which VcINDY
belongs (43). Biochemical topology analysis (63) and two-
dimensional crystallography (47) have since confirmed
FIGURE 5 Effect of site-specific mutations on
transport and substrate interactions in human
NaPi-IIa. (A) Tracer uptake (32P) data normalized
to WT for the mutants and noninjected (NI)
oocytes as control. Each data set is the mean 5
SE of data from two batches of oocytes (4–5
oocytes per batch). (B) Presteady-state relaxations
recorded from representative oocytes expressing
selected constructs in RU1 and RU2, together
with WT and NI as controls superfused in
100 mM Naþ. Bold label indicates active Pi trans-
port was also measured. Transient currents shown
in response to voltage steps as indicated, from
a holding potential ¼ –60 mV to two test poten-
tials: –160 (blue) and þ60 mV (red). Traces were
baseline corrected and are shown with the same
5500 nA range. Each relaxation was fit with a
double exponential function. Dotted traces is the
fitted fast component (relaxation time constant
<1ms) corresponding to endogenous membrane
charging and are comparable to the NI data in all
cases. For all mutants shown there was charge
movement in excess of the endogenous compo-
nent. To see this figure in color, go online.
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that, e.g., the 2HCT family that includes CitS and the AIT
family that includes VcINDY adopt similar architectures,
providing support for the use of hydropathy profiles to clas-
sify members of this 5TMþhairpin repeat fold.
In NaPi-II, the repeat has fewer TM helices, but that
repeat contains a reentrant hairpin before the last helix, as
in the ST[3] fold, giving a 3TMþhairpin repeat. The trun-
cated helices contribute to a stator domain (47) and there-
fore may have minimal effect on transport. Indeed, a
variety of lengths are observed in the ST[3] class, including
a truncation to a 4-TM helix repeat (63).
The low-resolution electron microscopy-based structure
of CitS hints that rearrangements of helices are possible
within the context of the same fold (47). We therefore ques-
tioned whether a model of NaPi-II could be improved by
using CitS as a guiding template. However, comparison of
the hydropathy plots of the repeats of CitS with those of
NaPi-IIa showed significant differences in the region
of the re-entrant hairpins and broken helices (Fig. S7).
These were reminiscent of differences between profiles of
VcINDYand CitS (Fig. S7). In contrast, the hydropathy pro-
files of NaPi-IIa and VcINDY share more characteristics
(Fig. 2 A). We therefore conclude that, although the three
protein families appear to share a common core fold,
VcINDY provides the most suitable available template.
Moreover, these comparisons (Fig. S7) provide support for
the proposal that a homology model based on VcINDY,
despite its modest resolution, provides an important step for-
ward in predicting the architecture and approximate binding
regions of NaPi-IIa.
We note that hydropathy profile comparisons are statisti-
cally poorly defined, therefore the final sequence alignments
were made with quantitative techniques in which detailed
sequence and secondary structure profiles represent each
repeat. The two strategies converged in their matching of
TM segments, and placed conserved residues from NaPi-II
at the binding region of VcINDY.
The QSSS repeats are hallmarks of all NaPi-II isoforms
from bacteria to human (64) and, according to this model,
help coordinate Pi, Na2, and Na3. When we mutated resi-
dues that contribute to these predicted coordination sites
in RU1 (S164, T195, S196) and RU2 (Q417, S418, and
S419), even using very conservative substitutions, transport
was either markedly affected or abolished completely.
These data, combined with previous evidence implicating
N199 (52) and S462 (54), provide strong support for their
involvement in substrate coordination. The Cys substitution
at S462 in RU2 is well tolerated in all NaPi-II isoforms,
however when subjected to thiol modification, cotransport
function is inhibited, although cation and Pi binding remain
(17,54,61). One scenario to explain this would be that bind-
ing of the last Naþ ion is restricted by having a bulky MTS
moiety at this site. In contrast, Cys substitution at N199 in
RU1 leads to a>10-fold reduction in the estimated apparent
substrate affinities (52), which is consistent with its pro-
posed proximity to both Pi and Na2. The effect of Cys sub-
stitution at Q417 in RU2 was much less dramatic (equivalent
to ~threefold and twofold increases in K0.5
Pi and K0.5
Na,
respectively; see Fig. 5 in (56)). This smaller deviation
from the WT behavior may reflect Q417’s proposed
proximity to Na3 only (Fig. 4). The possibility of the
substrate itself being directly coordinated in part by the
cosubstrate, as in the proposed coordination of Na2, Na3,
and Pi, and as observed previously for LeuT (20), under-
scores the notion of strictly coupled transport and offers a
molecular basis for the experimentally observed depen-
dence of the apparent affinity constants on the invariant sub-
strate (16,65).
Currently, there is insufficient evidence to locate the bind-
ing site of the first Naþ ion, designated Na1, (partial reac-
tion 1 4 2, Fig. 1 A). In the electroneutral isoform this
ion is hypothesized to interact allosterically with NaPi-IIc
and contribute to the overall cooperativity of Naþ activation,
but not to be translocated (17). In contrast, for the electro-
genic isoforms (NaPi-IIa and NaPi-IIb) the binding of a
Naþ ion to Na1 to the outward facing conformation (state 1)
is critical for conferring electrogenicity to the transport
cycle; moreover, in the absence of Pi, this ion is assumed
to contribute to the uncoupled leak (66). Our model pro-
poses that Pi is tightly coordinated with 2 Na
þ ions (at sites
Na2 and Na3), and together these would constitute the trans-
located, and effectively electroneutral, complex for both
electroneutral and electrogenic isoforms.
The detection of presteady-state charge movements in the
absence of external Pi provides indirect evidence that
conformational changes occur in response to changes in
membrane potential. For six of the seven mutants whose
cotransport function was compromised (Table 1, Fig. 5 A),
we were able to resolve such presteady-state relaxations in
the presence of 100 mM Naþ. The detection of these relax-
ation currents supported the notion that intrinsic charge
movements (analogous to gating currents in ion channels
(e.g. (67).) and displacement charge associated with the
interaction of a Naþ ion at the postulated Na1 site, most
likely still occurred in the mutated constructs. The lack of
transport function is therefore consistent with these muta-
tions drastically affecting Na2, Na3, or Pi coordination,
events that are common to both electroneutral and electro-
genic NaPi-II isoforms. Unfortunately, the small magnitude
of the presteady-state relaxations for these dysfunctional
mutants precluded more detailed analysis to ascertain
whether cation interactions had been altered specifically at
Na2 or Na3. Nevertheless, these observations will serve as
a basis for more detailed structure-function studies of
SLC34 proteins.
In conclusion, we propose a structural model for the
architecture of the human, Naþ-coupled phosphate transport
protein NaPi-II. Because the predictions of the substrate
coordination sites (Fig. 4) are based on a homology model
at low sequence similarity, they should be considered
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hypotheses that will help to guide experiments until more
detailed structural data for the SLC34 protein family can
be obtained. To our knowledge, the strategy used to define
equivalent regions in the template by identifying and sepa-
rating out the structural repeats is novel and may be applied
to model other transporters of as yet unknown architecture.
As the proposed model is relevant for all members of the
SLC34 family it should also provide an important step in
structure-function studies of all SLC34 proteins.
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ABSTRACT Transporters of the SLC34 family (NaPi-IIa,b,c) catalyze uptake of inorganic phosphate (Pi) in renal and intestinal
epithelia. The transport cycle requires three Naþ ions and one divalent Pi to bind before a conformational change enables trans-
location, intracellular release of the substrates, and reorientation of the empty carrier. The electrogenic interaction of the first
Naþ ion with NaPi-IIa/b at a postulated Na1 site is accompanied by charge displacement, and Na1 occupancy subsequently
facilitates binding of a second Naþ ion at Na2. The voltage dependence of cotransport and presteady-state charge displace-
ments (in the absence of a complete transport cycle) are directly related to the molecular architecture of the Na1 site. The
fact that Liþ ions substitute for Naþ at Na1, but not at the other sites (Na2 and Na3), provides an additional tool for investigating
Na1 site-specific events. We recently proposed a three-dimensional model of human SLC34a1 (NaPi-IIa) including the binding
sites Na2, Na3, and Pi based on the crystal structure of the dicarboxylate transporter VcINDY. Here, we propose nine residues in
transmembrane helices (TM2, TM3, and TM5) that potentially contribute to Na1. To verify their roles experimentally, we made
single alanine substitutions in the human NaPi-IIa isoform and investigated the kinetic properties of the mutants by voltage clamp
and 32P uptake. Substitutions at five positions in TM2 and one in TM5 resulted in relatively small changes in the substrate
apparent affinities, yet at several of these positions, we observed significant hyperpolarizing shifts in the voltage dependence.
Importantly, the ability of Liþ ions to substitute for Naþ ions was increased compared with the wild-type. Based on these findings,
we adjusted the regions containing Na1 and Na3, resulting in a refined NaPi-IIa model in which five positions (T200, Q206, D209,
N227, and S447) contribute directly to cation coordination at Na1.
INTRODUCTION
Inorganic phosphate (Pi) levels in humans are tightly regu-
lated to enable growth and metabolism and to prevent pa-
thologies related to vascular calcification. Naþ-coupled Pi
transporters of the SLC34 solute carrier family (NaPi-II)
are responsible for maintaining whole-body Pi homeostasis
and mediate epithelial transport of Pi in intestine and kidney
(1–3). Three isoforms catalyze the uphill transport of diva-
lent phosphate (HPO4
2) in the presence of a downhill
Naþ electrochemical gradient. Electrogenic isoforms
(NaPi-IIa and NaPi-IIb) are characterized by a transport
stoichiometry (Naþ:HPO4
2) of 3:1 and show voltage-
dependent cotransport rates, with one net positive charge
translocated per cycle. In contrast, the stoichiometry of
the electroneutral isoform (NaPi-IIc) is 2:1, its transport
kinetics show no voltage dependence, and no net charge is
translocated. This functional difference is postulated to arise
because NaPi-IIc does not release the first-bound Naþ ion to
the intracellular medium (4).
The interaction of one Naþ ion with the empty carrier is
thought to be the critical step in initiating the transport cycle
for both electrogenic and electroneutral isoforms (4,5). This
leads to the cooperative binding of a second Naþ ion, fol-
lowed by HPO4
2 and a third Naþ ion before translocation
occurs (Fig. 1). For the electrogenic NaPi-IIa/b transporters,
the voltage dependence of the overall transport kinetics can
be satisfactorily explained by assuming that only the empty
carrier reorientation (partial reaction 041; Fig. 1), and the
cation-carrier interactions between the first Naþ ion and the
Na1 site are voltage dependent (partial reactions 142,
046; Fig. 1). By implication, these partial reactions must
therefore involve charge displacements that are sensitive
to the transmembrane (TM) electric field. Indeed, when
rapid changes in membrane potential are applied to a mem-
brane containing a large population of NaPi-IIa/b, charge
movements manifesting as so-called presteady-state relaxa-
tions are readily detected. In the absence of external cations,
these presteady-state relaxations, which are analogous to the
gating charges observed in ion channel electrophysiology,
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arise from charges intrinsic to the protein, and additional
charge is detected when cations are present (5).
For the electroneutralNaPi-IIc transporter, the order of sub-
strate interactions remains the same, with two Naþ ions pro-
posed to interact before Pi. However, it is thought that the
first Naþ ion is not translocated and thus does not contribute
to the transport stoichiometry. Moreover, unlike NaPi-IIa/b,
the binding of the first Naþ ion toNaPi-IIc is not electrogenic,
meaning that it does not lead to detectable presteady-state re-
laxations, yet a cooperative interaction of two Naþ ions still
occurs (4). However, if a charged aspartic acid residue that
is found in all electrogenic isoforms (D224 in hNaPi-IIa) is re-
placed by a glycine at the equivalent site in the electroneutral
NaPi-IIc, the Pi cotransport becomes electroneutral (6).
The converse substitution in NaPi-IIc restores electrogenic
behavior, including presteady-state relaxations (7). This
behavior implicates D224 in conferring voltage dependence
to the transport cycle and potentially coordinating a Naþ ion
at Na1. Moreover, kinetic studies of the electroneutral
construct with restored electrogenicity (AAD-IIc) (8) estab-
lished that whereas cation interactions originating from the
external medium remained electroneutral, electrogenicity
appeared to arise from the empty carrier and from cytosolic
Naþ ion interactions (partial reactions 640 and 041;
Fig. 1). Thus, D224 appears to be intimately associated with
occupancy of Na1 from either side of the membrane.
Taking into account the highly conserved inverted repeat
symmetry of all NaPi-II isoforms, we recently identified
similar repeats in the x-ray crystallographic structure of a
Naþ-dicarboxylate transporter, VcINDY (9), which allowed
us to generate a homology model of the human NaPi-IIa pro-
tein based on VcINDY in an outward-facing conformation
(10). Only one Naþ ion site was identified in the 3.2 A˚
VcINDY crystal structure, and a second ion position was pro-
posed based on pseudo-symmetry considerations (9),
although, like NaPi-IIa/b, transport mediated by VcINDY is
electrogenic, and the Naþ/citrate stoichiometry is most likely
3:1 (11). Our structural model predicts sites for Pi and two
Naþ ions similar to those in VcINDY, and when these are
occupied, the model therefore corresponds to state 4 in the
NaPi-IIa transport cycle without considering Na1 occupancy
(Fig. 1). Importantly, mutations at the proposed Na2, Na3,
and Pi sites abolished cotransport function, and the observa-
tion of Naþ-dependent, presteady-state relaxations suggested
that the hypothesized Na1 interaction still occurred (10).
Here, we investigate the Na1-binding site, whose position
in the published structural model was not previously consid-
ered (10). We focus on eight residues close to D224, which,
as mentioned above, has been identified as a critical
determinant of electrogenicity and transport stoichiometry
(6–8,12). We noted that in the model, D224 is located at
the cytoplasmic end of TM3, i.e., deeper in the protein
than the previously identified Na2-Pi-Na3 substrate site.
This deep position would be consistent with a site that could
allow cation interactions also from the cytosol and would be
similar to the position of the Na1 site in the Naþ-dependent
aspartate transporter GltPh (13). Although it is not conclu-
sively involved, this region appeared to be a reasonable
starting point for identifying Na1-binding-site residues.
Site-directed mutagenesis and functional analysis, including
pre-steady state kinetics and Liþ substitution experiments,
confirmed the functional relevance of four of the eight pro-
posed amino acids in contributing to the Na1 site in NaPi-II
transporters. Refinements to the model based on these data
indicate how they may be arranged to form the site.
MATERIALS AND METHODS
Molecular biology
Mutations causing single amino acid changes were introduced into
human NaPi-IIa cDNA cloned into an oocyte expression vector using the
FIGURE 1 Kinetic scheme for the electrogenic
NaPi-IIa/b isoforms. Schematics represent the
conformational states identified by previous func-
tional analyses to show the occupancy of the pro-
posed substrate-binding sites. The physiologically
relevant cotransport cycle (clockwise, starting
from state 0) involves a voltage-dependent reorien-
tation of the unloaded carrier (state 0) to state 1
(assuming a hyperpolarized membrane potential),
and movement of a single Naþ ion to the proposed
Na1 site (state 2), followed by the cooperative
interaction of a second Naþ ion before divalent
Pi and a final Na
þ ion, resulting in occupancy of
the Na2-Pi-Na3 sites (state 4). A major transloca-
tion event then occurs (transition 4–5) and sub-
strates can be released to the cytosol (transition
5–6). The last Naþ unbinding event (transition
6–0) effectively frees the empty carrier intrinsic
charge to allow reorientation of the empty carrier to state 1 under the influence of a hyperpolarizing TM potential, in readiness for the next cycle. For
the electroneutral NaPi-IIc, the empty carrier reorientation is voltage independent and no detectable charge displacement is associated with any of the partial
reactions.
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QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technolo-
gies). Downscaled reactions were run according to the supplier’s instruc-
tions and primers were purchased from IDT Biotech (Integrated DNA
Technologies). All mutations were confirmed by Sanger sequencing
(Genevision, Newcastle, UK). The plasmids were linearized using XbaI,
and RNAwas transcribed using T3 RNA polymerase and the Message Ma-
chine kit (Ambion/ Life Technologies). The RNAwas assessed by agarose
gel electrophoresis and quantified by UV spectroscopy.
Oocytes
Oocytes were harvested from Xenopus laevis frogs (Xenopus Express
France, Vernassal, France) following standard procedures according to
Swiss Cantonal and Federal legislation. Defolliculated cells were incubated
in modified Barth’s solution containing (in mM) 88 NaCl, 1 KCl, 0.41
CaCl2, 0.82 MgSO4, 2.5 NaHCO3, 2 Ca(NO3)2, and 7.5 HEPES, adjusted
to pH 7.5 with TRIS, and supplemented with antibiotics (doxycycline
and gentamicin, 5 mg/l). Oocytes were injected with 50 nl of RNA
(0.2 mg/ml) and kept in modified Barth’s solution at 18C for 3–5 days
before analysis.
Solutions
The superfusing solutions contained (in mM) 100Na (100 NaCl, 2 KCl, 1.8
CaCl2, 1 MgCl2, 10 HEPES, pH 7.4 adjusted with TRIS) or 100Ch (the
same as for the 100 Na solution but with equimolar replacement of NaCl
with choline Cl). For intermediate Naþ concentrations, 100Na and 100Ch
were appropriately mixed to maintain the same osmolarity. For the
lithium-containing solutions (100Li and 50Na50Li), NaCl was replaced
equimolarly with LiCl to give the required concentration. Inorganic phos-
phate (Pi) was added to the superfusate from 1 M K2HPO4 and KH2PO4
stocks that were mixed to give pH 7.4, and further diluted in H2O to give
the required test concentration. All standard reagents were obtained from
either Sigma-Aldrich or Fluka (Buchs, Switzerland).
Functional assays
Radioisotope uptake assays were performed according to standard proce-
dures as described elsewhere (14) using 100Na solution and 1 mM cold
Pi to which
32Pi (specific activity 10 mCi/mmol Pi) was added. Standard
two-electrode voltage-clamp (TEVC) hardware was used for electrophysi-
ology (Turbo TEC-10CX; NPI, Tamm, Germany) and controlled using
pClamp 10 software (Molecular Devices, Sunnyvale, CA). Clampfit (Mo-
lecular Devices, Sunnyvale, CA) and Prism version 3.0, 5.0 (Graphpad
Software, San Diego, CA) were used for postacquisition analysis. The pro-
tocol for determining the steady-state Pi activation used voltage steps from
the standard holding potential (Vh ¼ 60 mV) to voltages in the range
of 160 mV to þ40 mV. Presteady-state current relaxations were typically
quantified for voltages in the range of 180 mV% V% 80 mV with four
signal averages. Current relaxations were typically fitted with a multiple
exponential function. The fastest component represented the linear capaci-
tive charging of the oocyte membrane (typically 0.350.6 ms, depending
on the oocyte). The slower component (typically >3 ms) was extrapolated
to the peak of the capacitive transient, at which time we assumed the mem-
brane was >90% charged, and numerically integrated to obtain the charge
moved (Q) for a step from the holding potential to the test potential. The
charge-voltage (Q-V) data were fitted with a Boltzmann function of the
form given by Eq. 1:
Q ¼ Qhyp þ Qmax
ð1þ expðz eðV0:5  VÞ=kTÞÞ; (1)
where V0.5 is the voltage at which the charge is distributed equally between
two hypothetical states, z is the apparent valency of an equivalent charge
that moves through the whole of the membrane field, Qmax is the total mo-
bile charge available,Qhyp is the charge of the hyperpolarizing limit and is a
function of Vh, and e, k, and T have their usual meanings.
Western blotting and immunocytochemistry
Oocytes were fixed in 3% paraformaldehyde and sections were blocked in
1% BSA/PBS for 15 min at room temperature. NaPi-IIa antibody raised
against a COOH-terminal peptide was diluted 1/400 in 0.02% Na-azide/
PBS and slides were incubated overnight at 4C. Sections were washed
twice with hypertonic PBS (PBS with additional 18 g NaCl/L) and once
in PBS for 5 min. Sections were incubated with secondary donkey anti-rab-
bit Alexa-488 antibody (Invitrogen) for 1 h, washed with PBS, and mounted
with Glycergel (DAKO). Fluorescence was detected using a fluorescence
microscope (Leica CTR600).
Bioinformatics
Sequences of NaPi-II transporters were identified from the NCBI nr20 data-
base (dated February 22, 2013) using HHblits (15). Sequence conservation
among the top 50 nonredundant sequences was analyzed using the Weblogo
v3 webserver (16).
Structural modeling
In our previous work, we built a homology model of human NaPi-IIa (10)
using a structure of VcINDY (9) (PDB ID: 4F35) as a template. In that
work, we identified VcINDY as a possible template, albeit with a low con-
fidence, using the HHpred server. We obtained further evidence of their fold
similarity by comparing the individual repeats of VcINDYand NaPi-IIa us-
ing HHalign and AlignMe (either in PST or PS mode), indicating similar-
ities with the region of the binding site of VcINDY, which was aligned to
the conserved QSSS motif of NaPi-IIa (10). We obtained the same result
when we aligned the family-averaged hydropathy profiles of the individual
repeats using AlignMe (10). Here, the published homology model of human
NaPi-IIa was refined in two stages, involving first TM2b and then TM5-6.
In each stage, the alignment between NaPi-II and VcINDY was adjusted
in regions with low scores according to ProQM analysis (see below) and/
or to be consistent with the experimental evidence. In addition, helical con-
straints were introduced according to secondary structure predictions (10)
for residues 202–205 (TM2b), 217–223 (TM3), 440–444, 448–452
(TM5a), 455–456, 461–462 (TM5b), and 493–505 (TM6).
The human NaPi-IIa model containing residues 97–249 and 346–505
(excluding the long extracellular loop, TM7, TM8, and both cytoplasmic
terminal domains) was built using Modeller v9.12 (17), alignments were
manipulated using Jalview (18), and models were assessed using Procheck
(19) as a measure of the chemical fidelity of bonds and angles. ProQM (20)
was used to quantify the agreement of the structural model with sequence
conservation, secondary structure predictions, and TM predictions for indi-
vidual residues, the entire model, and the template.
First, to position the side chains of residues Q206, D209, R210, and N227
in or close to the Na1-binding site according to the experimental data, we
progressively adjusted the alignment of residues 202–214 in TM2b relative
to the VcINDY template by one position at a time. We monitored agreement
with the experiments by using the distance between the Ca atom of N227
and the Ca atom of Q206, D209, or R210, as well as the angle between the
Ca atom of N227 and the CaCd bond of Q206, the CaCg bond of D209,
or the CaCz bond of R210. A shift of five residues relative to the initial
model resulted in the optimal arrangement of these residues to form the
putative Na1 site (Table S1 in the Supporting Material).
Second, we adjusted the alignment of TM5 and TM6 progressively until
we obtained a configuration that optimally positioned S447 proximal to and
oriented toward Q206, and at the same time positioned T451 close to S417
near the Na2-Pi-Na3 site (Table S2). We monitored this adjustment using
two CaCa distances (i.e., between S417 and T451, and between S447
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and Q206) and two angles (i.e., between the Ca atom of S419 and the
CaCd bond of T451, and between the Ca atom of S447 and the CaCg
bond of Q206).
In the refined alignment, the percentage of identical residues between the
template and model was ~14% in repeat unit 1 (RU1) and ~8% in repeat
unit 2 (RU2). The expected accuracy of a homology model with this level
of sequence identity to the template is 1.5–4 A˚ in the Ca positions,
assuming the correct alignment (21). In a final modeling stage, three Naþ
ions and a Pi substrate were included. Harmonic upper-bound distance re-
straints of 3.3 A˚ were imposed between the Naþ ion at Na1 and side-chain
O atoms of residues T200, Q206, D209, N227, and S447; the Naþ ion at
Na2 and side-chain O atoms of residues S164, T195, S196, N199, and sub-
strate Pi; the Na
þ ion at Na3 and side-chain O atoms of residues Q417,
S418, S419, T451, and T454; and the O atoms of Pi and side-chain O
atom of residue S164, or side-chain N atom of N199. We selected the model
with the lowest Modeller probability distribution function (Molpdf) score
out of a set of 2000 models, i.e., the model that was in best agreement
with all of the input constraints. In this model, only 0.7% of the residues
are in disallowed regions (I142 and L143), 1.8% are in generously allowed
regions of the Ramachandran plot, and all of these residues are located in
loop regions away from the binding sites and helix packing interfaces.
The total ProQM score increased from 0.555 in the published model (10)
to 0.572 after the refinements in TM2 and TM5-6. ProQM scores can range
from 0 to 1, with 1 being the most membrane-protein like, although typical
structures have ProQM scores of ~0.7 and the truncated template structure
has a ProQM score of 0.643. The refined model is provided in the Support-
ing Material as Model S1.
RESULTS
A putative Na1-binding region close to D224
in TM3
The universe of possible binding sites for Naþ in NaPi-IIa is
large because the core of the protein is littered with serine,
threonine, asparagine, and glutamine residues that are good
candidates for cation coordination (22). Therefore, to iden-
tify Na1, we narrowed down the options by focusing on the
region near D224 (see above) (6–8,12). Additional support
for the importance of this region comes from the reported
role of a position one turn away on TM3, namely, N227,
mutations of which led to impaired substrate affinities that
could be attributable to altered Na1 interactions (6) (Fig. 2).
The most reliable aspects of the published NaPi-IIa model
are its overall fold, the positioning of the residues in TM3,
and the regions around the Na2, Na3, and Pi sites, especially
the helical hairpins (HP1 and HP2), all of which agree well
with various experimental data (10). However, because of
the low sequence identity between NaPi-IIa and its template,
VcINDY (~10%), other predicted regions that to date have
not been validated in detail experimentally, such as the
more peripheral helices, may be less reliable. Relatively mi-
nor adjustments to the underlying sequence alignment be-
tween NaPi-IIa and VcINDY could shift the orientation and
vertical positioning of specific residues in the model while
still maintaining the overall fold. Therefore, we broadened
our search for putative Na1-site residues to any position
along the cytoplasmic halves of the two helices that are adja-
cent to TM3 in the published model, i.e., TM2b and TM5a
(10) (Fig. 2). This strategy identified nine hydroxylic, car-
boxylic, or amide-containing residues that could potentially
contribute to Na1, namely, T200, Q206, D209, and T211 in
TM2; N227 in TM3; and S447, N448, T451, and T454 in
TM5 (Fig. 2). We then individually mutated these residues
to alanine or to less severe substitutions (Q206N, D209E,
and N227Q), to examine their impact on transport function
(Table 1). Furthermore, we also included R210 from TM2
in our mutagenesis study because as a positively charged res-
idue in a putative cation-binding region, it may play a critical
functional role, as suggested by previous work (10).
Functional characterization: steady-state
response to Pi
We expressed the mutated transporters in Xenopus laevis
oocytes and first screened them for electrogenic function us-
ing a TEVC. Seven constructs with mutations in TM2 and
one in TM5 (Table 1) gave detectable responses to test appli-
cations of 1 mM Pi (in the presence of 100 mM Na
þ (100Na
FIGURE 2 Candidate Na1-binding-site residues in a published structural
model of human NaPi-IIa based on VcINDY. The model included two Naþ
ions (purple spheres) and one Pi anion (yellow and red sticks), and was
generated using the alignment described previously (10). The protein back-
bone is represented as cartoon helices with RU1 colored green and RU2 in
pink, and is viewed from along the plane of the membrane from the face
furthermost from the dimer interface in the template. TM2b and TM5a
are colored blue and cyan, respectively. Candidate Na1-binding-site resi-
dues are represented as spheres at their Ca positions. Residues whose mu-
tation had an effect on transport activity, apparent affinities for substrate or
ions, or steady-state currents are colored red or pink. The residue whose
mutation did not alter any of these parameters (T211) is colored blue. Res-
idues D224 and N227 are colored gray, and their side chain and Ca atoms
are represented as sticks and spheres, respectively.
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solution)) in the form of an inwardly directed change in the
holding current (typically with absolute Pi-induced currents
in the range of 20 nA to 150 nA) when voltage clamped
at 50 mV. The response to 1 mM Pi (at 60 mV) relative
to the wild-type (WT) response varied among constructs
(Table 1) and the largest deviation was documented for
T200A, which displayed only 14% of the WT response.
These changes in the magnitude of the response could result
from reduced surface expression, altered kinetics, or both. In
the case of T200A, themembrane stainingwas comparable to
that observed for the other constructs, suggesting that mem-
brane expressionwas not compromised (Fig. S1). Oocytes in-
jected with the cRNA coding for N227A (TM3) developed
leaky membranes 2–3 days after injection, which precluded
a detailed functional analysis. Three mutants with substitu-
tions in TM5 (N448A, T451A, and T454A) showed no
Pi-induced inward currents and were further assayed for
32P uptake (to test for the possibility of electroneutral trans-
port) and subjected to presteady-state assays (to detect charge
displacements associated with the empty carrier and cation
movements), western blotting, and immunocytochemistry
(Table 1). For these constructs, immunocytochemistry
confirmed that in each case the protein was expressed in
the membrane (Fig. S1), although the uptake data for these
mutants were indistinguishable from those obtained for
noninjected control oocytes (Fig. S2).
We further characterized the functional mutants by
measuring the Pi-dependent change in holding current (IPi)
as a function of membrane potential under four different
superfusing conditions (100Na þ 1 mM Pi, 100Na þ
0.1 mM Pi, 50Na þ 1 mM Pi, and 50Na50Li þ 1 mM Pi)
and compared their behavior with that of the WT (Figs. 3
and 4). Mutations affecting the architecture of Na1 were ex-
pected to have significant consequences for the current-
voltage (I-V) relation and/or the sensitivity to Liþ, and the
superfusion conditions were chosen to best highlight devia-
tions in these properties from WT behavior. Data were
normalized to the response to 1 mM Pi in 100Na at
100 mV for each construct to aid comparison. For the
WT, IPi with 100Na þ 0.1 mM Pi, 50 Naþ1 mM Pi, and
50Na50Li þ 1 mM Pi was ~50% of the response in
100Na þ 1 mM Pi at all membrane potentials in the test
range (160 mV to þ40 mV; Fig. 3, upper left) and similar
behavior was found for mutant T211A (Fig. 3, lower
center), which suggested that this position is not a critical
determinant of the kinetic profile.
In contrast, all other functional mutants showed devia-
tions from the WT profile (i.e., altered voltage dependence
and relative changes in IPi for the different superfusion con-
ditions), and these deviations were unique for each mutation
position. Moreover, the form of the changed I-V profiles de-
pended on the type of substitution, as can be readily seen by
comparing Q206A with Q206N, or D209A with D209E.
Whereas the alanine substitution at Q206 resulted in a mar-
ginal change in the response to 100Na þ 1 mM Pi, the more
conservative Q/N substitution significantly altered the
voltage dependence, which became more curvilinear, and
concomitantly increased the response when Liþ ions were
substituted for 50% of the external Naþ. In contrast, the
alanine substitution of D209 caused comparable changes
to Q206N, whereas the conservative D/E substitution at
209 had a less dramatic effect on the electrogenic profile.
Interestingly, like D209A and Q206N in TM2, the only
mutant in TM5 (S447A) that showed cotransport (IPi;
Fig. 3) and 32P uptake (Fig. S2) also showed a curvilinear
relationship in response to 1 mM Pi. However, for the other
superfusing conditions, especially 50Na50Li, its response
pattern was dissimilar to that of D209A and Q206N.
These qualitative comparisons between the WT and
mutant I-V profiles revealed that the mutagenesis had
TABLE 1 Overview of human NaPi-IIa constructs
Transmembrane Segment
Construct
Expression Transport Function Kinetics
WB IC 32Pi TEVC Steady State Pre-Steady State
WT þ þ þ 1.0 þ þ
TM2 T200A þ þ þ 0.145 0.02 þ 
Q206A ND ND ND 0.355 0.05 þ þ
Q206N ND ND ND 0.795 0.09 þ þ
D209A ND ND ND 0.355 0.05 þ þ
D209E ND ND ND 1.115 0.14 þ þ
R210A ND ND þ 0.375 0.04 þ þ
T211A ND ND ND 1.145 0.01 þ þ
TM3 N227A þ þ ND ND  ND
N227Qa þ ND þ þ þ ND
TM5 S447A þ þ þ 0.585 0.13 þ þ
N448A þ þ    
T451A þ þ    þ
T454A þ þ    þ
For TEVC transport function, values indicate mean5 SE fraction of Pi-induced current at60 mV relative to WT for n>5 cells per construct. WB, western
blot (total oocyte lysate); IC, immunocytochemistry; þ, experimental verification; , undetected/unresolved; ND, not done.
aSee Virkki et al. (6).
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resulted in both common changes to their profiles (voltage
dependence) and unique differences that we might expect
given their unique structural disposition. In particular, they
provided the first indication that the introduced changes at
206, 209, and 447 had possibly affected Na1. To analyze
these electrogenic profiles in more detail and gain insight
into their role in the Na1 interactions, we next focused on
specific features of voltage dependence, apparent substrate
affinities, and cation substitution by extracting relevant
data from the I-V profiles.
Steady-state voltage dependence
Superposition of the I-V data, normalized to 100 mV in
response to 100Na þ 1 mM Pi (i.e., close to saturation for
both substrates for the WT (23)), revealed that substitutions
in TM2 (206, 209, and 210) and TM5 (447) caused variable
hyperpolarizing shifts relative to the WT data (Fig. 4 A).
These data are depicted separately for mutants in which
either a polar residue (left panel) or charged residue (right
panel) was replaced, and the WT data are shown in each
case for comparison. The normalized I-V data for T211A
were similar to those for the WT, indicating that this site
was not critical for defining the steady-state voltage depen-
dence, as already noted. Mutant T200A showed a significant
outward component of current at depolarizing potentials,
whereas the I-V relations for the other constructs showed
only inward currents over the range of potentials tested.
Replacement of external Cl by MES reduced this outward
component, which suggested that it was in part due to an
FIGURE 3 Current-voltage (I-V) data for the WTand functional mutants with substitutions at sites in TM2. Each panel shows the normalized Pi-dependent
current (IPi) under four superfusion conditions: 100Na þ 1 mM Pi (black squares); 100Na þ 0.1 mM Pi (gray squares), 50Na þ 1 mM Pi (blue circles), and
50Na50Li þ 1 mM Pi (red circles). Data were pooled from more than three batches of oocytes and each point represents the mean5 SE of n > 10 oocytes.
Data for each oocyte were normalized to the control response to 1 mM Pi in 100Na at 100 mV. Data points are joined for graphical clarity.
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inward Cl flux in T200A similar to that reported previ-
ously, which may arise from a response of endogenous
channels to Pi (24). The hyperpolarizing shifts were most
pronounced for D209A and weaker for Q206N, D209E,
R210A, and S447A. Given that the voltage dependence of
NaPi-IIa arises from the partial reactions associated with
the empty carrier and the first Naþ ion interaction, these
data suggested that the mutagenesis at 206, 209, 210, and
447 had altered the kinetics of one or more partial reactions
that link states 6, 0, 1, 2, and 3 (Fig. 1). However, from these
data alone we were unable to discriminate between changes
to the empty carrier kinetics and/or Naþ interactions.
Apparent affinities for Pi and Na
D at 100 mV
We applied a two-point screening assay to determine
whether a mutation had significantly altered the apparent af-
finity for Pi (K0.5
Pi), by defining a Pi activation index (see
Supporting Results, Fig. S3, and Table S3) as the ratio of
IPi induced by 0.1 mM Pi to that induced by 1 mM Pi, always
in the presence of 100 mM Na (100Na solution; Fig. S3 C)
(25). For theWT voltage clamped at100 mV, this ratio lies
typically in the range of 0.4–0.5, consistent with the re-
ported K0.5
Pi of ~0.1 mM (6,23). An increase or decrease
in this ratio compared with the WT value would indicate
that in the presence of 100 mM Naþ, K0.5
Pi had decreased
or increased, respectively. Similarly, we defined a Naþ acti-
vation index as the ratio of the response to 1 mM Pi in the
presence of 50 mM Na (50Na solution) to that in the pres-
ence of 100 mM Naþ (see Supporting Results). For the
WT at 100 mV, this ratio was found to be ~0.5, consistent
with the reported K0.5
Na of ~50 mM (6,23). This ratio also
reflects how the maximum transport rate depends on
external [Naþ] under saturating [Pi].
For mutants Q206A, Q206N, D209A, and S447A, the Pi
activation indices were larger than theWT value (Fig. S3 C).
According to our two-point screening assay, the altered acti-
vation indices would correspond to an ~25% decrease in the
apparent K0.5
Pi, and therefore indicated that the mutagenesis
had resulted in a marginal effect on the apparent Pi affinities.
In contrast, T200A showed a significantly reduced Pi-activa-
tion index, which suggested that its apparent K0.5
Pi had
increased by ~8-fold. For the Naþ-activation assay, T200A
also showed a significantly reduced activation index,
whereas for D209E, R210A, and S447A, the indices were
closer to the WT value (23,26).
We concluded that, with the exception of T200A, only
marginal changes in apparent substrate affinities resulted
from the mutagenesis at 447 and at the other sites in TM2.
Cation selectivity
In the final steady-state assays, we examined the response of
the mutants to 1 mM Pi when 50% of the external Na
þ was
replaced with Liþ (50Na50Li solution). Liþ is proposed to
substitute for the first Naþ ion, but not for Naþ bound to
Na2 and Na3 (14). Thus, mutations that affect Na1 might
be expected to show altered electrogenic behavior in the
presence of Liþ. For the WT, we observed a small decrease
in the relative activity when we compared the Pi responses in
50Na and 50Na50Li solutions, and the response to 1 mM Pi
was ~50% of that observed in 100Na (Fig. 4 B), consistent
with previous findings for WT human NaPi-IIa (I.C.F. and
C. Ghezzi, unpublished data). In contrast, the ratio of the
response to 1 mM Pi in 50Na50Li relative to 100Na revealed
that the mutagenesis at positions 206, 209, and 210 resulted
in a significantly increased electrogenic response compared
with the same ratio measured for 50Na (Q206N, D209A,
and R201A; Fig. 4 B). The ratio reflects the ability of Liþ
to substitute for Naþ at a given membrane potential
(100 mV); thus, if Liþ substituted fully for Naþ, the ratio
would be unity. Given that Liþ is hypothesized to interact
with NaPi-IIa at the Na1 site, our data directly implicate po-
sitions 206 and 209 in coordinating a cation at Na1. Since
R210 is positively charged, it is extremely unlikely to coor-
dinate the Naþ ion directly. Nevertheless, these data suggest
that position 210 is close enough that the R/A mutation
FIGURE 4 Steady-state properties of TM2 mutants. (A) Normalized I-V
data for WT and mutants. Each data set is the IPi for 1 mM Pi in 100 Na
normalized to the response at 100 mV. (Left) WT and mutants involving
substitution of polar residues. (Right) WT and mutants involving substitu-
tion of acidic or basic residues. Data points have been joined for graphical
clarity. (B) The effect of cation replacement at 100 mV is depicted as the
ratio of IPi with 1 mM Pi superfusion of either 50Na þ 1 mM Pi (blue bars)
or 50Na50Liþ 1 mM Pi to the control response in 100 Naþ 1 Pi (red bars).
Each bar shows the mean ratio5 SE for n > 5 oocytes expressing the indi-
cated construct.
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affects either the electrostatics or sterics of Na1. It should be
noted, however, that when Liþ fully replaced Naþ as the
cosubstrate (100Li solution), no significant Pi-induced
change in the holding current was observed for the mutants,
which confirmed that Naþ was still required to complete the
transport cycle (data not shown), as previously reported for
the WT (27).
Functional characterization: presteady-state
responses
Presteady-state analysis allowed us to quantify the charge
displacements associated with conformational state changes
between states 6 and 2 (Fig. 1) in the absence of external Pi,
i.e., transitions between states associated with the empty
carrier and cation interactions preceding Pi binding, as
well as transitions following its cytosolic release (transition
640). We resolved presteady-state relaxation currents
induced by voltage steps for six mutants with substitutions
in TM2 and three mutants with substitutions in TM5
(Table 1). The activity of T200A was too small for reliable
presteady-state analysis, and for N448A we were unable
to resolve relaxations that could be separated from the
capacitive charging transient, even though the protein was
detected at the membrane (Table 1; Fig. S1). Integration
of the relaxation currents after baseline correction and
exclusion of the capacitive component yielded presteady-
state Q-V distributions that we fit with a single Boltzmann
function (Eq. 1, Materials and Methods) to obtain an
estimate of the maximum moveable charge (Qmax), the
mid-point voltage (V0.5), and the apparent valence (z).
Both Qmax and V0.5 were used as indicators of possible
changes to the occupancies of the states relevant to cation
interactions.
Representative presteady-state relaxation currents
evoked by voltage steps in the range of 180 mV
to þ80 mV from the 60 mV holding potential (Vh) are de-
picted in Fig. 5 A for the WT and for two mutants that
showed very different phenotypes (D209E and T454A).
Quantification of the relaxation currents is shown as Q-V
relationships for each construct for superfusion in the
absence of Naþ ions (0Na) and with 100 mM Naþ
(100Na). No relaxations were detected in the typical nonin-
jected (NI) control oocyte for either of the superfusates
(shown here for 100Na; Fig. 5 A). For the WT NaPi-IIa,
presteady-state relaxation currents were detected under
both superfusing conditions, as previously reported (23),
and with 0Na the charge movements were approximately
symmetrically distributed for equal positive and negative
steps around Vh. With 100 mM Na
þ present, the distribu-
tion became more asymmetrical with respect to the baseline
record at Vh, such that more charge movement was evoked
with depolarizing steps, reflecting the release of Naþ back
into the external medium.
The behavior was very different for mutant D209E,
which showed a more asymmetrically distributed charge
movement in 0Na, with more charge evoked by hyperpo-
larizing steps from Vh. Moreover, like the WT, in the pres-
ence of 100Na, additional charge movement was evoked,
although in contrast to the WT, the charge increase for
FIGURE 5 Presteady-state relaxations. (A)
Representative examples of presteady-state relaxa-
tions evoked by voltage steps in the range of
180 mV to þ80 mV from a 60 mV holding
potential for a typical noninjected (NI) oocyte,
the WT, and mutants D209E and T454A. Upper
data traces correspond to superfusion in 0 Na solu-
tion, and lower traces correspond to superfusion in
100Na solution. For each construct, Q-V data are
shown for the two superfusates. Gray dashed lines
help to visualize the charge distribution about the
holding potential. Continuous lines are fits to a sin-
gle Boltzmann function (Eq. 1). The parameters for
the fits for the individual cells shown are summa-
rized in Table S4. (B) Ratio of the estimated total
charge predicted from the Boltzmann equation fit
to data obtained by superfusion with 0Na to that
obtained by superfusion with 100Na (Qmax
0/
Qmax
100) for each construct. Data are shown as
mean 5 SE for n > 5 cells. Black, WT; gray,
mutants in TM2; white, mutants in TM5.
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D209E was detected for both hyper- and hypopolarizing
steps relative to Vh. Mutant T454A also showed a sig-
nificant asymmetry of charge movement with respect to
Vh; however, there was little difference in the magnitude
of the charge evoked, whether or not Naþ was present, apart
from a small depolarizing shift in the Q-V in 100Na (see
below).
To quantify these findings further, we first considered the
effect of the mutation on the Boltzmann fit parameters Qmax
and V0.5 when changing from 0Na to 100Na solutions. For
the WT, superfusion with 100Na increases Qmax by ~30%
(23) (Fig. 5 A), and we quantified this as the ratio of Qmax
in 0Na to Qmax in 100Na (Qmax
0/Qmax
100) (Fig. 5 B).
This ratio was used as an indication of whether the mutagen-
esis had altered the electrogenic properties of the apparent
Naþ ion interaction with the TM electric field before Pi
binding. Such alterations may reflect changes in the ability
of Naþ to bind in its site or changes in the ability of the pro-
tein to respond to Naþ binding. Like the WT, all mutants
with substitutions in TM2, as well as S447A in TM5,
showed an increase in total charge movement when the
superfusate was 100Na, although the relative increase varied
according to the site and substituted residue type. In
contrast, T451A and T454A in TM5 showed little difference
in Qmax whether external Na
þ ions were present or not, and
therefore exhibited distinct behavior from the other mutants
(see Fig. 5 A).
Significant shifts in the V0.5 were observed in the pooled
data for the mutants relative to the WT, and these shifts also
depended on the superfusion conditions (Fig. 6 A). As ex-
pected from the steady-state analysis, T211A behaved simi-
larly to the WT. Four of the mutants with substitutions
in TM2 (Q206A, Q206N, D209A, and D209E) and one
mutant in TM5 (S447A) that showed obvious hyperpolariz-
ing shifts in their steady-state I-V relations (Fig. 4 A) also
displayed significant hyperpolarizing shifts in V0.5 when
superfused with 100Na. In the absence of external Naþ
(0Na), we also found significant deviations of V0.5 from
the WT value (Q206N, D209E, R210A, and S447A),
which indicated that the mutagenesis had altered the
distribution of occupancies among states 0, 1, and 6
(Fig. 1). This was particularly obvious for mutants R210A
and S447A, for which we determined V0.5 values approach-
ing 100 mV for each construct (c.f. WT: 65 5 7 mV).
As noted above, we also observed a small Naþ-dependent
depolarizing shift in V0.5 for the two TM5 mutants
(T451A and T454A) when Naþ ions were present, even
though Qmax
0/Qmax
100 was close to unity (Fig. 5, A
and B). Their behavior suggested that Naþ ions still interact
with the protein, but only weakly with the TM electric field
(see Discussion).
Based on the altered steady-state voltage dependence of
IPi (Fig. 3), we hypothesized that the three mutants in
TM2 (D209A, D209E, and R210A) involving removal or
modification of the existing charged residues, and S447A
in TM5, which showed a similar curvilinear IPi-V relation-
ship, should also show correspondingly altered Naþ
interactions in a presteady-state analysis. Therefore, we
investigated the dependence of V0.5 on external [Na
þ] in
detail for these mutants (Fig. 6 B). Previous studies have
shown that with high external [Naþ], there is a near linear
relationship between V0.5 and log10[Na
þ], the slope of
which reflects the cooperativity of interaction between
Naþ ions and the empty carrier (5,14,23). This slope ap-
proaches ~116 mV/decade for two Naþ ions interacting
with the empty carrier (5,28). When the V0.5 versus [Na
þ]
data were replotted on a semi-log scale (Fig. 6 C), it was
obvious that the limiting slope behavior was severely
compromised for D209A/E and S447A. In contrast,
although R210A had a strongly hyperpolarized V0.5 in
0Na, its V0.5 approached that of the WT as [Na
þ] increased.
This suggested that a direct involvement in Na1 coordina-
tion is less likely for this position.
In summary, the presteady-state assays corroborate the
steady-state findings and provide further support for the as-
sociation of sites Q206, D209, and S447 with cation interac-
tions at Na1. The removal of charge at position 210 affected
the empty carrier equilibrium; however, at a sufficiently
high [Naþ] the WT state distribution was almost reached,
FIGURE 6 Quantification of midpoint voltage (V0.5) for WT and mu-
tants. (A) Comparison of V0.5 for superfusion in 100Na (solid bars) and
0Na (open bars) for each construct. Each bar represents the mean 5 SE
for n R 4 cells from at least two donor animals. (B) Dependence of V0.5
on external [Naþ] for mutants of two neighboring charged sites (D209
and R210) in TM2. Data points are joined by lines. (C) The same data as
in (B) plotted on a semilog scale. The continuous lines are best fits to the
data points predicted by a four-state model that accounts for the empty
carrier and sequential Naþ binding partial reactions (see Discussion). The
dashed line represents the theoretical limiting slope of 116 mV/decade ex-
pected at high [Naþ].
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suggesting that R210 is not directly associated with Na1 in
NaPi-IIa.
Refinement of the structural model of human
NaPi-IIa
Unlike Q206, D209, and S447, which are strongly impli-
cated in contributing to the Na1 site, T211 can be excluded
from Na1 (Figs. 3 and 4), consistent with the weak
sequence conservation of threonine at this position
(Fig. S4). The T200A mutation, on the other hand, caused
significant changes in the apparent affinity for both Naþ
and Pi (Figs. 4 B and S3 C), consistent with the strong
sequence conservation of this position (Fig. S4). Moreover,
although the signal was too small to allow presteady-state
currents to be analyzed, the voltage dependence of phos-
phate-induced currents was also altered by T200A, espe-
cially in the form of outward currents at depolarizing
potentials (Fig. 4 A), reminiscent of previous observations
for N227Q (23). The origin of these outward currents is not
clear. An inward chloride leak has been ruled out in the
case of N227Q (23), whereas in chloride-free solution,
the phosphate-induced outward currents were suppressed
for T200A. In any case, the similarity of the phenotypes
of N227Q and T200A suggests that these two residues
play a similar role in the voltage-dependent steps of
transport, and therefore may be proximal in the protein
structure.
Given the high confidence in the positioning of TM3 in
the structural model of NaPi-IIa based on the agreement
with accessibility measurements, it is reasonable to assume
that D224 and N227 are indeed >10 A˚ from the Na2-Pi-
Na3-binding regions, i.e., the tips of HP1 and HP2
(Fig. 2). Taking this assumption and all of the above data
into account, we refined the structural model of human
NaPi-IIa so that Q206 and D209 are on the same face of
TM2b and point toward TM3, while T211 is farther away
(see Materials and Methods; Fig. 7 B; Table S1). In this
model, T200 remains midway across the membrane near
the cytoplasmic end of TM2a, just before L2ab, with its
backbone carbonyl pointing into the Na1 site, and its side
chain can potentially orient either downward to Na1 or
upward toward the Na2-Pi-Na3 cluster.
The refinement of TM2b involved adjusting the sequence
alignment of NaPi-IIa with VcINDY by five positions (Table
S1; Fig. S5), which shortened the previously rather long
loop L2ab between TM2a and TM2b (cf. Figs. 2 and 7).
These adjustments resulted in other improvements. For
example, several evolutionarily variable, ionizable residues,
including D212, R214, and R215 (Fig. S4), were reposi-
tioned into the cytoplasmic loop (cf. Fig. S6, A and C), while
R210 was moved away from the Pi-binding site (Fig. 7),
consistent with the lack of effect of an R210A mutation
on the Pi apparent affinity (10). The model quality score
(ProQM) in the region of TM2b decreased somewhat after
the refinement (Fig. S7), indicating a slightly worse model.
This may be because conserved residues in the cytoplasmic
end of TM3 now point away from the core of the protein
(Fig. S6), which is atypical. Nevertheless, a comparison
with VcINDY suggests that in the complete protein these
residues will pack against the peripheral helices TM7 and
TM8, which are not modeled due to the absence of a reliable
template (Fig. S8). To test the effect of removing peripheral
helices on the ProQM score of the remaining core helices,
we compared the ProQM scores of the full-length structure
of VcINDY with the scores obtained for the segments used
as a template, i.e., after removing TM1-3, TM7-8, and the
other protomer (Fig. S9). Significant reductions in the
ProQM scores at TM5, TM9, and HP2b in the truncated
structure of VcINDY (Fig. S9 A) reflect the removal of pack-
ing interactions with TM7, the other protomer, and TM3,
respectively (Fig. S9, B and C). Therefore, a similar effect
may explain the reduction in the ProQM profiles for
TM2b/TM3 of the new NaPi-IIa model, in which those res-
idues are more exposed (Fig. S8). Importantly, in the refined
model, the residues from TM2 and TM3, which were
FIGURE 7 Refined structural model of human NaPi-IIa bound to three Naþ ions and one Pi anion. The Na
þ ions are shown as purple spheres and the Pi is
shown as orange and red spheres. Residues comprising RU1 and RU2 are colored in green and pink, respectively. (A) Close-up of the Na3-binding site,
viewed from the extracellular side of the membrane into the binding site. The Ca atoms of several residues predicted to form the Na3 site or to coordinate
Pi are highlighted (spheres). (B) Predicted Na1-binding site. The Ca atoms of the residues whose side chain and/or backbone atoms are predicted to form the
Na1 site are shown as green spheres. The Ca atoms belonging to residues R210 and D224 are highlighted as light blue spheres. (C) Overview of the human
NaPi-IIa model represented as cartoon helices, viewed from along the plane of the membrane.
Biophysical Journal 108(10) 2465–2480
2474 Fenollar-Ferrer et al.
implicated experimentally in Na1 binding, are clustered
together. Moreover, without imposing specific constraints
on their orientation, the side chain of R210 can readily con-
tact D224 (Fig. 7 B), consistent with their similar pheno-
types in altering the voltage dependence of the empty
carrier, as well as their likely involvement in either the re-
turn step (Fig. 1, 0/1) of the empty transporter or release
of the Na1 into the cytoplasm.
Informed by the functional and biochemical characteriza-
tion of mutants S447, N448, T451, and T454, we also modi-
fied the alignment in the region of TM5 and TM6 (Fig. S5),
placing T451 and T454 farther to the extracellular side and
closer to the predicted Na3 site, and placing S447 closer
to the other putative Na1-binding residues (Fig. 7 A;
Table S2). The resultant structural model has a dramatically
improved ProQM quality score in this region (Fig. S7 B), in
part due to the repositioning of three arginines into the
cytosol instead of facing the hydrophobic core of the mem-
brane in TM6 (cf. Fig. S6, B and D). In accordance with
PSIPRED secondary structure predictions (Fig. S5) and
the strong helical conservation pattern (Fig. S6 D), this argi-
nine-rich segment was modeled as a helix. Note that in the
model, this helix extends into the cytoplasm because there
are no additional constraints to fix its relative orientation
(Fig. S6 D), although its strong amphipathic character
(Fig. S5) suggests that in reality this segment will form a
helix that lies parallel to the membrane plane along the lipid
headgroups.
In summary, the experimentally guided refinements led to
a structurally reasonable model of the core of human NaPi-
IIa in which the overall fold is maintained (Supporting
Model S1). Compared with the earlier model, TM2 and
TM5-6 change by >5 A˚, and the loops L2ab and L5ab are
significantly shorter (Fig. S10). This new model illustrates
how T451 and T454 from TM5 may contribute to the pre-
dicted Na3- or Pi-binding sites (Fig. 7 A) together with
Q417, S418, and S419 from the HP2ab loop, whereas the
binding site for Na1 would be formed by T200, Q206,
D209, N227, and S447 (Fig. 7 B). Moreover, the model pre-
dicts that R210 and D224 point toward each other and are
located on the cytoplasmic side of the Na1 site (Fig. 7, B
and C).
DISCUSSION
In this work, we improved upon our previous homology
model of the human isoform of NaPi-IIa (SLC34A1) (10)
to incorporate the first Naþ ion-binding site (Na1). The
binding of Naþ at Na1 is the initiator of all subsequent
steps in the transport cycle, and the kinetics of binding
are a critical determinant of the overall transport rate and
the electrogenic properties. Our strategy for defining the
coordinating residues for Na1 involved bioinformatic pre-
diction of candidate positions based on the existing struc-
tural model, functional investigation of the effects of
single point substitutions at the predicted positions, and
further model refinement in the light of the functional
data. In addition to using conventional criteria for selecting
potential Naþ coordinating residues (serine, threonine,
asparagine, glutamine, aspartate, and glutamate), as seen
in available Naþ-coupled transporter structures (29–31),
we also took into account two salient functional properties
of NaPi-II proteins.
First, previous functional studies on both WT and
mutated constructs have revealed the importance of the
Na1-cation interaction in determining the electrogenic
properties of the NaPi-II transport cycle. The aspartic acid
at 224, which is conserved in all electrogenic isoforms, is
a key requirement for the 3:1 stoichiometry and transport
electrogenicity, and, by implication, the translocation of
the first Naþ ion through the protein (4,6–8). Therefore,
D224 became the focal point for identifying other side
chains in close proximity. Second, previous kinetic studies
have highlighted the involvement of the Na1 interaction
with an uncoupled leak, and proposed that in the absence
of substrate (Pi), Na
þ ions participate in a uniport mode
that involves cycling between states 0 and 6 (Fig. 1)
(23,24,26,32,33). This phenomenon is only observed for
the electrogenic isoforms. Although they were not function-
ally explored in this study because of their small magnitude,
the existence of uncoupled leak currents also implies
that the Na1 site must allow accessibility from either side
of the membrane with minimal rearrangements, and we
also used this feature as a criterion for selecting the initial
binding region.
Once we had proposed the positions, the goals of the
functional assays were twofold. First, we aimed to
distinguish between mutations at positions that were
more likely to be involved with Na1 and those that contrib-
uted to the Na2-Pi-Na3-binding region, as well as those
with little functional significance, by comparison with the
WT. Second, for the Na1-related mutations, we aimed to
further distinguish between effects on the empty carrier ki-
netics and those on the Naþ interactions, and thereby gain
more insight into the structure-function basis for electroge-
nicity, by using presteady-state assays. We then used the
interpretation of the functional data for the final model
refinement.
Discrimination between Na1 and Na2-Pi-Na3 sites
using steady-state assays
In our previous study (10), Ala or Cys substitutions at three
positions in TM2 and HP1 (S164, T195, and S196) and two
positions in HP2 (S418 and S419), which we associate with
Na2-Pi-Na3 coordination, caused a total loss of cotransport
function, yet evidence for cation interactions at Na1 was
still detected in the form of presteady-state relaxations in
the presence of 100 mM Naþ. In contrast, the mutagenesis
in the study presented here was well tolerated by the
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transporter, as evidenced by the complete cotransport cycle
remaining intact in most cases (Table 1). Notable exceptions
were three positions in TM5 (N448, T451, and T454), for
which we detected no transport activity from the respective
mutants. In the case of T451 and T454, presteady-state re-
laxations were also resolved (see below), suggesting that
those side chains were more likely to be associated with
the Na2-Pi-Na3-binding region. The basis for the lack of
any functional activity for N448A, which was expressed
in the oocyte membrane, is unclear. In all, only one mutant
showed WT-like behavior (T211A), and this was taken into
account in subsequent model refinement (see below).
In the steady-state cotransport mode, the kinetics of the
transport cycle for WT NaPi-IIa (Fig. 1) have been exten-
sively described in terms of macroscopic phenomenological
parameters, such as apparent substrate affinities derived
from standard TEVC assays (23,26). These parameters are
a function of the rate constants associated with all of the hy-
pothesized partial reactions in the transport cycle (Fig. 1),
and therefore deviations from the WT macroscopic kinetic
profile resulting from mutagenesis might be caused by
changes in the rates associated with more than one partial
reaction, leading to ambiguous interpretations. Thus, with
three partial reactions involving external Naþ interactions
for the cotransport cycle, any one or all of them might be
involved in determining K0.5
Na and K0.5
Pi.
With the exception of T200A, the two-point assay for
substrate activation (Fig. S3) indicated that the mutagenesis
at all considered positions did not cause large changes in the
apparent substrate affinities (Fig. S3 C). Nevertheless, small
but significant deviations were observed that would require
a more detailed analysis, beyond the scope of this study, to
identify the partial reactions affected. For example, in the Pi-
activation assay (Fig. S3 C), Q206A/N, D209A, and S447A
all showed increased activation indices, consistent with an
increased K0.5
Pi. This increase could arise indirectly from
changes to the Naþ interactions preceding Pi binding, the
Pi binding step, or a combination thereof. Indeed, for
Q206A the Naþ activation index was also increased, consis-
tent with an altered Naþ interaction involving partial
reactions (142 and 243; Fig. 1), whereas for Q206N,
D209A, and S447A, the Naþ activation index was not mark-
edly altered compared with the WT. Because deviations
fromWT behavior for the activation indices might be attrib-
utable to changes in more than one partial reaction in the
overall cotransport cycle, we were careful to avoid overin-
terpreting these data. This was particularly true for the
Naþ-inactivation data, which reflect the combined effect
of all five cation- and substrate-dependent partial reactions
(Fig. 1), including cation and substrate release to the
cytosol. Of all the mutants investigated, T200A showed
the largest deviation from WT behavior. Its very low func-
tional activity allowed us to perform only basic steady-state
assays, from which we concluded that K0.5
Na and K0.5
Pi were
significantly reduced based on the smaller activation indices
(Fig. S3). Similar effects were also reported for the N/C
substitution at 199 (32) and the N/Q substitution at 227
located on TM3 (6). Given the limited kinetic analysis, we
are unable assign this phenotype to either a direct effect
on Na1 interactions or more global effects involving the
Na2-Pi-Na3 site. As positions 199 and 200 are located be-
tween the proposed Na1- and Na2-Pi-Na3-binding regions,
with N227 close by (Fig. 7, A and B), we speculate that these
positions may play a critical role in the coupling between
the two regions, specifically in the observed apparent coop-
erativity of Na2 occupancy. Furthermore, the fact that the
N/A substitution at position 227 was not tolerated by
the oocytes suggests a critical role for the side chain
at 227 and corroborates the previous finding that only a
N/Q substitution yielded functional activity (6).
Despite the potential limitations of steady-state assays for
resolving effects unique to a specific partial reaction, the I-V
data (Fig. 3) revealed two significant deviations from WT
behavior that implicated the involvement of positions 206,
209, and 210 from TM2, and 447 from TM5 in coordinating
a cation at Na1.
First, alanine substitution at 209, 210, and 447 resulted
in the same qualitative hyperpolarizing shift in the voltage
dependence of IPi as observed for the more conservative
Q/N substitution at 206. This result is consistent with
the first Naþ interaction being a strong determinant of
voltage dependence, and also underscores how elements
of both structural repeats (RU1 and RU2) are involved
in cation coordination. Similar shifts in the steady-state
voltage dependence were reported in two structure-function
studies on the rat NaPi-IIa (34) and flounder NaPi-IIb (12).
In the former study, Cys was substituted at two conserved
sites (corresponding to I449 and A461 in TM5 of hNaPi-
IIa) (34). In the latter study, an A/C substitution was
also made at site 175 (corresponding to 203 in TM2 of
hNaPi-IIa) (12), and simulations of the A175C kinetics
could readily account for the observed shift in voltage
dependence by effectively increasing the dissociation con-
stant for the first Naþ binding partial reaction (142;
Fig. 1) (12). In our structural model, these conserved posi-
tions are involved in the packing of helices TM2 and TM5
with their neighbors, suggesting unspecified indirect effects
of these mutations and supporting the notion that the molec-
ular determinants of the steady-state voltage dependence are
shared between functionally important elements of the sym-
metry-equivalent repeat units.
Second, Liþ is proposed to bind only at Na1, where it
competes with Naþ ions for occupancy when both are pre-
sent in the external medium (14). This is a useful property
because it allowed us to discriminate between Na1 interac-
tions and those involving Na1 and Na2 when only Naþ was
present. Simulations based on an extensive kinetic analysis
of the flounder NaPi-IIb isoform predict that the dissociation
constant associated with partial reaction 243 (Fig. 1)—
leading to occupancy of Na2 by a Naþ ion—is significantly
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reduced when Na1 is occupied by Liþ. Moreover, Liþ occu-
pancy of Na1 was predicted to reduce the inward transloca-
tion rate of the fully loaded carrier to account for the smaller
IPi
max of the WT at hyperpolarizing potentials (see Fig. 3 C)
(14). In this study, superfusion with the 50Na50Li solution
increased the response to 1 mM Pi for Q206N, D209A/E,
R210A, and S447A, exceeding the response with 50Na.
In contrast, for the WT there was only a marginal change
in IPi over a wide voltage range when superfusing with either
solution (Fig. 3). This behavior established that Liþ ions
interact with the mutated constructs and are more readily
tolerated as a driving cation compared with the WT.
Although our data were consistent with the notion that
mutagenesis directly impacts only the Na1 site, and 100%
replacement of Naþ with Liþ resulted in no electrogenic ac-
tivity or 32P uptake (data not shown) (14), we cannot
exclude the possibility that for the mutants, both Na1 and
Na2 sites might bind Liþ and result in an overall cotransport
stoichiometry of 2 Liþ:1 HPO4
2:1 Naþ.
Presteady-state assays focus on Na1 and the
empty carrier
The presteady-state assays performed in the absence of
external Pi allowed us to restrict the number of occupied
conformational states and obtain additional insights into
the functional consequences of the mutagenesis. Voltage
steps applied to the membrane move the transporters be-
tween state 6 (extreme depolarizing potentials) and state 1
(0Na) or 3 (100Na) (extreme hyperpolarizing potentials),
with a distribution between the possible states at intermedi-
ate potentials that depends on the kinetics of the partial re-
actions. The Q-V data were fit with a single Boltzmann
function, which is strictly valid only for a two-state system
(35). Here, data resolution limitations and fit uncertainties
precluded fitting with a more complex function; however,
despite this limitation, two parameters from the single
Boltzmann fit analysis (Qmax and V0.5; Eq. 1) provided use-
ful indicators of the effects of mutagenesis.
For all mutants assayed, except for T451A and T454A,
there was an increase in estimated total displaceable
charge (Qmax) when external Na
þ was present, with the
Qmax
0/Qmax
100 ratio being comparable to the WT estimate
(Fig. 5 B). Therefore, we can conclude that the mutagenesis
did not alter the amount of charge displacement attributable
to Naþ ions under the influence of the TM electric field. In
this context, it should be noted that Qmax
100 describes both
the movement of the empty carrier and the additional charge
due to Naþ ion displacement. Constructs T451A and
T454A, for which we detected no cotransport activity, also
showed no significant dependence of Qmax on Na
þ. This
result indicated that Naþ movements to the Na1 and Na2
sites were severely compromised, consistent with the lack
of transport activity, although we cannot exclude the possi-
bility that the charge movement attributable to Naþ ions re-
mained undetected due to the resolution limitations of the
system. We note that the molecular rearrangements that
accompany the Naþ interaction with Na1 remain unresolved
and will require knowledge about the structure of NaPi-IIa
(or homologs thereof) in states other than the equivalent
of state 4 (Fig. 1).
The hyperpolarizing shift in the steady-state voltage
dependence of IPi was reflected in corresponding changes
in the presteady-state charge distributions of the mutants
(i.e., a hyperpolarizing shift of the midpoint voltage, V0.5;
Fig. 6 A) when 100 mM Naþ was present externally
(Q206A/N, D209A/E, and S447A). This was in accord
with the notion that the kinetics of transitions between states
associated with the empty carrier (states 0 and 1) and when
Na1 (states 2 and 6) or Na2 (state 3) is occupied (Fig. 1) are
the main determinants of the voltage dependence of the
overall cotransport cycle. In the absence of external Naþ,
there was more variation in the empty carrier equilibrium
potential (V0.5) among the constructs, which suggested
that the mutagenesis had also affected the distribution be-
tween states 6, 0, and 1, to an extent that depended on the
site mutated. Mutants D209E and R210A (TM2), and
S447A (TM5) showed significant hyperpolarizing shifts in
V0.5 when no external Na
þ was present. This indicated
that at the 60 mV holding potential, at which the WT
would be equally likely to be in state 0 or 1, the inward
orientation of the empty carrier (state 0) was more favored
for these mutants (Fig. 1). It should be noted that since we
had no direct access to the oocyte cytosol to manipulate
the intracellular [Naþ], we cannot fully exclude the possible
occupancy of Naþ bound from the inside (state 6), although
indirect evidence from kinetic simulations and the low inter-
nal [Naþ] for typical oocytes (<10 mM (36)) would be
consistent with a low occupancy of state 6 for the WT.
For the two nontransporting mutants in TM5 (T451A and
T454A), charge movement was detected in the absence
of external Naþ. This indicated that the conformational
change accompanying the empty carrier reorientation
(041; Fig. 1) in response to changes in the TM field still
occurred, although for T454A, V0.5 was further shifted in
the hyperpolarizing direction relative to the WT, consistent
with an inward facing orientation of the empty carrier
being favored, as also found for D209E, R210A, and
S447A. When Naþ was present in the external medium,
the ~þ20 mV depolarizing shift of V0.5 seen for both
T451A and T454A could be explained by an electroneutral,
or weakly electrogenic, interaction of Naþ with Na1. Given
the profound effect on function that mutagenesis had at
these sites, we propose that the side chains at 451 and 454
are critical for coupling the Na1 occupancy to the subse-
quent binding at Na2 rather than directly participating
in cation coordination at Na1. Indeed, their general pheno-
type was consistent with that of mutations at other sites in
TM5 that we propose to be nearer the Na2-Pi-Na3-binding
region (10).
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Two of the positions explored in this study were charged
(D209 and R210), and the finding that electrogenic activity
remained after charge removal indicates that the charge per
se at these positions was not critical for overall function and
might argue against their direct involvement at Na1. This
contrasts with the removal of negative charge at 224, which
results in electroneutral cotransport (6,7). Nevertheless,
since the alanine substitution at each position, or merely
changing the side-chain length (D209E), significantly
altered the electrogenic properties of the mutants, we
explored their presteady-state kinetics in more detail by
determining the dependence of V0.5 on external [Na
þ].
This dependence has been used to investigate the apparent
affinities of the Na1- and Na2-binding sites in the Naþ-
dependent sugar transporter SGLT1 (28). Similar to what
was found for SGLT1, analysis of presteady-state data
from WT NaPi-IIa and NaPi-IIb yields a relationship be-
tween V0.5 and log10[Na
þ] that is consistent with a sequen-
tial binding model for Naþ. At high [Naþ], this relationship
is linear and approaches a maximum slope of ~116 mV/
decade (5,14,23,28). Over the range of external [Naþ]
used in our assays, the data for D209A and D209E showed
no evidence of limiting slope behavior, which suggested that
the Naþ interactions had been compromised by mutagenesis
at position 209. For R210A, the empty carrier V0.5 was also
shifted in the hyperpolarizing direction relative to the WT;
however, its V0.5 value tended to approach that of the WT
at high [Naþ]. Based on this behavior, we concluded that
R210 was not critical for Na1 coordination, but that the
charge at this site was important for defining the equilibrium
between the empty carrier states. Interestingly, the polar-to-
nonpolar substitution at 447 also resulted in a comparable
hyperpolarizing shift to that of R210A for the 0Na superfu-
sion condition. However, this mutant showed a weaker
depolarizing shift in V0.5 when Na
þ was present that lay
between the WT and D209A/E values, suggesting an inter-
mediate effect on Na1 interactions.
We attempted to gain further insight into the significance
of these data by fitting them with the implicit function ob-
tained by modeling a four-state sequential binding scheme
describing the dependence of V0.5 on [Na
þ] (corresponding
to transitions between states 0, 1, 2, and 3; Fig. 1). The
variables in this model comprise the ratio of forward and
backward zero voltage rates for each partial reaction and
associated apparent valences (14,28) (Supporting Results).
Although our ability to discriminate between effects
only at Na1 or only at Na2 was limited by having only
five nonzero [Naþ] data points and a maximum
[Naþ] ¼ 100 mM, the fit parameters were nevertheless
consistent with significantly increased dissociation con-
stants for the first Naþ binding partial reaction compared
with the WT for D209A/E and S447A, whereas for
R210A the change was less dramatic. These findings further
confirmed the likely participation of D209 and S447 in
cation coordination at Na1. Changes were also observed
for the dissociation constant associated with the Na2 occu-
pancy partial reaction that would suggest that the mutagen-
esis had also impacted the cooperativity of Naþ interaction.
Taken together, the steady-state and presteady-state
functional data strongly implicated Q206, D209, D224,
and S447 as likely candidates for coordinating Naþ at
Na1. The positive charge at 210 appeared to be a critical
determinant of the kinetics of the 041 transition after cyto-
solic release of Naþ and coupling to the Na2 site.
A structural model of human NaPi-IIa including all
four binding sites
The low sequence identity between human NaPi-IIa and its
only available template structure, VcINDY, means that
although the overall fold is likely to be correct, key regions
should be optimized with the guidance of specific experi-
mental data. Preliminary data implicated D224 from TM3
in the role of Na1, and, helpfully, the vertical positioning
of the residues in this TM helix was one of the most reliable
aspects in the published model (10) because of the clear
agreement with the TM prediction from OCTOPUS (resi-
dues 224–244) and experimental accessibility data (6).
ThatNa1 is likely to be fairly close to the cytoplasmic surface
can be inferred from the leak mode observed in the absence
of substrate for the electrogenic forms of SLC34. Therefore,
we focused our efforts on residues close to D224 and on the
cytoplasmic halves of TM2 and TM5, i.e., the only two
helices contacting TM3 in this fold. This strategy allowed
us to identify nine candidate positions for the Na1 site,
only three to five of which are likely to be directly involved.
Remarkably, the experimental data described above delin-
eates the roles of most of the nine tested residues.
For the available template, only one alignment of TM2b
between NaPi-IIa and VcINDY was compatible with a
Na1 site in which D206 and N209 coordinate the ion, but
T211 does not. This adjustment had the added advantage
that a conspicuously long loop in the membrane (L2ab),
which previously could not be unambiguously modeled,
was significantly shortened, and several charged residues
could be repositioned into a more suitable aqueous environ-
ment (Fig. S6). The distinct behavior of mutations at T451
and T454 was reminiscent of previous results for residues
in the Na2-Pi-Na3-binding region of NaPi-IIa. Although
the published data do not delineate which residues
contribute to the Na2, Na3, or Pi sites in NaPi-IIa, they
nevertheless provide strong support for the involvement of
several residues in HP1 (S164, T195, and S196), HP2
(Q417, S418, and S419), and TM2 (N199) in contributing
to this binding region (10). The similar data for T451A
and T454A suggest that these two residues in TM5 also
contribute to this binding region, so we positioned T451
and T454 close to the tip of HP2 by adjusting the alignment
of TM5, shortening the L5ab loop, and improving the model
of TM6.
Biophysical Journal 108(10) 2465–2480
2478 Fenollar-Ferrer et al.
We note that S462, which we previously concluded might
be part of the Na2-Pi-Na3-binding region, and might coordi-
nate Na3, is now moved farther to the periplasmic end of
TM5b. Our earlier proposal was based on the observation
that Pi transport by an S462C mutant of rat NaPi-IIa was in-
hibited by an MTS reagent (34). However, it should be noted
that similar observations have been made for positions
remote from binding sites (e.g., the helical hairpin HP2 in
glutamate transporters) if the repacking of that segment is
required for transport (37). Therefore, we propose that an
alternative role should be assigned to S462, and that T451
and T454 may be positioned close to the Na2-Pi-Na3 cluster.
As described above, the type of side chain at 224 plays a
critical role in determining charge translocation and electro-
genicity by NaPi-II family members (6–8,12). After refine-
ment, the NaP-IIa model predicts a possible salt-bridge
between R210 (TM2) and D224 (TM3), with both residues
close to the Na1 site, but on the cytoplasmic side thereof.
Although a clear structural interpretation of the electrophys-
iological data is difficult, we speculate that when D224 is a
Gly, as in NaPi-IIc, R210 does not interact with TM3,
reducing the repulsion of R210 to the Na1 ion and allowing
the ion to remain bound during the 041 transition (Fig. 1).
In addition, in NaPi-IIa/b, formation of the salt-bridge by
D224 may be voltage dependent; thus, breaking of this
bridge could provide a pathway for the ion to leak in the
absence of Pi (24). Whatever the mechanism, it is clear
that these two residues are involved in distinguishing be-
tween the electrogenic and electroneutral isoforms. There-
fore, it will be essential to examine in further detail how
those positions and their valency relate to the voltage depen-
dence of transport.
In conclusion, the fact that residues from three distinct
TM segments (TM2, TM3, and TM5) come together to
form the Na1 site, as predicted by our models, provides
strong support for the predicted fold of NaPi-II transporters
and the choice of VcINDY as a template. Moreover, the re-
finements of TM2, TM5, and TM6 in this structural model
and the identification of the Na1 site residues provide a
firmer foundation for the future design of experiments to
define functionally critical aspects of transport by the
SLC34 family of proteins, as well as of VcINDY homologs
from the SLC13 family such as NaDC1 and NaDC3
(Fig. S11).
SUPPORTING MATERIAL
Supporting Results, eleven figures, four tables, and one structural model are
available at http://www.biophysj.org/biophysj/supplemental/S0006-3495(15)
00342-2.
AUTHOR CONTRIBUTIONS
C.F.-F.: bioinformatics and modeling. L.R.F.: analysis of computational
data. A.W.: molecular biology. M.P.: molecular biology, electrophysiology,
and data analysis. I.C.F.: electrophysiology and data analysis. T.K.: tracer
assays and immunohistochemistry. L.R.F., A.W., and I.C.F.: experimental
design and writing of the manuscript.
ACKNOWLEDGMENTS
We thank Eva Ha¨nsenberger for oocyte preparation, Mehdi Taslimifar
(Interface Group, Institute of Physiology, University of Zu¨rich) for valuable
assistance in MATLAB modeling, and members of the Theoretical Molec-
ular Biophysics Unit of the National Heart, Lung and Blood Institute for
useful discussions.
This work was supported by The Dunhill Medical Trust (AW SA10/0210),
the Swiss National Science Foundation (I.C.F.), the HartmannMu¨ller Foun-
dation (I.C.F.), and the Intramural Research Program of the NIH, National
Institute of Neurological Disorders and Stroke (L.R.F.).
REFERENCES
1. Biber, J., N. Hernando, and I. Forster. 2013. Phosphate transporters and
their function. Annu. Rev. Physiol. 75:535–550.
2. Forster, I. C., N. Hernando,., H. Murer. 2013. Phosphate transporters
of the SLC20 and SLC34 families. Mol. Aspects Med. 34:386–395.
3. Lederer, E. 2014. Renal phosphate transporters. Curr. Opin. Nephrol.
Hypertens. 23:502–506.
4. Ghezzi, C., H. Murer, and I. C. Forster. 2009. Substrate interactions of
the electroneutral Naþ-coupled inorganic phosphate cotransporter
(NaPi-IIc). J. Physiol. 587:4293–4307.
5. Forster, I. C., N. Hernando, ., H. Murer. 2012. Phosphate transport
kinetics and structure-function relationships of SLC34 and SLC20 pro-
teins. Curr. Top. Membr. 70:313–356.
6. Virkki, L. V., I. C. Forster,., H. Murer. 2005. Functionally important
residues in the predicted 3(rd) transmembrane domain of the type
IIa sodium-phosphate co-transporter (NaPi-IIa). J. Membr. Biol.
206:227–238.
7. Bacconi, A., L. V. Virkki,., I. C. Forster. 2005. Renouncing electro-
neutrality is not free of charge: switching on electrogenicity in a
Naþ-coupled phosphate cotransporter. Proc. Natl. Acad. Sci. USA.
102:12606–12611.
8. Patti, M., C. Ghezzi, and I. C. Forster. 2013. Conferring electrogenicity
to the electroneutral phosphate cotransporter NaPi-IIc (SLC34A3) re-
veals an internal cation release step. Pflugers Arch. 465:1261–1279.
9. Mancusso, R., G. G. Gregorio, ., D. N. Wang. 2012. Structure and
mechanism of a bacterial sodium-dependent dicarboxylate transporter.
Nature. 491:622–626.
10. Fenollar-Ferrer, C., M. Patti,., L. R. Forrest. 2014. Structural fold and
binding sites of the human Naþ-phosphate cotransporter NaPi-II.
Biophys. J. 106:1268–1279.
11. Mulligan, C., G. A. Fitzgerald, ., J. A. Mindell. 2014. Functional
characterization of a Naþ-dependent dicarboxylate transporter from
Vibrio cholerae. J. Gen. Physiol. 143:745–759.
12. Ghezzi, C., A. K. Meinild, ., I. C. Forster. 2011. Voltage- and sub-
strate-dependent interactions between sites in putative re-entrant do-
mains of a Na(þ)-coupled phosphate cotransporter. Pflugers Arch.
461:645–663.
13. Yernool, D., O. Boudker,., E. Gouaux. 2004. Structure of a glutamate
transporter homologue from Pyrococcus horikoshii. Nature. 431:
811–818.
14. Andrini, O., A. K. Meinild,., I. C. Forster. 2012. Lithium interactions
with Naþ-coupled inorganic phosphate cotransporters: insights into the
mechanism of sequential cation binding. Am. J. Physiol. Cell Physiol.
302:C539–C554.
Biophysical Journal 108(10) 2465–2480
Na1 Sodium Site in NaPi-II 2479
15. Remmert, M., A. Biegert, ., J. So¨ding. 2012. HHblits: lightning-fast
iterative protein sequence searching by HMM-HMM alignment. Nat.
Methods. 9:173–175.
16. Crooks, G. E., G. Hon,., S. E. Brenner. 2004. WebLogo: a sequence
logo generator. Genome Res. 14:1188–1190.
17. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by
satisfaction of spatial restraints. J. Mol. Biol. 234:779–815.
18. Waterhouse, A. M., J. B. Procter, ., G. J. Barton. 2009. Jalview
Version 2—a multiple sequence alignment editor and analysis work-
bench. Bioinformatics. 25:1189–1191.
19. Laskowski, R. A., M. W. Macarthur, ., J. M. Thornton. 1993.
PROCHECK—a program to check the stereochemical quality of pro-
tein structures. J. Appl. Cryst. 26:283–291.
20. Ray, A., E. Lindahl, and B. Wallner. 2010. Model quality assessment
for membrane proteins. Bioinformatics. 26:3067–3074.
21. Forrest, L. R., C. L. Tang, and B. Honig. 2006. On the accuracy of
homology modeling and sequence alignment methods applied to mem-
brane proteins. Biophys. J. 91:508–517.
22. Harding, M. M. 2004. The architecture of metal coordination groups in
proteins. Acta Crystallogr. D Biol. Crystallogr. 60:849–859.
23. Virkki, L. V., I. C. Forster,., H. Murer. 2005. Substrate interactions in
the human type IIa sodium-phosphate cotransporter (NaPi-IIa). Am. J.
Physiol. Renal Physiol. 288:F969–F981.
24. Andrini, O., C. Ghezzi,., I. C. Forster. 2008. The leak mode of type II
Na(þ)-P(i) cotransporters. Channels (Austin). 2:346–357.
25. Ehnes, C., I. C. Forster, ., H. Murer. 2004. Structure-function
relations of the first and fourth extracellular linkers of the type IIa
Naþ/Pi cotransporter: II. Substrate interaction and voltage dependency
of two functionally important sites. J. Gen. Physiol. 124:489–503.
26. Forster, I., N. Hernando,., H. Murer. 1998. The voltage dependence
of a cloned mammalian renal type II Naþ/Pi cotransporter (NaPi-2).
J. Gen. Physiol. 112:1–18.
27. Virkki, L. V., J. Biber,., I. C. Forster. 2007. Phosphate transporters:
a tale of two solute carrier families. Am. J. Physiol. Renal Physiol.
293:F643–F654.
28. Loo, D. D., X. Jiang,., E. M. Wright. 2013. Functional identification
and characterization of sodium binding sites in Na symporters. Proc.
Natl. Acad. Sci. USA. 110:E4557–E4566.
29. Yamashita, A., S. K. Singh, ., E. Gouaux. 2005. Crystal structure
of a bacterial homologue of Naþ/Cl—dependent neurotransmitter trans-
porters. Nature. 437:215–223.
30. Verdon, G., S. Oh, ., O. Boudker. 2014. Coupled ion binding
and structural transitions along the transport cycle of glutamate trans-
porters. eLife. 3:e02283.
31. Zdravkovic, I., C. Zhao,., S. Y. Noskov. 2012. Atomistic models of
ion and solute transport by the sodium-dependent secondary active
transporters. Biochim. Biophys. Acta. 1818:337–347.
32. Ko¨hler, K., I. C. Forster,., H. Murer. 2002. Identification of function-
ally important sites in the first intracellular loop of the NaPi-IIa
cotransporter. Am. J. Physiol. Renal Physiol. 282:F687–F696.
33. Ko¨hler, K., I. C. Forster,., H. Murer. 2002. Transport function of the
renal type IIa Naþ/P(i) cotransporter is codetermined by residues in
two opposing linker regions. J. Gen. Physiol. 120:693–705.
34. Lambert, G., I. C. Forster, ., H. Murer. 2001. Cysteine mutagenesis
reveals novel structure-function features within the predicted third
extracellular loop of the type IIa Na(þ)/P(i) cotransporter. J. Gen.
Physiol. 117:533–546.
35. Bezanilla, F., and C. A. Villalba-Galea. 2013. The gating charge should
not be estimated by fitting a two-state model to a Q-V curve. J. Gen.
Physiol. 142:575–578.
36. Sciortino, C. M., and M. F. Romero. 1999. Cation and voltage depen-
dence of rat kidney electrogenic Na(þ)-HCO()(3) cotransporter,
rkNBC, expressed in oocytes. Am. J. Physiol. 277:F611–F623.
37. Qu, S., and B. I. Kanner. 2008. Substrates and non-transportable ana-
logues induce structural rearrangements at the extracellular entrance
of the glial glutamate transporter GLT-1/EAAT2. J. Biol. Chem.
283:26391–26400.
Biophysical Journal 108(10) 2465–2480
2480 Fenollar-Ferrer et al.
BASIC RESEARCH www.jasn.org
Acute Adaption to Oral or Intravenous Phosphate
Requires Parathyroid Hormone
Linto Thomas, Carla Bettoni, Thomas Knöpfel, Nati Hernando, Jürg Biber, and
Carsten A. Wagner
Institute of Physiology, University of Zurich, Zurich, Switzerland; and National Centre for Competence in Research,
Zurich, Switzerland
ABSTRACT
Phosphate (Pi) homeostasis is regulated by renal, intestinal, and endocrine mechanisms through which Pi
intake stimulates parathyroid hormone (PTH) and ﬁbroblast growth factor-23 secretion, increasing phos-
phaturia.Mechanisms underlying the early adaptive phase and the role of the intestine, however, remain ill
deﬁned.We investigatedmineral, endocrine, and renal responses during the ﬁrst 4 hours after intravenous
and intragastric Pi loading in rats. Intravenous Pi loading (0.5 mmol) caused a transient rise in plasma Pi
levels and creatinine clearance and an increase in phosphaturiawithin 10minutes. Plasma calcium levels fell
and PTH levels increased within 10 minutes and remained low or high, respectively. Fibroblast growth
factor-23, 1,25-(OH)2-vitamin D3, and insulin concentrations did not respond, but plasma dopamine levels
increased by 4 hours. In comparison, gastric Pi loading elicited similar but delayed phosphaturia and
endocrine responses but did not affect plasma mineral levels. Either intravenous or gastric loading led
to decreased expression and activity of renal Pi transporters after 4 hours. In parathyroidectomized rats,
however, only intravenous Pi loading caused phosphaturia, which was blunted and transient compared
with that in intact rats. Intravenous but not gastric Pi loading in parathyroidectomized rats also led to
higher creatinine clearance and lower plasma calcium levels but did not reduce the expression or activity of
Pi transporters. This evidence suggests that an intravenous or intestinal Pi bolus causes rapid phosphaturia
through mechanisms requiring PTH and downregulation of renal Pi transporters but does not support a
role of the intestine in stimulating renal clearance of Pi.
J Am Soc Nephrol 28: ccc–ccc, 2016. doi: 10.1681/ASN.2016010082
Phosphate (Pi) homeostasis is achieved by the balanced
actions of intestinal absorption, renal reabsorption,
and bone mineralization/demineralization. Intestinal
absorption and renal reabsorption of Pi are mostly
mediated by Na+–dependent phosphate (NaPi)
cotransporters from the SLC34 family of solute
carriers, consisting of the renal NaPi-IIa and NaPi-IIc,
and the intestinal NaPi-IIb transporters.1 The activity
and expression of these transporters are downregulated
in response to increased dietary Pi intake, whereas Pi
deﬁciency promotes their upregulation.1,2 The
adaptive regulation of renal and intestinal Pi trans-
port is at least in partmediated by several hormones,
including ﬁbroblast growth factor-23 (FGF23), 1,25-
dihydroxy-vitamin D3 [1,25-(OH)2-vitamin D3], para-
thyroid hormone (PTH), insulin, and dopamine.2–6
PTH and FGF23 rise in response to Pi intake and
alone or together downregulate renal Pi trans-
porters, increasing phosphaturia.3,5 Similarly, dopa-
mine stimulates renal Pi excretion by reducing
renal Pi transporter activity and expression.7–9
1,25-(OH)2-vitamin D3 levels increase during Pi
deﬁciency and enhance renal and intestinal Pi ab-
sorption.3,10–12 Also, insulin stimulates expression
of renal Pi transporters and reduces phosphaturia.13
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The actions of FGF23, PTH, and 1,25-(OH)2-vitamin D3 are
coupled through multiple negative and positive feedback
loops.3,5,14
However, the exact roles of these hormones in the acute
and chronic response to changes in Pi intake are not fully
deﬁned. Moreover, the existence and role of additional
factors and mediators in the control of Pi homeostasis
have been proposed.15,16 Klotho, a cofactor for FGF23 sig-
naling, also exerts direct effects on renal Pi and calcium
transporters independent from FGF23.5,17,18 MEPE and
sFRP4 may act on renal and extrarenal targets to lower
plasma Pi.19–21 Also, the existence of a putative intestinal
phosphaturic factor has been postulated on the basis of
the rapid phosphaturic effect of duodenal Pi infusion; the
absence of changes in plasma Pi, PTH, and FGF23; its inde-
pendence from renal innervation; and the phosphaturic
effect of duodenal extracts from Pi-infused rats.22 However,
in humans, acute enteral and parenteral Pi loads cause dose-
dependent changes in phosphaturia only on changes in
plasma Pi and PTH, and a similar phosphaturic response
is observed with both routes of Pi administration. Thus, in
contrast to rodents, the human data are not consistent with
the presence of an intestinal Pi sensor.23 Local Pi sensing
mechanisms in kidney and other organs may be involved
in sensing changes in dietary Pi intake and may mediate or
modulate some of the effects on renal Pi handling. Evidence
for Pi sensing has been obtained from isolated parathyroid
gland cells in vitro,24,25 the opossum kidney–derived OK cell
line,26,27 bone, and vascular cells28–30
The aim of this study was to investigate the endocrine,
mineral, and renal responses to acute Pi loading in rats and test
for evidence for a role of the intestine in determining the
adaptive response by administering Pi either intravenously or
intragastrically.
RESULTS
Pi Loading Rapidly Elicits
Phosphaturia
Intravenous infusionofaPibolus (500mmolPi)
caused a rapid and transient increase in
plasma Pi concentration in intact rats (Fig-
ure 1A), with a peak after 10 minutes. Two
hours after infusion, plasma Pi had returned
to baseline values. A signiﬁcant, although
blunted, increase in plasma Pi was observed
after 10 minutes on infusion of 150 mmol Pi
but not with 50 mmol Pi (Supplemental Fig-
ure 1A). In contrast, plasma Pi did not
change in rats gavaged with 500 mmol Pi
(Figure 1A). The concentration of plasma
Pi remained normal after intravenous or in-
tragastric administration of 500 or 150mmol
NaCl (Figure 1A, Supplemental Figure 2A).
Intravenous infusion of 500 mmol Pi
rapidly and strongly increased urinary Pi
excretion within 10 minutes. Although
phosphaturia tended to decrease after
30 minutes, it remained high over 4 hours
after administration (Figure 1B). Infusions of
150 and 50 mmol Pi failed to induce any sig-
niﬁcant phosphaturic response (Supplemen-
tal Figure 1B). Intragastric administration of
500 mmol Pi increased urinary excretion of
Pi to a similar extent as intravenous admin-
istration; however, the onset of phosphatu-
ria was delayed compared with infusion,
reaching signiﬁcance only 60 minutes after
the Pi bolus (Figure 1B). Phosphaturia re-
mainedhigh over 4 hours postgavage (Figure
1B). Changes in the fractional excretion of Pi
Figure 1. Effect of intravenous and intragastric administration of Pi on body Pi dis-
tribution and renal excretion in intact rats. Rats were loaded with 500 mmol Pi or
saline intravenously or orally. (A) Plasma Pi, (B) urinary Pi/creatinine, (C) creatinine
clearance, and (D) cumulative Pi excretion. Four proﬁles are shown: saline intravenous
infusion (black), Pi intravenous infusion (red), saline intragastric gavage (green), and Pi in-
tragastric gavage (blue). Data are presented as the means6SEM. ANOVA test; n=5–9 per
group and time point. *P,0.05 versus time 0; **P,0.01 versus time 0; ***P,0.001
versus time 0.
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after the Pi bolus paralleled urinary Pi concentration (Supple-
mental Figure 3A). Neither intravenous infusion nor gavage
of 500 or 150 mmol NaCl affected the urinary excretion of Pi
(Figure 1B, Supplemental Figure 2B).
Creatinine clearance signiﬁcantly increasedwithin10minutes
after intravenous application of 500 mmol Pi and thereafter,
rapidly normalized (Figure 1C). Intragastric loading with
500 mmol Pi did not alter creatinine clearance (Figure 1C).
Similarly, administration of 500 or 150 mmol NaCl by infu-
sion or gavage had no effect (Figure 1C) (data not shown).
The cumulative urinary excretion of Pi showed a similar
level after 4 hours of the oral or intravenous bolus (Figure 1D).
Although a delay was observed in the gavage group, both
groups had excreted comparable amounts of Pi 4 hours post-
application, with mean values of around 230 and 280mmol Pi,
respectively, representing about 50%–60% of the initial Pi
load (500 mmol).
To examine possible organ storage of the nonexcreted Pi, we
assessed the Pi content in femurs, liver, and skeletal muscle in
tissues from rats infused and gavaged with Pi or NaCl. As
expected, the concentration of Pi in femurs was higher (10–20
times) than in the other two organs (Supplemental Figure 4).
However, in all three tissues, similar levels of Pi were measured
in samples from control and Pi-loaded rats.
The concentration of total Ca2+ in plasma slightly but sig-
niﬁcantly decreased on intravenous infusion of 500 mmol Pi
(Figure 2A). The reduction was already detectable 10 minutes
after the Pi bolus, and although it tended to normalize at the
latest time points, plasma Ca2+ remained low until the end of
the experiment (4 hours). Similar changes were observed on Pi
infusion with 150 mmol Pi but not observed with 50 mmol Pi
(Supplemental Figure 1C). In contrast, total plasma Ca2+ did
not change signiﬁcantly after intragastric administration of
500 mmol Pi (Figure 2A). Infusion or gavage with either 500
or 150 mmol NaCl did not alter total plasma Ca2+ (Figure 2A,
Supplemental Figure 2C).
The urinary excretion of Ca2+ remained unchanged after
intravenous or intragastric Pi or NaCl application (Figure 2B,
Supplemental Figures 1D and 2D). However, infusion with Pi
or NaCl caused a small, nonsigniﬁcant, and transient increase
in urinary Ca2+ excretion, possibly reﬂecting an acute volume
load (Figure 2B).
Pi Loading Causes an Immediate PTH Rise
In intact animals, intravenous infusion of 500 mmol Pi in-
creased plasma intact PTH levels sixfold within 10 minutes,
whereas in gavaged rats, a twofold increase was detected after
25 minutes, paralleling or even preceding the increase in uri-
nary Pi excretion (Figure 3A). In both cases, PTH remained
high 4 hours after Pi administration (Figure 3A). No changes
in the plasma levels of intact FGF23 (Figure 3B), 1,25-(OH)2-
vitamin D3 (Figure 3C), and insulin (Figure 3D) were
observed in rats after Pi administration. Plasma dopamine
signiﬁcantly increased at 4 hours after 500 mmol Pi infusion
but not gavage (Figure 3E), whereas urine dopamine was not
altered (Figure 3F). Infusion and gavage with saline had no
effect on the hormones analyzed.
The Pi Load Reduces Renal Pi Transporter Activity and
Expression
Flux measurements of 32Pi and 3H-D-glucose were performed
in brush border membrane vesicles (BBMVs) isolated from
kidneys collected 40 minutes and 4 hours after 500mmol Pi or
saline application to assess proximal tubular luminal Pi trans-
porter activity. In BBMVs from kidneys
extracted 40 minutes after application, all 32
Pi uptake components were similar in Pi-
loaded and control samples (Figure 4, A
and B). Similarly, no differences were
detected for the Na+-dependent uptake of
D-glucose (Figure 4E). In contrast, the total
Na+–dependentaswell asSLC34–mediated32
Pi transport activities were reduced in kid-
neys 4 hours after infusion with 500mmol Pi
(Figure 4C). 32Pi ﬂuxes also decreased, al-
though nonsigniﬁcantly, in the Pi-gavaged
animals after 4 hours (Figure 4D). The
Na+-dependent uptake of D-glucose remained
unaffected for4hours inPi-infusedor-gavaged
animals (Figure 4F).
The abundance of the major renal Pi
transporters NaPi-IIa and NaPi-IIc in renal
BBMVs isolated 40 minutes after infusion
or gavage with Pi or saline was unchanged
(Figure 5, A and B). The abundance of both
cotransporters was signiﬁcantly reduced in
kidneys collected 4 hours after infusion
Figure 2. Effect of intravenous and intragastric administration of Pi on Ca2+ plasma
levels and urinary excretion in intact rats. Rats were loaded with 500 mmol Pi or saline
intravenously or orally. (A) Plasma Ca2+ and (B) urinary Ca2+/creatinine. Four proﬁles
are shown: saline intravenous infusion (black), Pi intravenous infusion (red), saline in-
tragastric gavage (green), and Pi intragastric gavage (blue). Data are presented as the
means6SEM. ANOVA test; n=5–9 per group and time point. *P,0.05 versus time 0.
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with 500mmol Pi (Figure 5C), whereas the expression ofNaPi-IIa
but notNaPi-IIc was diminished 4 hours after intragastric loading
(Figure 5D).
PTH Is Required to Clear the Acute Phosphate Load
Because PTH increased very rapidly on Pi loading and
paralleled or even preceded phosphaturia, we tested the role
of PTH in the adaptive response in parathyroidectomized
(PTX) rats. Infusion of 500 mmol Pi caused a rapid increase in
plasma Pi in PTX rats (Figure 6A), peaking after 10 minutes
and decreasing thereafter. However, whereas
the levels of Pi fully normalized within
2 hours postinfusion in intact rats, Pi levels
remained elevated until the end of the exper-
iment inPTXanimals (Figure 6A).Gavage of
500 mmol Pi in PTX rats induced a slow rise
in plasma Pi (Figure 6A) in contrast with
the lack of effect of the Pi gavage in intact
animals (Figure 1A). Administration of
saline to PTX rats by infusion or gavage did
not alter plasma Pi (Figure 6A).
Infusionwith 500mmol Pi induced a fast
but small increase in urinary excretion of Pi
in PTX rats (Figure 6B). Maximal phospha-
turia was detected 10 minutes postinfusion,
similar to in intact animals (Figure 1B).
However, phosphaturia returned to baseline
within 2 hours after infusion in PTX rats,
despite elevated plasma Pi levels (Figure
6B).Moreover, gavage of Pi in PTXrats failed
to elicit any signiﬁcant phosphaturia (Figure
6B). Neither infusion nor gavage with saline
affected urinary Pi (Figure 6B).
In PTX rats, creatinine clearance in-
creased within 10 minutes of 500 mmol Pi
infusion and rapidly normalized thereafter,
whereas it was not altered with either Pi
gavage or saline administration (Figure 6C).
The cumulative urinary excretion of
Pi over 4 hours in PTX rats infused with
500 mmol Pi was of about 30 mmol (Figure
6D), equivalent to about 6% of the Pi load.
The cumulative urinary excretion of Pi over
4 hours in PTX rats receiving Pi by gavagewas
about 3mmol (Figure 6D), representing,1%
of the Pi load.
The content of Pi was higher in femurs
than liver and muscle in PTX animals, and
no differences were found between organs
extracted from saline-treated andPi-loaded
rats (Supplemental Figure 5).
Plasma total Ca2+ decreased slightly
within 10 minutes on 500mmol Pi infusion
in PTX rats (Figure 7A) and remained low
until the end of the experiment. In con-
trast, plasma total Ca2+ did not change signiﬁcantly in Pi–
gavaged PTX rats (Figure 7A). Administration of 150 mmol
NaCl by infusion or gavage did not alter plasma Ca2+.
Urinary excretion of Ca2+ in PTX showed no signiﬁcant
changes after administration of Pi or saline (Figure 7B).
As expected, plasma PTH was undetectable in PTX rats
under all conditions (Figure 8A). In contrast to intact rats,
FGF23 was elevated in PTX animals 4 hours after oral or intra-
venous Pi loading (Figure 8B). The plasma concentrations of
1,25-(OH)2-vitamin D3 (Figure 8C), insulin (Figure 8D), and
Figure 3. Effect of intravenous and intragastric administration of Pi on hormonal levels in
intact rats. Rats were loaded with 500 mmol Pi or saline intravenously or orally. (A) Plasma
intact PTH, (B) plasma intact FGF23, (C) plasma 1,25-(OH)2-vitamin D3, (D) plasma insulin,
(E) plasma dopamine, and (F) urine dopamine. Four proﬁles are shown: saline intravenous
infusion (black), Pi intravenous infusion (red), saline intragastric gavage (green), and Pi
intragastric gavage (blue). Data are presented as the means6SEM. ANOVA test; n=5–9
per group and time point. *P,0.05 versus time 0.
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dopamine (Figure 8E) as well as urine dopamine (Figure 8F)
remained unchanged under all conditions.
PTH Downregulates Renal Pi Transporters in Response
to Acute Pi Loading
Flux measurements of 32Pi and 3H-D-glucose in BBMVs from
PTX rat kidneys collected 4 hours postloading were similar in
samples fromPi-loaded rats and controls (Figure 9). The protein
abundances ofNaPi-IIa andNaPi-IIc in PTX
rats were similar in the Pi-loaded and saline-
treated animals 4 hours postadministration
(Figure 10).
DISCUSSION
Acute and chronic changes in plasma Pi
elicit adaptive responses in several hor-
mones that regulate renal and intestinal
epithelia–(re)absorbing Pi.1–3 High dietary
Pi increases the phosphaturic hormones
PTH, FGF23, and dopamine while decreas-
ing the levels of 1,25-(OH)2-vitaminD3,6–7,31
resulting in reduced expression and activity
of NaPi cotransporters in renal and intestinal
epithelia, blunting intestinal Pi absorption,
and increasing urinary excretion. However,
there are conﬂicting data regarding the se-
quence of events triggered by high dietary
Pi as well as the nature of the trigger itself.
PTH may have a key role in the acute renal
response, with other hormones coming
into play only later on,23,32–34 but the pres-
ence of yet–unidentiﬁed intestinal factor(s)
stimulating renal Pi excretion independent
from PTH has been proposed.22 Here, we
administered a Pi load to rats both
intravenously (to bypass the gastrointesti-
nal tract) and intragastrically and com-
pared the acute responses in intact and
PTX animals.
Our data show that, compared with
equimolar NaCl infusions and the time
point 0, the acute infusion of Pi elicited a
dose-dependent response that consisted at
the highest dose of (1) an immediate but
transient rise in plasma Pi, (2) an early
and transient increase in creatinine clear-
ance, (3) a rapid phosphaturic response,
(4) a fall in plasma total calcium, (5) a rapid
and sustained phosphaturia, and (6) a re-
duced expression and activity of renal Pi
transporters. Intragastric application of Pi
caused a qualitatively similar response in
the cumulative Pi excretion without a sig-
niﬁcant change in creatinine clearance and with no obvious
hyperphosphatemia, a lower and delayed rise in PTH, a non-
significant reduction in renal Pi transporter activity and lower
expression of only NaPi-IIa but not NaPi-IIc, and a slower
onset in phosphaturia. Infusion or gavage of NaCl had no
effects.
Several points are of major interest: the onset of phospha-
turia is paralleled by a rise in PTH in infused and gavaged
Figure 4. Effect of intravenous and intragastric administration of Pi on Pi and glucose
transport activities in renal BBMVs from intact rats. Rats were loaded with 500 mmol Pi
or saline intravenously or orally. Kidneys were extracted 40 minutes or 4 hours after
infusion or gavage, and Na+–dependent and –independent Pi and glucose transport
activities were measured. Pi transport was assayed in the presence or absence of the
SLC34 transport inhibitor phosphonoformic acid. (A) 32P uptakes 40 minutes after
intravenous infusion of saline (gray bars) and Pi (black bars). (B) 32P uptakes 40 minutes
after intragastric administration of saline (gray bars) and Pi (black bars). (C) 32P uptakes
4 hours after intravenous infusion of saline (gray bars) and Pi (black bars). (D) 32P
uptakes 4 hours after intragastric administration of saline (gray bars) and Pi (black bars).
(E) 3H-D-glucose uptakes 40 minutes after intravenous and intragastric administration
of saline (gray bars) and Pi (black bars). (F) 3H-D-glucose uptakes 4 hours after in-
travenous and intragastric administration of saline (gray bars) and Pi (black bars). Data
are presented as the means6SEM. Unpaired t test; n=5–9 per group and time point.
*P,0.05 versus saline group.
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animals and precedes changes in plasma dopamine, whereas
levels of 1,25-(OH)2-vitamin D3, FGF23, insulin, and urine
dopamine were not altered, suggesting an important role of
PTH. Early phosphaturia (40 minutes) occurred in infused
animals without obvious changes in the activity or abundance
of renal Pi transporters expressed in the brush border mem-
brane of the proximal tubule, which may be explained at least
in part by a higher tubular load in the infused animals, because
creatinine clearance had more than doubled and plasma Pi
levels were elevated. However, we noted also a partial
dissociation between the degree of phos-
phaturia, Pi transport activities in BBMVs,
and the abundance of the NaPi-IIa and
NaPi-IIc transporters as most evident in
the Pi-gavaged group after 4 hours. Activity
of NaPi-IIa transporters in the brush bor-
der membrane is inﬂuenced by lipid com-
position of the plasma membrane and in
situ cleavage by klotho and possibly, regu-
lated association with and dissociation
from NHERF1 through phosphorylation
of NHERF1 stimulated by PTH or dopa-
mine.17,35–37 We did not obtain evidence
for cleavage of NaPi-IIa as evident from
immunoblotting, but changes in lipid
composition or NHERF1 phosphorylation
were not tested and may contribute to the
dissociation of transport activity and NaPi-
IIa abundance.
Plasma PTH rises in vivo and in vitro in
response to a fall in ionized calcium or an
increase in Pi concentrations. Whether the
response to Pi is independent from calcium
has remained unclear, because Pi retains its
ability to stimulate PTH secretion, even in
the absence of a measurable fall in ionized
or total calcium.23–25,33,38 Along the same
line, in vitro incubation of human parathy-
roid glands with escalating concentrations of
Pi while keeping ionized calcium constant
stimulated PTH secretion.24,38 However, in-
hibitors of calcium–stimulated receptor–
mediated PTH secretion (calcimimetics)
have been shown to suppress Pi–induced
PTH secretion in vivo, suggesting a role of
the calcium-stimulated receptor, even in
the absence of changes of ionized calcium
levels.25 Here, plasma total calcium de-
creased in parallel with the rise in PTH,
allowing no clear distinction between a
calcium-dependent or -independent mech-
anism. However, infusion of 150 mmol Pi
caused a similar fall in plasma total cal-
cium as 500 mmol Pi, but the rise in PTH
was blunted and detected only 10 minutes
postadministration, suggesting that Pi may stimulate PTH
release synergistically or independently. The early response
of PTH found in our animal model is consistent with exper-
iments in humans and other rodent models.23,32,33
PTH is critical for the early response to Pi, independent
from the route of application. In PTX rats, massive and
sustained hyperphosphatemia developed with a more pro-
nounced fall in plasma total calcium than in intact rats. There
was a small and transient increase in renal Pi excretion in the
Pi–infused PTX group that is most likely attributable to the
Figure 5. Effect of intravenous and intragastric administration of Pi on the expression
of renal NaPi cotransporters in intact rats. Rats were loaded with 500 mmol Pi or saline
intravenously or orally. Kidneys were extracted 40 minutes or 4 hours postadministration,
and the abundance of NaPi-IIa and NaPi-IIc in brush border membranes was determined
by Western blot. Expression of cotransporters (A) 40 minutes after intravenous infusion of
saline (gray bars) and Pi (black bars), (B) 40 minutes after intragastric administration of
saline (gray bars) and Pi (black bars), (C) 4 hours after intravenous infusion of saline (gray
bars) and Pi (black bars), and (D) 4 hours after intragastric administration of saline (gray
bars) and Pi (black bars). Unpaired t test; n=5–9 per group and time point. *P,0.05 versus
saline group.
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combination of hyperphosphatemia and elevated GFR (as in-
dicated by higher creatinine clearance). Phosphaturia ceased
after normalization of creatinine clearance and the fall of
plasma Pi below about 5 mM. The transient
increase in creatinine clearance in the Pi-in-
fused animals is independent from PTH
and may involve other Pi–sensitive mecha-
nisms. The rise in plasma Pi and/or the
fall in plasma calcium may be (in)direct
triggers affecting factors controlling glo-
merular ﬁltration, such as vascular tone of
afferent and/or efferent arterioles, where
calcium channels play an important role.39
PTH is also required for the downregula-
tion of renal Pi transporters after 4 hours,
because this response was also blunted in
PTX rats. Thus, our results show that PTH
is required for the early response to high Pi
intake.
We detected only small or no changes in
FGF23, 1,25-(OH)2-vitamin D3, insulin,
and dopamine. The increase in dopamine
or FGF23 was found only at the latest time
point and is probably not responsible for
the massive phosphaturia at earlier time
points. In Pi–infused intact rats, the late
rise in plasma dopamine (but not in urine)
may enhance PTH-induced phosphaturia.
Dopamine acts via D1 receptors to down-
regulate NaPi-IIa in proximal tubules.7–9
The increase in FGF23 in PTX rats occurs
between 50 and 240 minutes after the Pi
bolus (because of the small volumes of
blood that could be collected, only a few FGF23 determina-
tions were possible). This ﬁnding suggests ﬁrst that, in the
absence of PTH, FGF23 levels adapt more acutely to the Pi
overload and second, that systemic Pi can
regulate FGF23 production and/or stability
independently of PTH. Interestingly,
FGF23 production by osteocytes is not
directly regulated by Pi40 and instead,
requires previous production of PTH and
activation of protein kinase A and Wnt
pathways by PTHR123,41,42
Intestinal Pi sensors and an intestine–
derived phosphaturic factor had been pos-
tulated on the basis of experiments
with rats infused with Pi into duodenum.
This mechanism would allow for a rapid
crosstalk between intestine and kidney
and provide a feedforward mechanism
preventing a potentially detrimental hyper-
phosphatemia.22 The existence of such
feedforward mechanisms has been shown
for potassium and salt.43–46 However,
Scanni et al.23 had found, in healthy hu-
mans, that the rate of elimination and over-
all quantity of Pi excretion did not depend
Figure 6. Effect of intravenous and intragastric administration of Pi on renal excretion
in PTX rats. PTX rats were loaded with 500 mmol Pi or saline intravenously or orally. (A)
Plasma Pi, (B) urinary Pi/creatinine, (C) creatinine clearance, and (D) cumulative Pi
excretion. Four proﬁles are shown: saline intravenous infusion (black), Pi intravenous
infusion (red), saline intragastric gavage (green), and Pi intragastric gavage (blue). Data
are presented as the means6SEM. ANOVA test; n=4–6 per group and time point.
*P,0.05 versus time 0; **P,0.01 versus time 0.
Figure 7. Effect of intravenous and intragastric administration of Pi on Ca2+ plasma levels
and urinary excretion in PTX rats. PTX rats were loaded with 500 mmol Pi or saline in-
travenously or orally. (A) Plasma Ca2+ and (B) urinary Ca2+/creatinine. Four proﬁles are
shown: saline intravenous infusion (black), Pi intravenous infusion (red), saline intragastric
gavage (green), and Pi intragastric gavage (blue). Data are presented as the means6SEM.
ANOVA test; n=4–6 per group and time point. *P,0.05 versus time 0.
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on the route of application (intravenous versus intraduodenal
infusion). Consistently, our data do not provide any evidence
for a role of the intestine in promoting phosphaturia. More-
over, in the absence of PTH, no phosphaturia could be elicited
by intragastric Pi infusions.
The cumulative urinary elimination of the Pi bolus reached
only about 50%–60% after 4 hours in intact animals, whereas
normophosphatemia was achieved much faster, suggesting
that a large amount of Pi had been eliminated by other routes
(i.e., intestinal tract), extravasated and accumulated in tissues,
or complexed in blood into a pool that is not measurable
by the Fiske–Subbarow method. Scanni et al.23 showed that
urinary excretion of Pi accounted for 100%
of the intravenous Pi overload in humans,
but full elimination required 120 hours; the
authors rule out a contribution of the gas-
trointestinal tract in the elimination of Pi.
We quantiﬁed the Pi content in femurs as
well as liver and skeletal muscle. Pi content
in bones is much higher than in the other
two organs, and the measured values were
so high that a rough estimation of the total
amount of Pi stored in the skeleton
(assuming a 10% contribution to body
weight and a comparable composition of
all bones) suggests that, even if all of the
nonexcreted Pi would have been accumu-
lated in bones, this would only result in a
small change of content (approximately
0.5%), nondetectable with the Fiske–
Subbarow method. Although similar estima-
tions predicted that partial accumulation of
Pi in liver and skeletal muscle could be de-
tectable, we failed to observe any changes.
Thus, other approaches should be used to
identify the organs responsible for a tran-
sient accumulation of a large excess of Pi.
In summary, our data indicate that (1)
normophosphatemia is rapidly re-established
after intravenous and intragastric Pi load-
ing by mechanisms largely depending on
the ability of the kidneys to excrete Pi; (2)
an efﬁcient phosphaturic response re-
quires increased levels of PTH and reduced
expression of renal Pi transporters; (3)
these compensatory responses are, to a
major extent, similar, regardless of
whether Pi bypasses the gastrointestinal tract;
and (4) reduced plasma Ca2+ together
with elevated Pi may trigger the secretion
of PTH in intravenously loaded animals.
Our ﬁndings leave two major issues unre-
solved, namely the identity of the com-
partment responsible for the rapid
quenching of a large fraction of the loaded
Pi and the nature of the signal that triggers the stimulation of
PTH release.
CONCISE METHODS
Animal Experimental Protocol
Male Wistar rats (Charles River Laboratories, Wilmington, MA)
weighing 250–350 g were adapted to a low-Pi diet (0.1%) for 5 days.
After an overnight fast in metabolic cages with free access to water,
animals were anesthetized with 3% isoﬂurane/air and placed on a
heated pad to maintain body temperature at 37°C–38°C. Rats inhaled
Figure 8. Effect of intravenous and intragastric administration of Pi on hormonal levels
in PTX rats. PTX rats were loaded with 500 mmol Pi or saline intravenously or orally. (A)
Plasma intact PTH, (B) plasma intact FGF23, (C) plasma 1,25-(OH)2-vitamin D3, (D)
plasma insulin, (E) plasma dopamine, and (F) urine dopamine. Four proﬁles are shown:
saline intravenous infusion (black), Pi intravenous infusion (red), saline intragastric gavage
(green), and Pi intragastric gavage (blue). Data are presented as the means6SEM.
ANOVA test; n=4–6 per group and time point. *P,0.05 versus time 0.
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constantly a low dose of anesthesia (1%–2% isoﬂurane/air) until the
end of the experiment. Catheters (BPE-T 50; Instech) were placed
into the femoral vein, femoral artery, and urinary bladder (for in-
fusion of solutions and collection of blood and urine, respectively). A
Ringer solution (116 mM NaCl, 1.2 mM KCl, 1 mM CaCl2, and
2.7 mM NaHCO3) containing 5% glucose was infused continuously
at a rate of 3.0 ml/h until the end of the experiment. To determine
baseline values, blood and urine samples were collected over a period
of 30 minutes after the start of the Ringer infusion. In the infusion
protocol, 1 ml either Na2HPO4/NaH2PO4 (500, 150, or 50 mM; pH
7.4) or NaCl (500 or 150 mM; pH 7.4) was infused immediately after
the baseline sampling within 2–3 minutes. For gavage, 1 ml either
500mMNaH2PO4/Na2HPO4 (pH 5) or NaCl (500 or 150mM; pH 5)
was administered directly into the stomach by using a gavage tube
(FTP-15–100; Instech). Blood and urine samples were collected at
different time intervals postinfusion or postgavage. At the end of
sample collections (40minutes or 4 hours), the animalswere euthanized,
and blood, kidneys, intestine (duodenum, jejunum, and ileum), liver,
muscle, and femur were harvested. Blood samples (both from interme-
diate time points and at termination) were centrifuged immediately
on collection, and plasma was aliquoted.
Plasma and organs were store at 280°C until
further used.
In addition, an identical experimental pro-
tocol to the one described above was performed
in 350–450 g PTX male rats (Charles River Lab-
oratories) receiving 1% calcium gluconate in
drinking water.
All animal experiments were according to
Swiss and international laws of animal pro-
tection, and all protocols were approved by the
appropriate local veterinaryauthority (Kantonales
Veterinäramt Zürich).
General Analytic Measurements
The concentration of Pi in plasma and urine was
determined according to the Fiske–Subbarow
method (Randox). Plasma and urinary levels
of calciumwere measured using a Quantichrom
Calcium Kit from Bioassay System. The concen-
tration of creatinine in plasma was enzymatically
measured using a peroxidase-antiperoxidase-
creatinine kit (Biomed), whereas urinary cre-
atinine was measured according to the Jaffe
method. Fractional excretion of Pi was calcu-
lated using the formula: [urine Pi 3 plasma
creatinine]3100/[plasma Pi 3 urine creatinine].
The creatinine clearance was estimated from
plasma and urinary creatinine concentrations
and urine volume.
The concentration of glucose in plasma was
measured by using Accu-Chek (Roche, Basel,
Switzerland). ELISA kits were used to measure
the concentrations in plasma and/or of intact
PTH(Immutopic), intactFGF23(Kainos), insulin
(CrystalChemInc.),anddopamine(LDN).Plasma1,25-(OH)2-vitamin
D3 was determined with an RIA kit from IDS. Protein concentrations
in renal brush border membranes were determined with the Bio-Rad
Protein Assay (Bio-Rad, Hercules, CA).
Isolation of Renal BBMVs and Flux Measurements of 32
Pi and 3H-Glucose
Kidney cortex and medulla were dissected from frozen kidneys and
homogenized in a buffer containing 300 mMmannitol, 5 EGTA, and
12 Tris-HCl, pH 7.1; BBMVs were isolated according to the Mg2+
precipitation method as described in detail.47 Uptake of 32Pi and 3
H-glucose was measured in three different solutions, all three con-
taining 300 mM mannitol plus 20 mM HEPES-Tris, pH 7.4 and
125 mMNaCl, 125 mM KCl, or 125 mM NaCl. The uptake solutions
contained either 0.125 mM K2HPO4/KH2PO4, pH 7.4 as cold sub-
strate and 32Pi as a tracer or 0.125mMD-glucose as cold substrate and
3H-D-glucose as tracer. To measure the incorporation of 32Pi/3H-glucose,
10 ml freshly prepared BBMVs were incubated for 1 minute or 2 hours
with 40 ml different uptake solutions. The 1-minute time point was
chosen, because 32Pi/3H-glucose uptake was in the linear phase of
Figure 9. Effect of intravenous and intragastric administration of Pi on Pi and glucose
transport activities in renal BBMVs from PTX rats. PTX rats were loaded with 500 mmol
Pi or saline intravenously or orally. Kidneys were extracted 4 hours after infusion or
gavage, and Na+–dependent and –independent Pi and glucose transport activities in
isolated BBMVs were measured. Pi transport was assayed in the presence or absence
of the SLC34 transport inhibitor phosphonoformic acid. (A) 32P uptakes 4 hours after
intravenous infusion of saline (gray bars) and Pi (black bars), (B) 32P uptakes 4 hours
after intragastric administration of saline (gray bars) and Pi (black bars), and (C) 3H-D-
glucose uptakes 4 hours after intravenous and intragastric administration of saline
(gray bars) and Pi (black bars). Data are presented as the means6SEM. Unpaired test;
n=4–6 per group and time point.
J Am Soc Nephrol 28: ccc–ccc, 2016 PTH Controls Acute Phosphate Clearance 9
www.jasn.org BASIC RESEARCH
the maximal transport rate as determined earlier.47 After the indi-
cated incubation time, uptakes were stopped by transferring 20 ml
sample to 1 ml ice cold stop solution (100 mMmannitol, 5 mM Tris-
HCl, 150 mM NaCl, 5 mM Pi, and 5 mM glucose). The resulting
suspension was then spotted onto a ﬁlter and vacuum washed with
10 ml ice cold stop solution. Filters were ﬁnally transferred into plastic
vials, and on addition of 3 ml scintillation medium (PerkinElmer,
Waltham,MA), the retained radioactivity wasmeasured on ab-counter
(TRI-CARB 2900TR; Packard). All measurements were carried out in
triplicate. The Na+-dependent uptakes were calculated by subtracting
the uptake values obtained in the K+ medium from those measured
in the Na+ medium (total uptake). Because phosphonoformic acid is a
competitive inhibitor of SLC34 cotransporters (NaPi-IIa and NaPi-IIc),
SLC34-mediated uptake was determined by subtracting the
uptake values obtained in the presence of phosphonoformic acid
from the Na+-dependent values. The remaining BBMVs that were not
used in the uptake experiments were stored immediately at280°C for
further experiments.
Immunoblotting
The protein expression levels of NaPi-IIa and NaPi-IIc in renal brush
border membranes were quantiﬁed by immunoblotting. To this end,
20 mg brush border membranes were solubilized in Laemmli buffer
and separated on 10% SDS-PAGE, and then, they were transferred to
polyvinylidene diﬂuoride membranes (EMD Millipore, Billerica,
MA). After blocking nonspeciﬁc binding with 5% milk powder in
Tris-buffered saline containing 0.1% Tween-20 for 40 minutes, the
blots were incubated overnight at 4°C with primary antibodies
against NaPi-IIa (1:4000),48 NaPi-IIc (1:2500),49,50 and b-Actin
(1:10,000; Sigma-Aldrich, St. Louis, MO). After washing and further
blocking, blots were incubated with appropriate secondary antibodies
for 2 hours at room temperature. Finally, mem-
branes were exposed to chemiluminescent sub-
strate for 5 minutes, and protein signals were
detected on an LAS-4000 Luminescent ImageAn-
alyzer (Fujiﬁlm, Tokyo, Japan). All of the images
were quantiﬁed with Advanced Image Data
Analyzer (Raytest). The expression of both
cotransporters was normalized to the abun-
dance of b-Actin.
Determination of Pi in Tissues
Tissues (liver, skeletal muscle, and femur) col-
lected from intact and PTX rats 4 hours after
infusion or gavage were dried in an oven at 70°C
for 24 hours. Samples were weighed, transferred
into a silica crucible, and burned to ashes in an
electric furnace at 700°C for 12 hours; 1 N HCl
was used to dissolve the Pi present in ashes, and
after centrifugation, supernatants were collected
for Pi determination by the above–mentioned
Fiske–Subbarow method.
Statistical Analyses
Statistical signiﬁcances were calculated by t test
or one-way ANOVA (Bonferroni) as indicated. P,0.05 was consid-
ered signiﬁcant. Results are presented as means6SEM.
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